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Stem cell derived models of hepatocytes have potential in toxicity testing and regenerative  
medicine. Despite global efforts drug-induced liver-injury (DILI) remains a major concern for 
the pharmaceutical and healthcare industries and is a considerable cause of morbidity and 
mortality. Therefore, efforts are being made to reduce its incidence through toxicity 
screening to prevent the release of unsafe compounds to market. Current models of DILI 
are flawed, either lacking in terms of physiological relevance in the case of hepatic cell lines 
or in terms of reproducibility and availability in the case of human primary hepatocytes 
(hPH). Stem cell-derived hepatocyte models offer a theoretically unlimited source of 
potentially high-quality hepatocytes for toxicity testing. However, currently they are 
hindered by lack of maturity compared with hPH as in the case of pluripotent stem cell-
derived hepatocyte-like cells (PSC-HLCs), or are incompletely phenotyped, in the case of 
human liver organoids.  
Hypoxic conditions improve the stemness of PSCs, in addition, during embryogenesis cells 
are exposed to hypoxic conditions. Furthermore, there is a range of oxygen concentration 
across the liver lobule which is implicated in their phenotype. We hypothesised that iPSC-
HLCs differentiated under hypoxic conditions (5% O2) would adopt a perivenous phenotype 
with higher CYP expression. Two differentiations protocols, one growth factor-based, the 
other small molecule-based were also compared. These results showed little difference 
between oxygen conditions but suggested that cells differentiated under traditional 
normoxic conditions experience some degree of hypoxia. Additionally, we found little 
difference between differentiation protocols, suggesting the cheaper, and more 
reproducible small molecule-based protocol should be used in future studies. 
Human liver organoids derived from EpCAM-positive cells were established and their 
phenotype was examined using iTRAQ. These results showed that organoids offer good 
recapitulation of the phenotype of hPH particularly regarding transporter phe notype. 
The current demand for donor organs outstrips supply. Consequently, there have been 
efforts in recent years to find alternate sources of cells and tissue for transplant.  PSCs offer 
a potentially unlimited source of cells for this purpose. However, the risks associated with 
the use of stem cells for transplant are incompletely understood. There are concerns 
regarding the tumorigenic potential of stem cells used for transplant, based not only on the 
inherent ability of pluripotent cells to form teratomas in vivo but also regarding the more 
insidious genetic changes introduced during isolation and culture.  
The effects of the 20q11.21 amplicon, a common aberration occurring in approximately 
20% of PSC-lines after extended culture and providing a selective advantage in vitro were 
examined when differentiated into HLCs and injected intrasplenically into SCID mice. We 
generated luminescent PSCs with known 20q11.21 status, tracked their engraftment over 
approximately 4 months. Our results demonstrated worsened liver histology and increased 
luminescence in animals injected with cells containing the amplicon. 
These studies revealed little no advantage to the use of hypoxic conditions for the 
production of HLCs but suggest potential for the future use of hyperoxia. The investigation 
into the proteomic phenotype of organoids revealed a good approximation of many liver 
specific genes including CYPs, phase II enzymes and transporters but were hindered by the 
inability to successfully cryopreserve the organoids. Despite issues with engraftment, the 
presence of 20q11.21 appears to worsen liver histology, future studie s should screen 
against its use. Repeat studies should consider the use of alternate animal models to better 
facilitate cell engraftment  
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1.1 Adverse drug reactions and drug-induced liver-injury 
Despite concerted global effort, adverse drug reactions (ADRs) are still a major concern for 
the pharmaceutical and healthcare industries. Drug-induced liver-injury (DILI) is the class of  
adverse drug reactions discussed herein. DILI is a leading cause of acute liver failure in the 
UK and the US (O’Grady, 2005; Reuben et al., 2010) and is responsible for 6.5-6.7% of all 
hospital admissions where 0.15-0.32% of which culminate in death (Lazarou et al., 1998; 
Pirmohamed, 2004). A recent study investigated the incidence of DILI in the Icelandic 
population and found an incidence of 19.1 cases per 100,000 individuals per year 
(Björnsson et al., 2013) this is similar to a previous study carried out in France which 
reported an incidence of 13.9 cases of DILI per 100,000 individuals per year (Sgro et al., 
2002). An important caveat to the Icelandic study is that patients with paracetamol 
(acetaminophen, APAP) toxicity were excluded from the total estimate which have been 
shown by other studies to account for nearly half the cases of DILI (Larson et al., 2005). The 
incidence of DILI has been shown to increase in hospital inpatients to 1.4%, approximately 
100-fold higher than in the general population (Meier et al., 2005). 
Concomitantly, unexpected hepatotoxicity discovered post-marketing is the largest single 
cause of drug retractions; between 1953 and 2013, 81 drugs were withdrawn worldwide 
due to hepatotoxicity, 18% of the total number of retractions (Onakpoya et al., 2016), the 
largest proportion followed by immunotoxicity and cardiotoxicity. Drug withdrawals are 
expensive to the pharmaceutical industry, a recent study showed that developing a new 
compound to the point of market approval costs, on average, $2.558 billion, increasing to 
$2.87 billion when post-marketing research and development costs are included (DiMasi et 
al., 2016). These huge sums of money are wasted in the case of toxicity being detected 
post-marketing leading to withdrawal. These figures include the costs of compounds w hich 
were unsuccessful in the development pipeline, highlighting the unsatisfactory nature of 
current toxicity detection techniques at the early stages of drug development which ideally 
should prevent progression of unsuitable compounds to the expensive later stages of 
toxicity testing. 
In addition to the large sums of money wasted on unsuccessful compounds, a great deal of  
time and effort are invested into unsuccessful compounds which could have been more 
effectively used developing other projects had toxicity been detected sooner. Therefore, for 
reasons of cost, resource management and most crucially, health, it is imperative to 
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develop techniques for rigorously detecting hepatotoxicity during the early stages of drug 
development. 
DILI can typically be divided into two classes, idiosyncratic and predictable. Predictable DILI 
is epitomised by the type of toxicity cause by paracetamol overdose. The toxicity is dose -
dependent and occurs in all individuals with sufficient dose. In the case of paracetamol, 
toxicity occurs when the normal detoxification mechanisms are overcome, therefore 
although the toxic dose may differ from person to person due to inter-individual 
heterogeneity, toxicity will always occur with sufficient dose. Under normal conditions, 
paracetamol is metabolised by sulfation and glucuronidation and to a minor extent by 
CYP2E1 and CYP1A2 to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI) 
which is then conjugated and detoxified by the intracellular reducing agent, glutathione 
(GSH). Under conditions of overdose, the intracellular pools of GSH are depleted and NAPQI 
instead binds to cellular macromolecules, leading to dysfunction and eventually necrotic 
cell death. Thusly the characteristic focal necrosis in the pericentral regions of the liver, 
where CYP2E1 is expressed most highly is indicative of paracetamol toxicity.  
On the contrary, idiosyncratic DILI is poorly understood, it does not occur in all individuals  
and does not always follow dose-response patterns, typically occurring at therapeutic levels 
above a certain threshold. Idiosyncratic DILI is rare; thus, it is often difficult to predict in 
clinical trials or preclinical trials. However idiosyncratic DILI is thought to be responsible for 
13% of cases of ALF in the US (Ostapowicz, 2002) and therefore is a major concern. There is 
some evidence that factors such as age, sex and liver disease status can influence the 
occurrence of idiosyncratic DILI (Hussaini and Farrington, 2007), in addition some genetic 
and immune factors appear to predispose an individual (Fontana, 2014; Hussaini and 
Farrington, 2007). 
Specific human leukocyte antigen (HLA)-types can predispose an individual towards 
idiosyncratic DILI. HLA-type refers to the highly polymorphic variants of the gene complex 
which encodes the major histocompatibility complex, a key component of the immune 
system which presents antigen fragments to the innate immune system and is also involved 
in leveraging the adaptive immune system. For example, HLA-B*-5701 predisposes 
individuals to DILI when taking flucloxacillin and also predisposes towards abacavir 
hypersensitivity (Kim and Naisbitt, 2016). Interestingly however, HLA-B*-5701 is only a 
weak positive marker for flucloxacillin toxicity affecting only approximately 1 in 100 
patients with the polymorphism but is strongly predictive of abacavir hypersensitivity. 
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Similarly, HLA-DRB1*16: 01-DQB1*05: 02 increases the incidence of liver injury from 
flupirtine (Daly et al., 2009; Nicoletti et al., 2016). However, despite knowledge of these 
predisposing factors, these toxicities are still classed as idiosyncratic DILI because the toxic 
effects do not manifest in all individuals with the ‘at-risk’ HLA-type. Involvement of HLA-
types in DILI suggest an immune component to idiosyncratic DILI. Typically, although many 
patients may develop symptoms like idiosyncratic DILI, they are very mild (alanine 
aminotransferase (ALT) <3x ULN) and are tolerated out with continued use of the drug, this 
phenomenon is termed clinical adaptation. Current opinion holds that idiosyncratic DILI 
represents a failure of the liver to adapt to the presence of a drug or its metabolite which 
acts as a hapten, stimulating an immune response against the hepatocytes where the 
hapten is produced. 
The role of immune tolerance in idiosyncratic DILI has recently been demonstrated in two 
mouse models firstly by Metushi et al. where transgenic mice with an impaired immune 
tolerance phenotype were treated with amodiaquine producing a slightly greater extent of  
liver injury than immune tolerance-competent mice. Following this experiment, the authors 
tested amodiaquine on wild-type mice producing transient liver injury which resolved with 
clinical adaptation. When PD-1(-/-) mice were treated with both amodiaquine and anti-
CTLA4 (preventing immune tolerance), the liver injury produced was severe and sustained, 
indicating the relevance of immune tolerance to idiosyncratic DILI.  
1.2 Structure of the liver 
The liver is the major hub of xenobiotic metabolism, it responds to a wide variety of 
xenobiotic compounds and attempts to convert them into non-toxic by-products. 
Hepatocytes make up most of the cells in the liver, approximately 80% by mass and 60% of  
the total cell number. They contain many liver-enriched enzymes involved in xenobiotic 
metabolism, most notably transporters and the cytochromes P450 (CYPs). The liver is 
strategically positioned as the first pass organ after absorption from the gastrointestinal 
tract, and therefore receives the highest dose of absorbed xenobiotics. In addition to 
xenobiotic metabolism, the liver is also responsible for secreting serum proteins such as 
albumin and α1-antitrypsin and producing urea. The liver is also implicated in the regulation 
of blood glucose; glycogen is stored and released from the liver under the control of insulin 
and glucagon secreted from the pancreas. 
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The liver is divided into lobes; each of these lobes is made up of smaller lobules which are 
roughly hexagonal in cross-section and fit together in a lattice. Blood enters the lobule 
through the portal triad (periportal region), the blood then flows along the lobule via the 
sinusoid and drains through the central vein (the pericentral region, figure 1). Along the 
sinusoid, hepatocytes are tightly packed together where they perform xenobiotic 
metabolism and other functions during the passage of blood. These hepatocytes exhibit a 
spectrum of phenotypes along the sinusoid specialising in different areas of xenobiotic 
metabolism. For example, expression of CYP2E1, responsible for the metabolism of 
paracetamol and ethanol is restricted to pericentral regions of the liver (Dicker and 
Cederbaum, 1991). This explains the localised pericentral damage seen during paracetamol 
overdose and presents a challenge to in vitro models of drug-induced liver injury where the 
zonation of the lobule is not intact which must nonetheless be able to detect toxicity to all 
zones of the liver. 
Oxygen tension varies across the liver lobule, upon entry blood is highly oxygenated and is 
depleted of oxygen across the lobule. This gradient in oxygen is  functional in determining 
Figure 1 
Diagram of zonation across the liver lobule - Hepatocytes vary substantially depending on 
their location in the liver. For example, the expression of CYP2E1 and glutathione is higher 
in pericentral regions of the liver lobule and lower in the periportal zones which can 
functionally affect cells during paracetamol overdose. The levels of oxygen are higher in the 
periportal zone and decrease as blood flows towards the pericentral zone. This helps drive  
the change in phenotype of the hepatocytes across the lobule. 
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the phenotype of hepatocytes and plays a role in determining the expression of the various 
hypoxia inducible factors that govern this phenotypic change (Kietzmann, 2017). The effects 
of oxygen on the maintenance and differentiation of hepatocytes and hepatocyte -like ce lls 
(HLCs) are poorly understood and will be revisited in chapter 3. 
1.3 Models of Hepatotoxicity 
Currently, a battery of tests and predictions are used to inform the decisions made during 
the drug discovery and development process. These include in silico, in vivo and in vitro 
techniques before compounds are tested in humans. However, these technique s are 
imperfect, in silico models are informed by in vitro and in vivo data and are not entirely 
discriminatory in their identification of toxic compounds. Furthermore, it is difficult to 
ascertain whether false positives are being reported which may lead to unnecessary 
attrition of potentially useful drugs and the results may be difficult to interpret.  
1.3.1 In vivo models 
In vivo models involve the use of animals as surrogate models for humans, typically using 
mice, rats, dogs, mini-pigs or the cynomolgus monkey. The use of animals for research is an 
ethically challenging topic which has been contentious for well over a century (Saffron, 
1975). Because of their similarity to humans, research on great apes has been deemed 
unethical across the EU and they are no longer used for research in the UK or the EU except 
in cases where there is direct benefit to the tested species or in the case of a life -
threatening condition to humans where no other species can be used (Institute of Medicine 
and National Research Council, 2011). Whilst ethical concerns regarding the great apes are 
important, they also represent the closest non-human in vivo model for testing of new 
compounds and the ban of their use forces animal testing to be carried out in lower 
mammals where there are issues with translatability of findings to humans (Hackam, 2007) . 
Despite some issues with translatability, testing in animal models is still required before 
first-in-man studies for a new compound (Committee for Medicinal Products for Human 
Use, 2007) which may be interpreted as confidence in their efficacy. Through initiatives 
such as the NC3Rs based on ‘The Principles of Humane Experimental Technique’ (Russell 
and Burch, 1992) there are drives to replace, refine and reduce animal research, including 
the use of improved and complex in vitro models. 
The drive to reduce the use of animals in pharmaceutical testing is not solely ethical. The 
issues with translatability of findings in animals to humans are challenging. This is well-
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demonstrated in the clinical trials of fialuridine, a nucleoside analogue developed for the 
treatment of hepatitis B which ultimately led to the deaths of 33% of the treated cohort in 
clinical trials with a further 2 patients receiving emergency liver transplants. The toxicity of 
fialuridine was unexpected and animal trials in mice, rats, dogs, and primates were not 
successfully predictive. It has since been demonstrated that the absence of toxicity in 
animal models was likely due to the lack of mitochondrial expression of the nucleoside 
transporter ENT1 which is found in humans but not in the tested animals. This was 
confirmed in studies with TK-NOG mice, which showed hepatotoxicity in response to 
fialuridine but only when the animals had humanised livers (Xu et al., 2014). 
In addition to the fialuridine trial, several other high-profile failures of drugs in first-in-man 
studies demonstrate the inadequacy of animal models to sufficiently predict human 
toxicity. These studies include the TGN1412 trial, where despite the use of  animal studies 
for the novel CD28 ‘superagonist’ and use of a dose 500 times lower than found to be safe 
in animals all six of the patients suffered from cytokine storm and were hospitalised 
(Suntharalingam et al., 2006). Additionally, recent trials for the fatty acid amide hydrolase 
inhibitor BIA 10-2474 were conducted in France, animals studies were not predictive of the 
toxicity observed in first-in-man trials where five patients suffered neurological injuries and 
a sixth died (Moore, 2016). 
1.3.2 In vitro models 
With regards to drug hepatotoxicity, in vitro models use both single cell types and 
combinations  to identify toxic compounds. These models include the use of cancer cell 
lines such as the ubiquitous HepG2 or Huh-7, human primary hepatocytes (hPH) and 
primary hepatocytes from other model species and stem cell-derived models.  
1.3.2.1 Human primary hepatocytes 
Freshly isolated hPH are considered the gold standard in vitro model for predicting 
hepatotoxicity in humans, because of their high metabolic relevance to humans, hPH 
express xenobiotic metabolism enzymes, and transporters at similar leve ls to those found in 
human liver which is necessary to faithfully recapitulate the DILI environment. However, 
hPH have several disadvantages, including scarcity due to the need for donor tissue or 
cadaveric liver, inter-donor variability including expression of cytochrome P450s and 
transporters. For example, CYP2D6 is involved in the metabolism of approximately 25% of 
drugs on the market but is highly variable in the human population (Kroemer and 
Eichelbaum, 1995; Teh and Bertilsson, 2012). Approximately 10% of the Caucasian 
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population are CYP2D6 null and a further 7% are CYP2D6 ultra-rapid metabolisers (Steijns 
and Van Der Weide, 1998; Stüven et al., 1996); this variation can confound repeat studies 
using hPH as it is highly unlikely that several hPH isolations from the same individual will 
occur and thus experimental repeats will use cells with different genetic origin. It is possible 
to cryopreserve hPH so that they may be used on several occasions although the loss of 
mature phenotype and viability which occurs renders the process sub-optimal (Terry et al. ,  
2010, 2006). Furthermore, even though hPH may be cryopreserved, there is a hard limit on 
the number of cells which can be used from any single donor determined by the number of  
cells isolated at the time of tissue donation and since hPH are non-proliferative in vivo, they 
may only be cryopreserved on a single occasion. 
The final issue confounding the use of hPH is dedifferentiation. Dedifferentiation is 
characterised by the progressive loss of mature hepatic characteristics including expression 
of xenobiotic metabolism enzymes and transporters, loss of the characteristic morphology 
and eventually loss of cell viability. Dedifferentiation begins immediately after the liver 
tissue is isolated from the host blood supply. Large scale changes in expression of 
MicroRNAs have been observed in as little as 30 minutes after isolation (Lauschke et al., 
2016). Because of the rapid dedifferentiation of hepatocytes their useful lifespan in vitro is 
typically considered to be only a few days (Rowe et al., 2013). Practically, this means that 
hPH are useful mainly for acute toxicity testing, which is problematic considering that many 
drugs exhibit toxicity only after chronic use. Indeed, idiosyncratic DILI often only presents 
after prolonged use of a drug. 
1.3.2.2 Immortalised cell lines 
Immortalised cell lines are heavily used in toxicity testing. Despite some disadvantages, 
their ease of use and low cost have often made them the in vitro model of choice for 
hepatotoxicity testing. Immortalised cell lines are derived from cancers and have the 
capacity to replicate indefinitely. The capacity for infinite replication in combination with 
other hallmarks of cancer cells (Hanahan and Weinberg, 2011) such as loss of contact 
inhibition and increased proliferation rate make them useful in vitro models for rapid, high-
throughput toxicity screening. 
There are several immortalised cell lines commonly used for hepatotoxicity testing, (HepG2, 
Huh-7 and HepaRG) which are favoured for their ease of use and low cost. They also 
represent a static line that is suitable for experimental repeats and can be expected to yield 
similar results. By contrast, hPH from different donors may produce differing results 
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depending on their gene and protein expression profiles (Gerets et al., 2012). In addition, 
immortalised cell lines may be used for toxicity testing where minimal or no bioactivation is 
required. For example, a recent study showed the utility of HepG2 cells in mitochondrial 
toxicity testing where the metabolic plasticity of Warburgian cells is advantageous 
(Kamalian et al., 2015). 
The lack of physiological relevance to human liver, is the main limitation of all immortalised 
cell lines used for hepatotoxicity testing. It has been shown that the gene expression of 251 
drug metabolising enzymes and transporters of several commonly used hepatoma cell lines 
(including HepG2 and Huh-7) correlated poorly to hPH from 4 donors (Guo et al., 2011) 
although some improvements have been observed in 3D culture, as will be discussed in 
section 1.7. Additionally, the static nature of immortalised cell lines means that they are 
unlikely to show any substantial improvement over time whereas stem cell differentiation 
protocols and protocols for the isolation and maintenance of hPH are dynamic and 
constantly improving. Furthermore, immortalised cell lines represent the phenotype of only 
a single donor which is limiting when considering the low frequency of some genotypes 
susceptible to idiosyncratic DILI in the population. 
1.3.2.3 Stem cell-derived models 
Stem cells are undifferentiated cells capable of differentiating to other cell types; they are 
described based on their capacity to differentiate. Totipotent cells can differentiate into all 
cell types including all germ layers and extraembryonic tissue; only cells in the first few 
divisions after embryogenesis are totipotent. Despite recent controversial reports, 
totipotent stem cells have not been derived from adult cells (Obokata et al., 2014b, 2014a) . 
Pluripotent cells can differentiate into cells of all germ layers. Induced pluripotent stem 
cells (iPSCs) and embryonic stem cells (ESCs) fall under this category. Multipotent cells can 
differentiate towards several cell types but fewer than pluripotent stem cells, for example, 
haematopoietic cells that can differentiate into several blood cell types are considered 
multipotent. 
Embryonic stem cells and pluripotent stem cells are often compared as both are commonly 
used in the field. Embryonic stem cells are derived from the inner cell mass of discarded 
fresh or frozen blastocysts. However, the use of embryonic material is politically and 




Induced pluripotent stem cells (iPSCs) were recently discovered and derived in human cell s 
by the Yamanaka group (Takahashi et al., 2007; Takahashi and Yamanaka, 2006). By 
overexpressing four factors, commonly known as the Yamanaka factors, Oct4, Sox2, Klf2 
and c-Myc, a differentiated cell can be reverted to a pluripotent state. This sidesteps many 
of the confounding ethical issues surrounding the use of embryonic stem cells (ESCs) whilst 
also offering some advantages unique to iPSCs. One such advantage is the ability to use 
most cell types as the starting cell, practically this means the iPSCs can be relatively simply 
derived from easily accessible cells such as fibroblasts or nucleated blood cells. In addition, 
iPSCs can be isolated from individuals with known phenotype. The advantages of this are 
mainly twofold, since cells retain the phenotype of the donor individual through isolation, 
reprogramming and differentiation, cells can be isolated from individuals with a known rare  
phenotype in order to model it in vitro (Raya et al., 2009). Moreover, iPSCs are candidates 
for personalised medicine in the individual from which they were derived, since the y will 
not be recognised as foreign upon transplantation during cell therapy. Once derived, iPSCs 
can be differentiated into any somatic cell type. This is typically achieved by use of a 
differentiation protocol which relies on mimicking the conditions found during 
embryogenesis to produce the desired cell type. These protocols typically take the form of  
sequential addition of growth factors to the culture medium though other techniques can 
also be used such as small molecule mimics of growth factors and environmental triggers. 
Furthermore, the use of iPSCs is advantageous as the donor phenotype is known and can be 
replicated in the resultant cells. This phenomenon has been exploited several times in 
recent years, and several disease modelling iPSC cell lines have been developed (Dimos et 
al., 2008; Ebert et al., 2009; Soldner et al., 2009; Ye et al., 2009). Using gene correction, iPSC 
lines may be effectively ‘cured’ of genetically based diseases. Examples of this approach 
include: Parkinson’s disease, where LRRK2 mutant iPSCs were generated and corrected 
(Nguyen et al., 2011; Reinhardt et al., 2013); α1-antitrypsin deficiency (Yusa et al., 2011); 
congenital erythropoietic porphyria (Bedel et al., 2012) and Fanconi anaemia (Raya et al., 
2009). iPSCs are also advantageous insofar as the risk for immune rejection with 
transplanted cells to the original donor are circumvented. 
Acute liver failure is responsible for many deaths each year and liver- or liver cell transplant 
is often the only curative solution. iPSCs can be differentiated into HLCs and may be useful 
to treat such cases of liver failure. Indeed, humanisation of animal livers has been achieved 
in recent years with human iPSC-derived HLCs (iPSC-HLCs) (Takebe et al., 2014). These ce lls 
were able to rescue animals from otherwise fatal liver damage (Takebe et al., 2014). The 
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use of iPSC-HLCs could also allow for cell transplant without the use of long-term 
immunosuppression and its associated effects and offer an appealing model for toxicity 
testing given their renewable nature and ability to reproducibly model rare phenotypes.  
There is concern that stem cell therapies may pose an oncogenic risk to the recipient. This is 
due not only to the teratoma-forming ability of the undifferentiated cells but also due to 
possible accumulation of mutations in the culture of iPSCs. The rate of mutations in iPSCs is 
incompletely understood, one study indicated that around half of the 6-12 mutations found 
in protein coding genes over extended iPSC culture were synonymous and that of the 
remaining mutations, no enrichment in cancer-causing genes was observed (Cheng et al., 
2012). Whilst other groups have found that iPSC rapidly accumulate significant mutations in 
culture such as the gain of 20q11.21, a large duplication that appears to confer a survival 
advantage to the cells in vitro by increased expression of the anti-apoptotic gene, BCL-XL 
(Nguyen et al., 2014). 
The mRNA and miRNA profiles of hESCs differs from the profiles of iPSCs and the 
differentiation propensity of early-passage iPSCs is reported to be skewed in favour of  the 
cell type of origin. However, this bias towards the original cell type appears to be lost with 
Figure 2 
Schematic of gene correction in iPSCs derived from a diseased patient – Replacement of 
disease-causing genes is possible using genetic techniques. Since iPSCs maintain the 
phenotype of the donor from which they were derived it is possible to correct the defect 
and produce non-disease cells in vitro. Eventually, it may be possible to transplant non-
diseased cells of matching genotype into diseased patients once key safety concerns have 
been addressed. 
Replacement or removal of disease-
causing gene or knock-in of missing or 
non-functional gene 
e.g. A1AT deficiency, Fanconi anaemia 
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increased passage number. A recent study in our laboratory comparing the differentiation 
propensity of iPSCs towards iPSC-derived HLCs derived from donor-matched fibroblasts and 
hepatocytes found no inherent advantage conferred by deriving iPSCs from the same cell 
type as the target differentiated cell (Heslop et al., 2017).  
iPSCs may be derived from any mature nucleated cell through overexpression of four 
transcription factors known as the Yamanaka factors: Oct4, Sox2, Klf -2 and c-myc. This 
technique was pioneered by the Yamanaka group in 2006, first in mice (Takahashi and 
Yamanaka, 2006) and subsequently in humans (Takahashi et al., 2007). Many methods of 
delivery have been assessed to produce iPSCs ranging from integration of additional copies 
of the genes to direct transfection of the proteins. These methods can largely be divided 
into two groups, integrative and non-integrative methods where the integrative methods 
rely in the integration of the chosen pluripotency factors into the genome of the cell. 
Integrative methods are generally more efficient than their non-integrative counterparts 
but come with the caveat that the cells are being genetically modified, this can cause 
disruption to the cell’s normal functions and is an oncogenic risk. This concern is 
heightened by the integration of potent oncogenes such as c-Myc and in sum, means that 
iPSCs produced by integrative methods are not considered suitable for use in cell therapies 
in humans due to concerns of tumorigenicity. 
By contrast, non-integrative methods are generally more inefficient than their integrative 
counterparts, sometimes by a large margin but they are advantageous insofar as that no 
genes are integrated into potentially oncogenic or otherwise potentially dangerous 
positions in the genome. Non-integrative methods include non-integrating or replication 
deficient viruses such as Sendai virus and direct transfection with RNA molecules or 
proteins to effect pluripotency (Gonzalez et al., 2011). PSCs produced by these methods are 
considered suitable for cell therapies. 
Stem cells are undifferentiated, that is, they are not committed towards any mature cell 
fate. This is similar to the cells found in the embryo during the very early periods of 
development prior to gastrulation where the three germ layers are formed. Directed 
differentiation of stem cells is a process which aims to mimic embryogenesis in vitro to 
produce a mature cell fate. Crucially, unlike embryogenesis, a directed differentiation 
protocol typically aims to produce only a single cell type rather than a whole organism. 
During differentiation, cells are directed through a series of developmental checkpoints 
which correlate to stages of embryogenesis. For example, when producing hepatocyte like  
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cells, definitive endoderm is the first checkpoint the cells reach followed broadly by hepatic 
endoderm and subsequently HLCs. The cells are guided through these checkpoints by timed 
sequential addition of growth factors. The focus of chapter 3 and will be in the generation 
of HLCs from iPSCs or ESCs. There are a range of protocols that have been developed over 
the past decade to produce HLCs, some of which are summarised below and in Table 1. 
Early differentiation protocols used embryoid body formation to produce HLCs, wherein 
undifferentiated cells are allowed to form clusters and differentiate spontaneously 
(Itskovitz-Eldor et al., 2000). However, this approach is now uncommon with most 
differentiations being initially performed in monolayer culture. The stochastic nature of 
non-directed differentiation of HLCs leads to unsatisfactory reproducibility and purity of the 
resultant cells. Early experiments with embryoid body formation showed the capability  of 
ESCs to produce HLCs in vitro (Hamazaki et al., 2001) and in vivo (Choi et al., 2002). 
Early directed differentiation protocols used a single stage to induce hepatic differentiation; 
for example, the addition of sodium butyrate to hESCs, resulted in 10-15% purity of HLCs 
(Rambhatla et al., 2003). Shirahashi et al. showed 20% FBS, human insulin and 
dexamethasone plated on collagen-I, improved albumin synthesis in human and murine 
ESCs (Shirahashi et al., 2004). Schwartz et al. showed that addition of FGF4 and BMP2 in 
embryoid bodies plated on collagen-I improved expression of several mature hepatic 
markers including albumin, HNF1 and several CYP enzymes amongst others (Schwartz et al., 
2005). 
Multi-stage differentiation protocols are currently the commonly used type of protocol, 
which as previously described involves directing cells towards several developmental 
checkpoints during differentiation, mimicking embryogenesis. Teratani et al. demonstrated 
an early multi-stage directed hepatic differentiation in similar format to those currently in 
murine embryonic stem cells and used leukaemia inhibitory factor and retinoic acid in cells 
cultured on gelatine followed by HGF, FGF1 and FGF4 in ESM on gelatine followed by 
oncostatin M (OSM) on collagen (Teratani et al., 2005). This protocol demonstrates the 
general format of HLC differentiation protocols commonly used today, though the exact 
details and growth factors vary greatly and have been refined over the past decade. A 







Notable findings Cell 
type 
Culture format Differentiation factors 
Chien et al., 2015 hPSC 
Co-culture with 
MEF, EB formation 
AA, FGF4, BMP2, HGF, 
KGF, OSM, DEX, 
miR122 
─ 
Improvement in hepatic phenotype when miR-122 used in 
differentiation in 3D. Increased expression of AFP,  
CYP2E1, CYP3A4. Improved Urea secretion and LDL 
uptake. 
Zhang et al., 2014 hPSC Nanopillar 
AA, FGF2, BMP4, OSM, 
HGF, Dex 
>80 Protocol paper. Spheroid size examined. 





AA, Wnt3a, FGF2, 
FGF4, HGF, Follistatin 
80 
AFP, ALB, CX32, ARG1, HNF4A, FVII, ASGPR-1 and PEPCK 
significantly increased in 3D. Increased and sustained 
albumin secretion in 3D vs. 2D. 






aFGF, HGF, OSM, Dex 44-60 
Earlier expression of Albumin and G6P in 3D. Increased 
AFP and urea production in 3D vs. 2D 
Pettinato et al., 
2016 
hPSC 
Embryoid bodies in 
agarose microwells 
FGF2, AA, TGF-ß. 
FGF4, BMP4. WIF-1, 
DKK-1. HGF, OSM. 
80 
Novel use of wnt inhibitors. Increased albumin, AFP and 
fibrinogen secretion and in intracellular urea 
concentration with inhibitor. ALB CK18 CYP1B1, 2C9, 2B6 
3A4, 3A7 and 1A2 expression increased with inhibitor use. 
Gieseck et al., 2014 hPSC RAFT 




Improved phenotype in 3D culture. Increased expression 
of CYP3A4, ABCC2, UGT1A1 and decreased expression of 
AFP and CYP3A7. 
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HGF, FGF4. OSM, Dex 47.23-68.19 
Comparison of synthetic scaffolds: dextran–gelatin, 
chitosan–hyaluronic acid and gelatin–vinyl acetate. 
Reduced AFP expression and increased HNF4a, ALB, G6P 
α1AT in 3D 





AA, FGF2. FOXA2, AA, 
FGF2. FOXA2, HNF1α, 
HGF, FGF1, -4 & -10. 
HGF, OSM, FGF4, Dex. 
- 
Increased ALB, CYP1A1, CYP1A2, CYP3A7, CYP2B6, CYP2C8, 
CYP2C19 CYP2E1, UGT1A1, UGT1A3, GSTA1, MDR1, BCRP, 
MRP2, SLCO1B3, SLCO2B1, NTCP, OCT1, OAT2, ABCB4, 
ABCC3 ABCC6, AhR, CAR, PXR and PPARα in 3D vs. 2D 
Leclerc et al., 2017 hPSC Biochip with flow 
AA. FGF2, BMP4. HGF, 
OSM. 
- 
Increased HIF, HNF4α, CD144, CD31, ALB, CYP3A4 and 
CYP1A2 in 3D vs. 2D 






EGF, FGF2. HGF, FGF2, 
FGF4, DMSO. OSM, 
Dex, DMSO. 
- 
Increased AFP, CYP3A4, urea production and glucose 
consumption in 3D. 
Takayama et al., 
2017 
hPSC Monolayer 
FGF2. AA. BMP4, 
FGF4. HGF, EGF, HGF. 
OSM. 
99.997 
Used sequential laminin basement layer to generate highly 
purified HLCs 
Siller et al., 2015 hPSC Monolayer 
CHIR99021. DMSO. 
Dihexa, Dex 
83.2-91.0 Use of small molecule-based protocol to generate HLCs 
Heslop et al., 2017 hPSC Monolayer 
AA, WNT3a. DMSO. 
HGF, OSM, Dex. 
- 





Hepatocyte-like cell differentiation protocols – differentiation protocols using both 2D and 3D culture techniques. This summary highlights the similarities 
between protocols in recent years. Generally, the use of growth factors has remained constant, e.g. AA, HGF, OSM, HGF et c. Other alterations to 
differentiations protocols have produced the largest changes seen in recent years such as the movement towards 3D cultures an d the use of advanced 
basement matrices such as laminins allowing for greater purity in differentiated cells. Starting cell type and culture conformation and major growth factors 
used are shown. Differentiation efficiency is shown if reported. Abbreviations:   AA - Activin A, aFGF - Acidic fibroblast growth factor, AFP - Alpha 
foetoprotein, ALB - Albumin, ARG1 - Arginase 1, ASGPR-1 - Asialoglycoprotein receptor 1, BMP2 - Bone morphogenic protein 2, CX32 - Connexin 32, CYP - 
Cytochrome P450, DEX - Dexamethasone, DKK-1 - Dickkopf-related protein 1, DMSO - Dimethyl sulfoxide, EB - Embryoid body, EGF - Epidermal growth 
factor, FGF2 - Fibroblast growth factor 2, FGF4 - Fibroblast growth factor 4, FVII - Factor 7, G6P - Glucose 6-phosphate, hESC - Human embryonic stem cell, 
HGF - Hepatocyte growth factor, HLC - Hepatocyte-like cell, hMSC - Human mesenchymal stem cell, HNF4a - Hepatocyte nuclear factor 4α, hPSC - human 
pluripotent stem cell, KGF - Keratinocyte growth factor, LDL - Low density lipoprotein, MEF - Mouse embryonic fibroblast, OSM - Oncostatin M, PEPCK - 
Phosphoenolpyruvate carboxykinase, RAFT - Real Architecture for 3D tissues, TGF-B - Transforming growth factor β, UGT - Uridine 5'-diphospho-
glucuronosyltransferase, WIF-1 - Wnt inhibitory factor 1 
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Although HLCs can now be differentiated in large numbers with acceptable purity there are still 
caveats to their use as models of hepatic toxicity. The primary disadvantage encumbering their use is 
their lack of functional maturity when compared with hPH in terms of expression of xenobiotic 
metabolism enzymes and transporters necessary for recapitulation of hepatic toxicity. Though 
improvements have been reported, there is still no catch-all protocol for producing HLCs with 
functional maturity to match hPH. Various attempts have been made to improve maturity of HLCs in 
addition to various combinations of cytokines, some of which will be discussed in the following 
paragraphs. 
One such attempt to improve maturity of iPSCs utilises miR-122, a highly-conserved and hepatocyte-
enriched microRNA that has been shown by several studies to improve the diff erentiated status of 
HLCs when overexpressed in stem/progenitor cells (Chien et al., 2015; Davoodian et al., 2014; Deng 
et al., 2014; Doddapaneni et al., 2013). Conversely, removal of miR-122 prevents hepatocytes 
forming from hepatoblasts in zebrafish (Xu et al., 2013) and the loss of miR-122 in liver cancer is 
correlated with the loss of the mature hepatic phenotype (Coulouarn et al., 2009). 
A recent study delivered miR-122 complexed with PU-PEI (polyurethane-graft-short-branch 
polyethyleneimine copolymer in nanostructured amphipathic carboxymethyl-hexanoyl chitosan), to 
iPSCs and enhanced the maturation of iPSC HLCs. The miR122-iPSC HLCs expressed higher levels of 
gene and protein markers for hepatic function compared to miR-scrambled-iPSC HLCs including 
increased expression of CYP2E1, CYP3A4 and AFP and enhanced LDL uptake and urea secretion 
(Chien et al., 2015). 
Shan et al. identified small molecules classed as functional and proliferative hits via high-throughput 
screening using hPH co-cultured with fibroblasts (Shan et al., 2013). Two of these compounds, FH1 
and FPH1, were able to improve longevity and induce proliferation of typically non-replicative hPH in 
ex vivo culture. These compounds also showed promise in iPSC differentiation leading to an 
increased tendency to differentiate towards the hepatic lineage and exhibiting improved phenotypic 
maturity with improved albumin expression and phase I-III enzyme expression comparable to hPH, 
notably, BSEP was reported to reach equal levels to those found in hPH. These results are promising 
improvements to the phenotype of iPSC-HLCs (Shan et al., 2013). 
Avior et al. hypothesised that the acquisition of some mature hepatic characteristics in foetal 
hepatocytes is driven by the change in nutrition source and exposure to gut flora in neonates. 
Lithocholic acid and vitamin K2 have been shown to induce PXR and CAR expression and were 
investigated in this study for their potential to drive the maturation of ESC-HLCs. When added to 
differentiating ESC-HLCs, lithocholic acid and vitamin K2 were shown to improve the expression of 
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CYP2C9 and CYP3A4 and increase the ability of the ESC-HLCs to correctly predict toxicity in known 
hepatotoxins (Avior et al., 2015). These results demonstrate the importance of a broad 
understanding of the physiological changes that drive liver maturation in vivo and suggest that 
environmental cues should also be considered for differentiation protocols.  
Similarly to environmental cues, it is also important to consider the culture environment of stem 
cells. ESCs and iPSCs are commonly cultured on mouse embryonic f ibroblasts (MEFs) or Matrigel, 
however both culture techniques rely on animal-derived components and are not ideal for the 
culture of human cells. Therefore, alternative culture matrices have been investigated including 
laminins and several attachment glycoproteins such as vitronectin and fibronectin. If stem cells are 
to be used in large-scale applications such as drug toxicity testing or in cell therapies, it is important 
to consider the challenges in production of a large number of cells whilst resisting  spontaneous 
differentiation. Techniques such as those described here may help increase the stability of iPSCs and 
ESCs in culture. 
Laminins are highly specific cell-adhesion proteins expressed at certain developmental stages of 
embryonic development. Their use as a basement matrix has been shown to improve cell 
proliferation in iPSCs but not ESCs (Lam and Longaker, 2012). Several laminin isoforms including 
laminin (LN)-511, -521 and -332 have been investigated as basement matrices for ESCs or iPSCs. The 
specificity of laminins arises from the expression pattern of integrins on the cell surface, laminins 
have an α and a ß subunit. Miyazaki et al. showed the dominant integrin subunits in hESCs were α6 
and ß1 which bound most strongly to LN-332 which could be used as a basement matrix whilst 
retaining pluripotency (Miyazaki et al., 2008). Similarly, Rodin et al. used LN-511 alone and LN-521 in 
combination with E-cadherin both of which are also dependent on integrin α6ß1, to culture hESCs 
and hiPSCs. In the case of LN-511 hESCs and hiPSCs were cultured for 4 months without loss of 
pluripotency or abnormal karyotype (Rodin et al., 2010). The combination of LN-521 in combination 
with E-cadherin was sufficient for the long-term culture of hESCs without the use of ROCK inhibitors 
(Rodin et al., 2014). Additionally, Takayama et al. recently demonstrated a differentiation protocol 
for the highly efficient production of HLCs by changing the laminins used over the differentiation 
protocol, initially, a mixture of LN111 and -511 was used which was then replaced with LN-111 
alone, followed by LN-111 and collagen IV (Takayama et al., 2017). These results demonstrate the 
utility of laminins in stem cell culture to control the type of cells present in culture, due to the 
specificity of laminins to certain tissue types they will be useful either in the maintenance of 
undifferentiated cells or the purification of cells during differentiation.  
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Vitronectin and fibronectin are cell-attachment proteins which, similarly to laminins, interact with 
integrins. Both have been investigated as potential basement matrices to support the 
undifferentiated growth of ESCs and iPSCs. Fibronectin, whilst able to support the growth of iPSCs 
and ESCs by attachment to the α6ß1 integrin, when compared with Matrigel and laminins was 
shown to be inferior in term of cell attachment and proliferation (Lam and Longaker, 2012). 
Vitronectin has shown promise in several studies as a defined substrate to support the growth of 
ESCs and iPSCs, attaching to cells by the αVß5 integrin and supporting growth and proliferation 
(Braam et al., 2008; Rowland et al., 2010). 
1.4 Modulation of oxygen concentration in stem cell cultures 
In addition to basement matrix, the amount of oxygen in the culture environment has been shown 
to be important for the undifferentiated maintenance of stem cells. Indeed, hypoxic conditions are  
necessary for the early stages of mammalian embryo development (Dunwoodie, 2009). 
Directed ESC or iPSC differentiation protocols aim to closely mimic the conditions found during 
embryonic development in order to produce cells as close as possible to their in vivo counterparts. 
During development the concentrations of oxygen available to the developing embryo are 
considerably lower than to cells cultured in atmospheric oxygen levels, typically  between 1.5-5.3% 
(Badger et al., 2012). Moreover,  the concentration of oxygen is known to vary across the liver lobule  
from 30-65 mmHg O2 and influences the phenotypic difference between periportal and perivenous 
hepatocytes (Kietzmann, 2017). 
Hepatotoxicity is often exacerbated by the metabolic enzymes enriched in the liver, a prime example 
of which is the metabolism of paracetamol to NAPQI, its reactive metabolite, predominantly by 
CYP2E1. Since the expression of CYP2E1 and other metabolic enzymes is enriched in the pericentral 
zone, this hepatocyte phenotype may be of more interest in hepatotoxicity  testing than that of a 
periportal hepatocyte which deal more with other hepatic functions.  
In addition to differentiation of stem cells, expansion and long-term maintenance can be 
challenging. Stem cells often differentiate spontaneously during culture and hypoxic conditions have 
been shown to reduce the occurrence of this (Ezashi et al., 2005; Prasad et al., 2009). Hypoxic 
conditions appear to increase ‘stemness’ in many types of stem cell cultures including dental pulp, 
mesenchymal, embryonic, pluripotent, and tendon-derived stem cells (Ahmed et al., 2016; Badger et 
al., 2012; Ejtehadifar et al., 2015; Forsyth et al., 2006; Zhang and Wang, 2013) . In this case, an 
increase in stemness refers to an increased tendency for stem cells to divide without differentiating 
and show increased expression of pluripotency markers such as Sox2, Nanog and Oct4.  The increase 
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in ‘stemness’ has been shown to be related to an increase in notch signalling under hypoxic 
conditions. Moreover, hypoxic culture has been shown to reduce the spontaneous differentiation 
associated with long-term culture of ESCs (Ezashi et al., 2005) and to reduce the burden of oxidative  
stress and the incidence of chromosomal aberrations which are associated with protracted stem cell 
culture (Forsyth et al., 2006). 
Oxygen concentration has also been shown to modulate the way in which ESCs attach to their 
basement matrix. Kumar et al. showed that αVβ5 (the integrin mainly responsible for attachment to 
vitronectin) and CD44 (responsible for hyaluronic acid attachment) were shown to be modulated by 
oxygen and that ESCs switched under hypoxic conditions. 
1.5 Complex Hepatic Models Including iPSC-HLC models 
Advances in complex culture systems seem likely to improve the application of iPSCs in drug safety 
assessment. Previous studies have compared conventional 2D monolayer culture with complex 3D 
and co-culture systems for phenotype and functionality. Compared to 2D, 3D or co-culture systems 
generally produce more physiologically relevant characteristics including: better inflammatory 
pathways with cytokine profiles in response to toxins more similar to those found in vivo (Cantòn et 
al., 2010); better xenobiotic metabolism capacity including increased expression of xenobiotic 
metabolism enzymes and albumin (Bokhari et al., 2007; Elkayam et al., 2006), and formation of more 
in vivo-like cell morphology, polarisation and organisation (Bissell et al., 2002; Liu et al., 2004). These 
characteristics were achieved by recreating a physiological microenvironment (heterogeneous cell 
types, spatial architecture, mechanical and chemical composition of extracellular matrices) which 
improves cell-cell and cell-extracellular matrix interactions, and restores molecular and stromal 
signaling (e.g. cytokines, integrin, adhesion molecules) (Astashkina and Grainger, 2014). 
The interaction of hepatocytes with other non-parenchymal cells such as Kupffer cells, endothelial 
cells and stellate cells is crucial to maintaining the pharmacological responses of the liver. Non-
parenchymal cells activate inflammatory pathways and the release of growth factors and reactive 
oxygen species in response to toxins; therefore, they are important for inducing and regulating DILI.  
Efforts have been made to develop complex culture systems, with the aim of maintaining hepatic 
cells for longer in vitro without significant depletion of the normal hepatocyte functions (Roth and 
Singer, 2014). Examples of these culture approaches include micropatterning (Zeng et al., 2007), 
spheroid culture (Fey and Wrzesinski, 2012; Ohkura et al., 2014; Takayama et al., 2013; Wang et al., 
2015), bioreactors (Caralt et al., 2014; Shafa et al., 2012) and culture incorporating flow (Clark et al., 




Co-culture models combine multiple cell types in the same system, initially these experiments were 
performed in 2D transwells where the cells are separated by a permeable membrane  but have since 
been combined with 3D-culture (Lan and Starly, 2011; Nagamoto et al., 2012). hPH co-cultured with 
non-parenchymal cells such as Kupffer cells showed improved function (Rose et al., 2016). 
Micropatterned co-culture (MPCC) has been developed with the intent of producing a stable and 
functional hepatic model for drug screening. hPHs were seeded into a micropatterned extracellular 
matrix and surrounded by fibroblasts. This culture system maintained the hepatic phenotype and 
functions including enzyme activity, gene expression, and albumin secretion for up to 6 weeks and 
was supportive of hepatitis C viral infection, Plasmodium falciparum and P. vivax life cycles (Khetani 
and Bhatia, 2008; March et al., 2015). 
Recently, iPSC-HLCs were shown to have better predictivity of hepatotoxicity in MPCC than in 
conventional culture, with sensitivity and specificity comparable to hPH (Ware et al., 2015). iPSC-
HLCs in MPCC were treated with 47 drugs (37 known hepatotoxicants and 10 non-liver toxicants). 
IC50 values (concentration that decreased the measured endpoints by 50%) for assays of albumin, 
urea and ATP were used for binary decisions of toxicity. iPSC-HLCs in MPCC had 65% sensitivity for 
hepatotoxicants (24 out of 37) compared with hPH-MPCCs at 70% sensitivity and 35% in 
conventional culture. Nagamoto et al. showed improved maturation of iPSC-HLCs with upregulation 
of CYP gene expression and albumin secretion when co-cultured with murine fibroblasts and 
collagen-I where an intact sheet of fibroblasts was overlaid onto the HLCs (Nagamoto et al., 2012). 
Recently, Takebe et al. produced liver buds consisting of human iPSCs differentiated towards hepatic 
endoderm in combination with human umbilical vein endothelial cells and mesenchymal stem cells 
(Takebe et al., 2014). The liver buds were transplanted into NOD SCID mice where they integrated 
into the vasculature of the animal and showed characteristics of mature hepatocytes. These results 
show the importance of the complex signaling cues present in vivo to the maturation of iPSC-HLCs. 
These cues are largely unknown and are therefore difficult to replicate in vitro though their 
replication may lead to an improved phenotype for iPSC-HLCs. 
1.7 3-Dimensional culture 
Traditional cell culture is performed in 2-dimensional (2D) plates where the cultured cells are 
allowed to spread flat. Three-dimensional (3D) culture attempts to better mimic in vivo conditions by 
allowing formation of microtissues. 3D culture techniques vary widely but can be broadly divided 
into the scaffold-based techniques and scaffold-free techniques. Scaffold-based techniques use a 
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matrix for the cells to adhere to, these scaffolds may be either biological or synthetic in nature and 
each provides certain advantages and disadvantages. With scaffold-based techniques, cells are 
mechanically held together and develop cell adhesion over time. Scaffold-free techniques do not 
include a scaffold for the cells to attach to, instead relying on the deposition of extracellular matrix 
from the cells and the formation of cell-cell junctions. 
The use of biological-scaffold based 3D-culture for hepatic models has been attempted in several 
studies. For example, recently hESC-HLC spheroids were produced using an algimatrix scaffold. 
hESCs were differentiated in monolayer culture to definitive endoderm and transferred to 3D 
algimatrix scaffolds (Ramasamy et al., 2013). Spheroids of varying size were formed, with size 
dependent on seeding density. These spheroids showed improved expression of differentiation 
markers and maturation such as apolipoprotein F, tryptophan dioxygenase, and CYP3A4 compared 
with 2D differentiation. In addition, spheroids have been produced using the HepG2 cell line 
embedded in Matrigel. These spheroids appeared to improve the maturation status of the HepG2 
cells, producing rudimentary bile canaliculi inducing cell polarity and modestly increasing expression 
of some xenobiotic metabolism enzymes and transporters including CYP2E1, -1A2 and -2D6 and 
UGT1A1 -2A3 and -2B4 amongst others. The spheroids also showed increased expression of albumin, 
AhR and PxR (Ramaiahgari et al., 2014). 
Another biological scaffold-based approach has been used in the generation of regenerative liver 
organoids from EpCAM positive hepatic progenitor cells. These cells were embedded in BME2 matrix  
to form organoids which could be differentiated to both the hepatic and biliary lineages (Broutier et 
al., 2016; Huch et al., 2015). This is an interesting model of liver regeneration in vitro which may help 
to alleviate the scarcity of highly functional liver cells that previously, only hPH could provide. 
Gieseck et al. reported an improvement in cell maturation by transferring fully differentiated iPSC 
HLCs in 2D culture to the proprietary Real Architecture for 3D Tissues (RAFT) system as single cells or 
small epithelial clumps (Gieseck et al., 2014). RAFT creates cell-seeded hydrogels by mixing cells with 
neutralised collagen in a 96-well format. Compared to 2D culture, cells in 3D clumps showed a more 
hepatocyte-like gene profile of hepatic markers and CYP3A4 activity was maintained for 75 days. 
Polarisation and bile canaliculi formation were also induced in 3D clump culture, highlighting the 
importance of maintaining cell-cell interactions for the hepatic phenotype. 
Decellularised tissues are perhaps the most ambitious type of biological scaffolds. They aim to 
remove the cells from donor tissue to leave an extracellular matrix scaffold. This scaffold is then 
repopulated with cells from another source, such as HLCs (Bao et al., 2016). In combination with 
spheroid culture prior to seeding the scaffold, decellularised scaffolds were shown to improve 
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secretion of albumin and urea when compared to 2D or scaffold-free culture and also increased 
expression of several hepatic genes including CYP1A1, CYP1A2, Albumin and AFP in HLCs (Bao et al. ,  
2016). 
The alternative to scaffold-based culture techniques is scaffold-free culture. Many studies have 
utilised scaffold-free techniques to produce hepatic spheroids. These techniques typically rely on the 
use of specialised cell culture equipment including ultra-low attachment plates, micropatterned 
plates and hanging drop plates. The cells are then left to self -aggregate forming cell-cell links and 
depositing their own ECM. 
Ultra-low attachment plates have an inert, hydrophilic and neutrally-charged coating which prevents 
cell attachment, forcing cells to form 3D structures. This technique is advantageous due to its 
relatively low cost and ease of use but has disadvantages in that the size of spheroids may only be 
controlled by the number of cells added to the well limiting the total number of spheroids that can 
be produced simultaneously. Spheroids have been produced using ultra-low attachment plates from 
a plethora of cell types including hPH (Bell et al., 2016; Hendriks et al., 2016), iPSC-HLCs 
(Subramanian et al., 2014) and cancer cell lines (Hutchinson and Kirk, 2011). 
Nanopillar or micropatterned plates are other methods that have been used to generate hepatic 
spheroids. Nanopillar plates were first developed in 2004 and use a microscale architecture to direct 
cell attachment and enable the simultaneous production of many spheroids of equal size (Otsuka et 
al., 2004). Initially, rat primary hepatocytes (rPH) were used to demonstrate the formation of 
spheroids in these plates showing albumin secretion at consistent levels for one month (Otsuka et 
al., 2004). Nanopillar plates have subsequently been used in the formation of hepatic spheroids and 
have been shown to improve hepatic functions and more closely recapitulate hepatocyte polarity 
when compared with 2D culture (Fukuda et al., 2006; Takahashi et al., 2010). 
Recently, Takayama et al. used nanopillar plates in differentiation of ESC- and iPSC-HLCs to improve 
the maturity of the hepatic phenotype in the resultant spheroids (Takayama et al., 2013). These 
spheroids exhibited improved albumin secretion and expression of metabolic enzymes and 
transporters including CYP1A1, CYP1A2, CYP2E1, MDR1 and others. Furthermore, iPSC-HLCs in 
spheroid culture were shown to have increased sensitivity when compared with HepG2 spheroids to 
several known hepatotoxicants including nefazodone, clozapine, amiodarone and dantrolene 
amongst others. Similarly, Zhang et al. used micropatterned plates which utilised small cavities in 
place of nanopillars to produce iPSC-HLC spheroids which exhibited an improved hepatic phenotype 
when compared with 2D culture (Zhang et al., 2014). The 96-well (or higher) format of 
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micropatterned plates makes them amenable to high-throughput screening a sought-after property 
in novel hepatic models. 
Tong et al. recently developed a novel approach to incorporating flow into hPH spheroid models. 
Using a glass coverslip and a membrane treated with polyethylene glycol they were able to 
immobilise spheroids. The authors report that constraining the spheroids reduced the loss of the 
cells during medium changes and improved their phenotype relative to collagen-sandwich culture. 
Perfused constrained culture produced an increase in CYP2B1/2 and CYP3A2 activity and CYP1A2 
was increased in constrained culture regardless of the incorporation of flow (Tong et al., 2016). 
In summary, these studies demonstrate the importance of 3D architecture in the maturity and 
stability of hepatic cell models. This is unsurprising given the increased similarity to physiological 
conditions which 3D models can reproduce which 2D models cannot.  
1.8 Organoids 
The liver is highly regenerative, capable of reforming liver mass even after extensive hepatectomy. 
The mechanisms surrounding this regeneration are incompletely understood, though it is thought 
that two major mechanisms exist to repopulate the hepatocytes after damage. In the case of  acute 
damage such as hepatectomy, the hepatocytes are induced to re-enter the cell cycle and rapidly 
produce more hepatocytes, this mechanism of hepatocyte regeneration has been demonstrated in a 
recent lineage tracing experiment and is thought to be the homeostatic mechanism by which 
hepatocytes are produced (Yanger et al., 2014). The secondary method relies on the liver resident 
stem cells known as the oval cells, which are thought to be found at the tips of the biliary tree. The 
existence of these cells has been the subject of some debate though recent studies have 
demonstrated their function. The oval cells are bipotent progenitors capable of producing both 
cholangiocytes and hepatocytes in the ‘oval cell response’  (Huch et al., 2015). The oval cell response 
is activated after chronic damage to all hepatocytes in the liver. Until recently, these proliferative 
responses were not reproducible in vitro, however, the recent development of organoid cultures has 
enabled their recapitulation. 
Organoids are 3D cell models that form several organ-specific cell types and self-organise into in 
vivo-like structures. Though organoids are sometimes likened to spheroids, they differ in terms of 
their derivation and structure. Organoids may be produced from organ-resident or pluripotent stem 
cells, for example, LGR5+ cells have been used recently in the generation of intestinal and hepatic 
organoids (Huch et al., 2015; Sato et al., 2009). Organoids are thought to be more genetically stable 
than PSCs and are also able to recapitulate donor phenotype in a similar manner. For example, α1-
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antitrypsin deficiency and Alagille syndrome have both been modelled using hepatic organoids 
(Huch et al., 2015). 
Liver organoids were first produced in 2013 by Huch et al. by expansion of LGR5+ cells in the murine 
liver, hollow cyst-like structures of epithelial cells were formed (Huch et al., 2013). These cells were 
found to be part of the liver’s regenerative response and were cultured for more than 12 months, by 
administration of a differentiation medium containing EGF, FGF10, A38-01 and DAPT cells were 
directed towards a more hepatocyte-like fate showing expression of several mature hepatic markers 
including albumin and cytochromes P450. These were not expressed at levels equal to those found 
in hPH, moreover, not all the cells differentiated towards a hepatocyte fate with approximately 10% 
of the cells adopting a biliary fate instead. Nonetheless, these cells were able to engraft in Fah 
deficient mice and form functional hepatocytes and reverse otherwise fatal liver damage (Huch et 
al., 2013). 
The same group later published a detailed protocol of a similar procedure in mice and humans, 
showing the process to isolate organoids from bile duct cells (Chol-Orgs) (Broutier et al., 2016; Huch 
et al., 2015). This protocol aimed to exploit the oval cell response to produce a mixed population of 
cholangiocytes and hepatocytes and utilised a similar differentiation technique as before to produce 
hepatocytes which could be used in transplant or toxicity testing. Moreover, these organoids were 
demonstrated to recapitulate the phenotype of the donor in vitro, in this case, the authors used α1-
antitrypsin deficiency and Alagille syndrome as model conditions to demonstrate this effect (Huch et 
al., 2015). This is significant as this attribute has previously been associated mainly with traditional 
stem cell model such as iPSCs. Further still, these organoids were shown to be genetically stable, 
particularly compared with iPSCs which are regarded as unstable in comparison. Liver organoids 
showed fewer de novo base substitutions in vitro (63-139) than had previously been reported for 
iPSCs (1,058-1,808) over a similar period in culture (Huch et al., 2015). 
In 2018, the Clever’s group published a new protocol for the generation of organoids from human 
hepatocytes instead of cells from the biliary tree (Hu et al., 2018). This protocol was intended to 
capture the hepatocyte proliferation response that is thought to be the homeostatic method of 
hepatocyte regeneration. The new technique uses isolated hepatocytes embedded in a Matrigel 
matrix which are induced to proliferate using an optimised hepatocyte organoid (Hep-Org) medium 
(Advanced DMEM/F12 supplemented with: RSPO1, B27 (without vitamin A), EGF, N-acetylcyste ine, 
gastrin, CHIR99021, HGF, FGF7, FGF10, A83-01 and Nicotinamide). These organoids were 
morphologically distinct from cholangiocyte organoids, displaying a compacted bunch-of-grapes 
morphology instead of a cystic one. Hep-Orgs demonstrated a superior hepatocyte phenotype to 
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Chol-Orgs with greater expression of AFP, Albumin, HNF4a, CYP1A2 and CYP3A11 though not to the 
same level as hPH. Conversely, Chol-Orgs showed greater expression of cholangiocyte markers such 
as CK19 than either Hep-Orgs or hPH. Hep-Orgs clustered more closely with proliferating hPH than 
nonproliferating hPH, suggesting recapitulation of the hepatocyte expansion response, indeed 
experiments with mice with tagged hepatocytes demonstrated that the organoids arose solely from 
mature hepatocytes. Similarly to Chol-Orgs, Hep-Orgs were also capable of repopulating the murine 
liver following injury and proliferating therein (Hu et al., 2018). 
Organoids are typically cultured in domes of a gel matrix such as Matrigel or BME-2 where they form 
hollow spherical structures or what is referred to as a ‘bunch-of-grapes’ morphology (Figure 3) . This 
distinguishes them, in addition to their self-organisation properties from spheroids. Organoids are 
dependent on the support of the surrounding matrix, whilst a spheroid can maintain its structure 
independently. 
The main advantages associated with organoids compared with PSC-derived cells appears to be the 
ability to maintain genetic stability over long culture periods whilst retaining the ability to proliferate 
extensively and form mature cell types with organ-like structures. This contrasts with PSC models 
which have been reported to accrue genetic aberrations in culture and are currently unable to fully 
recapitulate the mature hepatic phenotype. 
Similarly to iPSC-derived cells, organoids are able to recapitulate the phenotype of the cell from 
which they were derived. For example, the Clevers lab were able to derive hepatic organoids from a 
patient with A1AT deficiency which also showed the diseased phenotype (Huch et al., 2015). 
Furthermore the Tuveson lab were able to derive organoids from pancreatic cancers that 
recapitulated the progression of the disease in vitro (Boj et al., 2015). 
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However, organoids do not show the same degree of plasticity in their differentiated fate as PSC 
models which is limited typically to only a few organ-relevant cell types. Conversely, the starting ce ll 
type for PSC-models does not appear to influence the ability to form other cell types through 
differentiation (Heslop et al., 2017). This raises implications for the potential use of organoids in cell 
therapies, if tissue from the target organ is required to produce organoids, this will necessitate 
invasive biopsies. 
1.9 Perfusion Bioreactors 
Perfusion bioreactors aim to restore in vivo cellular mechanosensitivity by incorporating flow into 
cell culture conditions. In these bioreactors, cells are very often seeded into scaffolds combining 3D 
culture with flow. Cells in this type of culture are continuously perfused with culture medium which 
is pumped around the cells. Several pumping mechanisms have been employed e.g. pneumatic, 
peristaltic, gear or propeller and aim to achieve a flow rate that mimics in vivo circulation. Culture 
Figure 3 
Culture setup and morphology of organoids – Figure shows a cartoon depiction of the culture 
conformation and morphology of organoids. Organoids are cultured in a gel dome, typically 
comprised of Matrigel or BME-2 submerged in culture medium. Organoids form either a cystic, 
spherical morphology (left) or a ‘bunch of grapes’ morphology (right).  
Chapter 1 
28 
with flow allows continuous exposure of the cell to nutrients and oxygen, as well as in vivo-like shear 
stress, which are important conditions for cell expansion and maturation (Caralt et al., 2014). 
Currently, the literature on use of dynamic perfusion culture with iPSCs is limited. One study applied 
perfusion culture to undifferentiated iPSCs and found an increased proliferation rate (Yoshimitsu et 
al., 2014). Another study has shown improved phenotype and longevity of iPSC-cardiomyocytes 
when cultured with flow (Mathur et al., 2015). iPSC derived liver models incorporating flow are 
emergent but generally in their infancy, several attempts have been made to produce improved 
hepatic models by using flow. Schepers et al. designed a novel microfluidics system to culture iPSC-
HLCs in 3D culture and with co-culture with fibroblasts. The results of this study showed increased 
albumin production in 3D cultured cells and inducible expression of several CYP enzymes including 
CYP1A1 and CYP2C9 (Schepers et al., 2016). 
In addition, several in vitro liver models without the use of iPSC-HLC have been produced. Lee et al.  
utilised an osmotic pump to co-culture hPH spheroids with hepatic stellate cells showing an 
improvement in albumin and urea excretion and enhanced cytochrome P450 enzyme expression 
(Lee et al., 2013). Darnell et al. cultured HepaRG cells in a 3D multicompartment capillary membrane 
bioreactor under dynamic conditions (Darnell et al., 2011). These cells showed stable P450 metabolic 
capacity over several weeks, as well as polarity of transporter expression and bile canaliculi 
formation.  
The LiverChip is a dynamic culture perfusion system developed by CN Bio (formerly Zyoxel), that 
incorporates flow and uses a scaffold to culture cells in 3D. 3D culture with flow has been shown to 
enhance maturation of iPSC-HLCs and maintain functional hepatocytes with improved viability and 
longevity and increased ability to predict and distinguish hepatotoxicity of known hepatotoxic 
compounds from less-toxic analogues (Rowe et al., 2014a, 2014b; Vivares et al., 2015). In the 
LiverChip system, cells are seeded into coated scaffolds in 12 or 36 wells and perfused via pneumatic 
micropump-controlled flow, mimicking the architecture of hepatic sinusoids.  Clark et al. used a 
modified LiverChip system to identify new therapeutic strategies for metastasis by incorporating the 
hPHs and non-parenchymal cells (The authors note that a “full complement” of non-parenchymal 
cells were used but do not further specify) and breast cancer cells in a microfluidic cell culture 
system incorporating flow (Clark et al., 2014). 
In summary, the use of complex culture systems in iPSC HLC differentiation has demonstrated 
notable advantages in cell maturity and longevity (e.g. albumin and urea secretion maintained for 
months, gene profile shifting from foetal to mature hepatocyte, sustained and inducible CYP activity 
over long term). However, more efforts are required to develop methodology to p roduce more 
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stable and homogenous iPSC HLCs, as well as to decipher the mechanisms and key signaling 
pathways involved in hepatocyte differentiation and maturation. Furthermore, the development of  
reliable, practical and standardised culture systems that are amenable to high-throughput screening 
should also be considered. Nonetheless, the application of iPSC HLCs in complex culture systems 
shows great potential for DILI safety assessment, particularly in high-throughput screening and 
chronic toxicity assessment. 
1.10 Alternate uses of hepatocyte-like cells in toxicity assessment 
iPSC HLCs currently lack many of the key qualities required to be a one -for-all model of 
hepatotoxicity; however, that does not preclude the use of iPSC HLCs in modelling other less 
metabolically dependent endpoints. In the short term, a pragmatic approach should be adopted to 
find a purpose in which the relatively immature phenotype of iPSC-HLCs is suitable. 
One such use is as a model of mitochondrial perturbation. Recent work has shown that HepG2s may 
provide a model of mitochondrial perturbation that is more amenable to mechanistic studies than 
human hepatocytes (Kamalian et al., 2015). However, HepG2s are genotypically abnormal and lack 
physiological translatability; therefore, iPSC HLCs may provide a more physiologically relevant model 
of this perturbation. Research has shown that iPSC HLCs, like hepatocytes, but unlike pluripotent 
stem cells, can survive in galactose/ornithine-based culture which forces cells to use oxidative 
phosphorylation in the absence of glucose (Tomizawa et al., 2013), suggestive of a bio-energetic 
switch during differentiation to a situation which is more similar to hepatocytes. The use of human 
iPSC HLCs derived from patients with Alper’s syndrome, a disease which increases susceptibility to 
valproic acid-derived hepatotoxicity, were successfully used to model this increased toxicity 
compared to control iPSC HLCs (Li et al., 2015). Furthermore, the mechanism of toxicity, more 
frequent bursts of superoxide generation, was delineated using these cells; therefore, in cases 
where toxicity is not dependent on metabolism, iPSC HLCs are valuable models of toxicity.  
Further, DILI-induced cholestasis may also be modelled. Many drugs associated with cholestasis, 
such as cyclosporin A, rifampicin and glibenclamide, have been found to be a competitive inhibitor of 
the bile salt export pump (BSEP) (Böhme et al., 1994; Byrne et al., 2002; Leuthold et al., 2008), 
preventing the export of bile salts and resulting in their cytotoxic accumulation and consequently, 
DILI (Krahenbuhl et al., 1994). iPSC HLCs have been shown to have some degree of BSEP activity 
(Ulvestad et al., 2013) and may therefore be able to triage compounds with cholestatic liability 
through inhibition of this mechanism.  
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The advent of gene modulation technology, in the form of Zinc fingers, TALENs and CRISPR/Cas9, 
also provides the capacity to achieve mechanistic studies of hepatotoxicity. Yusa et al. reported such 
work was feasible in the context of gene therapy, demonstrating that the defective gene in the 
alpha-1-antitrypsin deficiency could be corrected using zinc finger nucleases in iPSCs and be 
functional in the resulting HLCs (Yusa et al., 2011). CRISPR/Cas9 knock out technology has also been 
successfully applied to pluripotent stem cells (Ding et al., 2013) and the differentiation of these ce lls 
to HLCs may provide human in vitro disease models or equivalents of ex vivo cells from knockout 
mice which are commonly used to understand the mechanisms which underlie hepatotoxicity of a 
given compound (Musunuru, 2013).  
The recapitulation of the patient genotype is a fundamental advantage of iPSC HLCs over more 
traditional and hESC-derived models of hepatotoxicity. DILI is often idiosyncratic in nature and may 
occur in only very small numbers of patients, in the case of abacavir, flucloxacillin and flupirtine, 
which are immune-mediated and associated with specific HLA-types (Daly et al., 2009; Martin et al., 
2004; Nicoletti et al., 2016); iPSCs allow for the selection of patients with risk-associated HLA-types. 
The testing of these HLA-typed HLCs with immune cells with the same HLA-type may provide a 
unique model of DILI. Such investigation would currently be dependent on the toxicological profile of 
the drug, i.e. is metabolism required before HLA presentation. Nevertheless, HLA-associated toxicity 
is currently only feasible in iPSC-based models and the development of a human in vitro system able  
to screen for immune-mediated idiosyncratic DILI would represent a paradigm shift in hepatotoxicity 
modelling.  
Furthermore, once metabolically-competent HLCs are established, simpler iPSC HLC panel-based 
screening representing the major genotypic variations present in the population (e.g. CYP2D6 null 
genotype (Takayama et al., 2014)) would enhance current compound screening models utilising the 
restricted genotypic range of animal strains and cell lines. 
1.11 Risks of the use of HLCs for cell therapies 
The current demand for donor organs outstrips supply. In addition, there is substantial risk 
associated with the transplant surgery itself, risk of organ rejection and complications associated 
with lifelong immunosuppression such as risk of infection and cancer (Adam et al., 2000; Hsu and 
Katelaris, 2009). Consequently, there have been efforts in recent years to find alternate sources of 
cells and tissue for transplant. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) 
offer a potentially unlimited source of cells for this purpose. However, the risks associated with the 
use of stem cells for transplant are incompletely understood. There are concerns regarding the 
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tumorigenic potential of stem cells used for transplant, based not only on the inherent ability of 
pluripotent cells to form teratomas in vivo but also regarding the more insidious genetic changes 
introduced during isolation and culture. 
The use of liver cells for cell therapy hold promise as an alternative treatment for late -stage liver 
disease. Whilst the technique has been attempted in both human and animal models there are 
multiple potential issues to be investigated and overcome before it can be used routinely (Nicolas et 
al., 2016). Human and porcine primary hepatocytes have been successfully transplanted into 
humans though concerns of immune rejection and xenozoonosis in the case of animal hepatocytes 
have been raised (Zhou et al., 2015). Stem cells have the capacity to self-renew whilst maintaining a 
pluripotent state. Consequently, stem cell derived HLCs are a theoretically unlimited source of 
hepatocytes for cell therapies. The use of iPSC derived HLCs may also circumvent the need for 
immunosuppression in recipients since pluripotent stem cells can be derived from any individual.  
There is concern that stem cell derived HLCs may pose an oncogenic risk in their recipients. 
Undifferentiated stem cells are known to readily form teratomas in vivo. This is the basis of an in vivo 
teratoma-forming assay where undifferentiated cells are injected into an immunocompromised 
animal model in order to demonstrate formation of the three major germ layers (Wesselschmidt, 
2011). Whilst teratomas are typically benign, there is the possibility for them to become malignant, 
particularly with solid tumours. 
Differentiation protocols are typically less than 100% efficient and an undifferentiated population of  
cells remain. Currently, it is unclear whether the undifferentiated portion of cells are fully 
pluripotent or capable of teratoma formation. Previous studies where HLCs were injected into 
immunocompromised mice have shown tumour formation in the injected animals (Payne et al., 
2011). However, a recent study demonstrated that by purification of differentiated cells using 
Laminin-111, undifferentiated cell populations as low as 0.003% could be achieved, furthermore, 
these cells were not capable of colony formation despite expression of Tra-1-60, a marker of 
pluripotency (Takayama et al., 2017). Other studies have also shown no tumour formation in mice 
injected with HLCs without purification (Basma et al., 2009). In summary, these results show that 
great care should be taken to remove undifferentiated cells before administration of stem cell-
derived cells to patients, the possibility for teratoma formation from undifferentiated cells is clearly 
extant. 
In addition to concerns regarding teratoma formation from undifferentiated cells, there is also the 
concern that cells accrue mutations over time in culture. These mutations typically confer a survival 
advantage to the cell in vitro such as increased rate of proliferation and decreased differentiation 
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and are known as culture adaptations (Nguyen et al., 2013). These mutations are of concern for ce lls 
intended for transplant or cell therapy since the mechanisms by which cells adapt to culture are 
similar to some of the characteristics of cancer cells. For example, resistance to cell death and 
increased proliferation are characteristics associated with cancerous cells and are advantageous to a 
cell’s survival in vitro but may pose an oncogenic risk in vivo (Hanahan and Weinberg, 2011). 
A selective pressure is applied during in vitro culture to for stem cells to self-renew. This in part 
accounts for the recurring patterns of mutations observed in stem cells in culture, in particular, 
recurrent mutations of chromosomes 12, 17, 20 and X are observed (Amps et al., 2011). The 
20q11.21 amplicon is one such common mutation, occurring in as many as 20% of ESC and iPSC lines 
after prolonged culture and confers a survival advantage (Amps et al., 2011). The 20q11.21 minimal 
amplicon is approximately 0.55Mb in length and encodes HM13, ID1, BCL2L1, KIF3B and an 
immature form of miR-1825. The amplicon size is variable and can also encode other nearby genes, 
including the potential oncogene, TPX2. Recent studies have demonstrated that BCL2L1 is likely to 
be the key driver of the survival advantage observed in carrier cells (Avery et al., 2013; Nguyen et al.,  
2014). Although not the source of the survival advantage conferred in vitro, ID1 is another gene 
expressed in the 20q11.21 minimal amplicon that is a potential oncogene. 
A recent study demonstrated that BLC2L1 is responsible for the improved survival of cells expressing 
gain of 20q11.21. BCL2L1 encodes BCL-XL which was shown to have 3-fold increased protein 
expression and 2.3-fold increased mRNA expression in cells with the gain of 20q11.21 compared to 
wild-type (Nguyen et al., 2014). This is of particular concern for cells intended for transplant as BCL-
XL is a classical proto-oncogene that exerts an anti-apoptotic effect. BCL2L1 also encodes BCL-XS, a 
pro-apoptotic protein. However, this has been shown to be the minor splice variant and was not 
detectable at the protein level (Nguyen et al., 2014). Overexpression of BCL-XL improves cell survival 
by reducing apoptosis during passaging when cell-to-cell contact is lost. This increase in protein 
expression confers a significant survival advantage over wild-type and cells with the amplification 
have double the colony-forming efficiency of wild-type cells (Nguyen et al., 2014). 
1.12  Objectives 
In this thesis we investigated a range of emerging stem cell-derived models of hepatotoxicity, 
including iPSC, ESC-derived HLCs and human hepatic organoids. In addition, we examined the effects 
of a commonly-occurring genetic aberration in the HLCs on the tumorigenic potential of hepatocyte  
like cells in immunocompromised mice. 
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Specifically, we examined the effects of the amplicon 20q11.21 which occurs frequently in 
pluripotent cells which have been extensively cultured. We produced luminescent hESC lines with 
known 20q11.21 status and differentiated them to HLCs before injecting them intrasplenically into 
the acutely damaged livers of immunocompromised mice. We hypothesised that presence of the 
20q11.21 amplicon would predispose carrier cells to tumour formation in vivo. 
The second major project of this thesis compared the effects of hypoxic culture conditions on the 
differentiation of normoxic culture conditions and also examined two differentiation protocols,  one 
traditional and one based on small molecules (Table 1) (Heslop et al., 2017; Siller et al., 2015). We 
hypothesised that hypoxic culture would produce a culture environment closer to that of a 
pericentral hepatocyte with the associated increase in CYP expression and other markers of a 
pericentral phenotype. We also sought to determine whether the cheaper small molecule -based 
protocol performed as effectively as a more traditional growth factor-based approach. 
The third project of this thesis examined the use of human liver organoids derived from EpCAM+ 
cholangiocytes as a model of hepatotoxicity. We established protocols in our lab for the isolation, 
culture, cryopreservation and differentiation of human liver organoids and then assessed their 
proteomic phenotype. Using this data, we sought to determine if human liver organoids derived 






2.1  Stem Cells 
2.1.1  Derivation 
The iPSCs in chapter 3 were derived in-house from human primary hepatocytes and fibroblasts using 
the CytoTune II Sendai virus reprogramming kit (Thermo Fisher Scientific, Paisly, UK) as detailed in 
Heslop et al. (2017). 
2.1.2   Maintenance 
2.1.2.1  General maintenance 
For routine maintenance, medium was changed daily. For iPSCs cultured on growth factor-reduced 
(GFR)-Matrigel (Corning, Flintshire, UK), Essential 8 medium was used (Table 2, all Thermo Fisher 
Scientific). ESCs were cultured in NutriStem hPSC XF Medium (Corning). Cells were passaged 1:4 
approximately every 5-6 days or when approaching confluency. 
2.1.2.2  Preparation of culture plates 
During these works, PSCs were almost exclusively cultured in multiwell tissue culture plates 
prepared by one of two methods. These methods were: coating with GFR-Matrigel, and coating with 
laminin-521 (ln-521, Biolamina, Stockholm, Sweden). 
2.1.2.2.1 GFR-Matrigel 
Growth factor reduced Matrigel (GFR-Matrigel) was used as a basement matrix for iPSC culture. 
125µL aliquots of GFR-Matrigel were thawed on ice and diluted to 12mL with DMEM (Sigma-Aldrich, 
Dorset, UK) under aseptic conditions. DMEM was kept ice cold during this procedure to prevent the 
GFR-Matrigel from solidifying prematurely. The diluted GFR-Matrigel was then plated out using half  
culture volume for the plate in question (Table 3). Matrigel was left to solidify for 1 hour at room 
temperature before being transferred to a CO2 incubator at 37 °C for later use. Before use in iPSC 
culture, the DMEM used to dilute the GFR-Matrigel was removed. 
2.1.2.2.2 Lamninin-521 
Ln-521 was used as a basement matrix for the culture of ESCs. Ln-521 aliquots were thawed at room 
temperature and were diluted 1:20 with DPBS (Life Technologies). Ln-521 solution was plated at 1.5 
mL per well of a 6-well plate and then incubated either overnight at 4 °C or for 2 hours at 37 °C.  
2.1.2.3  Passaging 
2.1.2.3.1 iPSCs 
Non-enzymic passaging was employed for the routine maintenance of PSCs. For passage of iPSCs, 
gentle cell dissociation reagent (GCDR, Stemcell Technologies, Cambridge, UK) was used. Medium 
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was removed and the cells were washed once with 1 mL of GCDR. A further 1 mL of GCDR was added 
and incubated at room temperature for approximately 6 minutes or until the appearance of a white  
‘halo’ effect was noted microscopically around the cells indicating detachment. GCDR was then 
removed taking care not to dislodge the cells. The loosened cells were then scraped into culture 
medium and plated out into GFR-Matrigel prepared tissue culture plates. 
2.1.2.3.2 ESCs 
Non-enzymic passaging was also employed for the routine maintenance of ESCs. Culture medium 
was removed, and cells were washed twice with phosphate buffered saline  Without calcium or 
magnesium (Thermo Fisher Scientific). Cells were then incubated in prewarmed 0.5 mM EDTA (Sigma 
Aldrich, Dorset, UK) at 37 °C for 5 minutes. After 5 minutes the cells were checked for signs of 
detachment, indicated by the cells ‘balling up’. If detachment was not observed cells were incubated 
at 37 °C for an additional 1-2 minutes and rechecked up to a maximum of 10 minutes. Once 
detachment was observed, the EDTA was gently removed and replaced with culture medium and the 
cells were scraped. The cells were gently agitated by pipetting up and down to break up larger 
clusters and plated into ln-521 prepared tissue culture plates. 
2.1.2.4  Cleaning 
iPSCs often differentiate spontaneously in culture, it was necessary to manually remove the 
unwanted differentiated cells. Differentiated cells were removed under aseptic conditions using an 
Evos XL Core microscope (Thermo Fisher Scientific). Cells were assessed for differentiation 
morphologically and were scraped away using a small pipette tip. 
2.1.2.5  Cryopreservation 
iPSCs were cryopreserved in liquid nitrogen for long-term storage. Cells were washed once with 
GCDR to remove culture medium and detached from the culture plate by incubating with fresh GCDR 
for 6-8 minutes at room temperature. The cells were frequently checked until the appearance of a 
white halo was noted indicating detachment. GCDR was then removed and replaced with 1 mL of 
freezing medium. Cells were scraped into this medium, transferred to cryovials and frozen at -80 °C 
using a Mr. Frosty™ Freezing Container (Thermo Fisher Scientific) following the manufacturer’s 
usage instructions. After 24-hours at -80 °C, the cryovials were transferred to liquid nitrogen storage. 
2.1.2.6  Thawing 
Cells were thawed from liquid nitrogen by quickly transferring the cells to a 37 °C water bath and 
gently swirling until a small pellet of ice remained in the cell suspension. This suspension was then 
transferred to aseptic conditions and the volume was increased to 10mL using the intended culture 
medium in order to dilute the dimethyl sulfoxide (DMSO) in the freezing medium. The cell 
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suspension was then centrifuged (200 g, 10 minutes) and the supernatant discarded. The pellet was 
resuspended in culture medium and immediately transferred to prepared culture plates increasing 
the volume to culture volume (Table 3) where necessary and swirled to ensure even distribution of  
the cells. The plates were then transferred to a CO2 incubator overnight to allow the cells to attach. 
Medium was changed 24 hours later. 
2.1.2.7  Hypoxia 
Some work in chapter 3 was carried out under hypoxic conditions; ‘normoxic’ conditions were a 
humidified 5% CO2 atmosphere at 37 °C, other gases uncontrolled. Cells in hypoxic conditions were 
treated identically to those cultured under normal conditions with the exception that they were 
cultured in a Whitley H35 HEPA Hypoxystation (Don Whitley Scientific, West Yorkshire, UK). The 
controlled atmosphere was 90% N2, 5% O2, 5% CO2 and 70-80% humidity at 37 °C. Small adjustments 
to the humidity of the atmosphere (within the range of 70-80%) were made as necessary to prevent 
excessive condensation inside the instrument. 
Culture under hypoxic conditions precluded any cleaning of spontaneously differentiating cells and 
any microscopy that was performed on cells under hypoxic conditions was done quickly in plates 
wrapped in film to reduce loss of the atmosphere inside. 
2.1.3  Differentiation 
Several protocols for the differentiation of iPSCs to HLCs were used and compared during these 
works. 
2.1.3.1  Protocol 1 
Figure 4 shows schematic overviews of the two differentiation protocols used in chapter 3. Figure 4A 
shows the protocol taken from Heslop et al. (2017), which uses a serum-free, growth-factor based 
approach. The protocol is 22 days in length and is divided into three major stages, specification of 
definitive endoderm, from day 1-5, which is also divided into two subsections: day 1-3 where cells 
are treated with Wnt3a and activin A, and days 4-5 where cells are treated with Activin A alone; 
specification of hepatic endoderm from day 6-12 where cells are treated with DMSO and hepatic 
maturation where cells are treated with HGF, OSM and dexamethasone This protocol will be 
referred to as protocol 1. 
iPSCs were grown to >80% confluency on GFR-Matrigel-coated plates. Twenty-four hours prior to 
initiation of differentiation, 10µM Y-27632 ROCK inhibitor was added to E8 medium. To initiate 
differentiation, cells were first washed with PBS before incubation with Accutase (Stemcell 
Technologies) at 37 °C until cell detachment was observed. Once cells started to detach, the 
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remainder of the cells were washed from the plate by gently pipetting the Accutase over the cells. 
The Accutase and cells were transferred to a centrifuge tube and any remaining cells were washed 
off the plate and added to the centrifuge tube with a volume of PBS equal to the volume of Accutase 
used. The cell suspension was centrifuged (200 g, 10 minutes) and the supernatant discarded. 
Once pelleted, the cells were transferred into differentiation medium 1 (Table 2) supplemented with 
10µM Y-27632 ROCK inhibitor (Sigma Aldrich). These cells were transferred to freshly prepared GFR-
Matrigel-coated plates and incubated under the chosen oxygen conditions for 24 hours. Medium 
was changed daily until day 5 of differentiation omitting Y-27632 ROCK inhibitor after day 1 and 
Wnt3a after day 3. On day 6 the medium was changed to differentiation medium 2 (Table 2) and 
changed every other day for 7 days. On day 12, the medium was changed to differentiation medium 
3 (Table 2) and changed daily for 10 days. 
2.1.3.2  Protocol 2 
Figure 4B shows the protocol taken from Siller et al. (2015) This protocol is 17 days in length and 
uses small molecules in place of traditional growth factors and contains serum during the final stage. 
Similarly to the protocol shown in Figure 4A, this protocol is divided into three major sections. The 
first section (day 1-2) uses a 24-hour pulse of CHIR99021 to direct definitive endoderm specification 
followed by 24 hours without treatment. The second stage (day 3-7) drives hepatic specification via 
treatment with DMSO. The third stage directs hepatic maturation using Dihexa and dexamethasone. 
The exact composition of each media in both protocols is shown in chapter 2. All subsequent 
analyses using iPSCs were undertaken on either fully differentiated cells, collected at the end of  the 
differentiation protocol. This protocol will be referred to as protocol 2. 
iPSCs were grown to >80% confluency on GFR-Matrigel-coated plates. Twenty-four hours prior to 
initiation of differentiation, 10µM Y-27632 ROCK inhibitor was added to culture medium. To initiate 
differentiation, cells were first washed with PBS before incubation with Accutase at 37 °C until cell 
detachment was observed. Once cells started to detach, the remainder of the cells were washed 
from the plate by gently pipetting the Accutase over the cells. The Accutase and cells were 
transferred to a centrifuge tube and any remaining cells were washed off the plate and added to the 
centrifuge tube with a volume of PBS equal to the volume of Accutase used. The cell suspension was 
centrifuged (200 g, 10 minutes) and the supernatant discarded. 
Once pelleted, the cells were transferred into differentiation medium 4 (Table 2) for 24 hours. On 
day 2 the medium was changed to differentiation medium 4 without CHIR99021 for a further 24 
hours. On day 3 the medium was changed to differentiation medium 2 (Table 2) and changed every 
Chapter 2 
39 
other day for 5 days. On day 8 the medium was changed do differentiation medium 5 (Table 2) and 
changed daily for 10 days. 
2.1.3.3  Tumorigenicity Chapter Protocol 
ESCs were grown to 30-60% confluency on ln-521-coated plates in NutriStem medium. On day 1 
medium was changed to differentiation medium 1 (Table 2) and changed daily for 3 days. On day 4, 
medium was changed to differentiation medium 2 (Table 2) and changed every other day for 5 days. 
On day 9 the medium was initially changed to differentiation medium 6 (Table 2), though for reasons 
discussed in chapter 5 this was later changed to differentiation medium 7 (Table 2). In both cases, 
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  Figure 4 
Schematic of differentiation protocols used in chapter 3 – (A) Overview of protocol 1 as described by Heslop et al. (2017) (B) Overview of protocol 2 
as described by Siller et al. (2015). 
Each section of the differentiation protocols is colour-coded, orange and yellow indicated formation of definitive endoderm, green indicates hepatic 
specification and blue indicates hepatocyte maturation. The culture medium used, and major additives and their concentrations  are indicated below 
each section and are covered in full detail in chapter 2. Abbreviations: B27 - B27-supplement, DMSO – Dimethyl sulfoxide - HGF - Hepatocyte growth 





2.1.4  Embryoid body formation 
Undifferentiated hESCs in 6-well plate format were disassociated using gentle cell disassociation 
reagent and scraped into KSR medium (Table 2) supplemented with 10µM Y-27632 ROCK inhibitor. If  
the cells were previously cultured on MEFs, they were removed by gravitational separation and cells 
plated in 24-well non-tissue culture treated plates in triplicate (1:1 ratio). After 24 hours, cells were 
resuspended by gently pipetting medium up and down and transferred to a new plate to reduce 
attachment. Medium was changed every 48 hours without ROCK inhibitor. For gene expression 
comparisons, cells were cultured for 16 days before lysing in QIAzol (Qiagen, Manchester, UK). For 
characterisation experiments, cells were cultured for 7 days, before transfer to attachment factor 
coated 24-well tissue culture treated plates for re-attachment. Cells were cultured for a further 7 
days before fixing with 4% (v/v) paraformaldehyde (PFA, Sigma Aldrich) for immunofluorescence 
assessment. 
2.1.5  Staining 
Cells were prepared for immunofluorescence at day 8 of the ESC differentiation protocol, embryoid 
bodies were also prepared identically.. All solutions containing normal donkey serum were 
centrifuged (15,000 g, 6 minutes) prior to use avoiding pellets when pipetting. Cells were fixed for 15 
minutes in 4% PFA and washed 3 times in Dulbecco’s PBS (Thermo Fisher Scientific) . Fixed wells were 
blocked with 10% normal donkey serum (Abcam, Cambridge UK). 
Primary antibodies were diluted in 1% normal donkey serum and 0.1% triton in DPBS. Rabbit anti-
human HNF4α antibody (Santa Cruz Biotechnology, Heidelberg DE) was diluted 1:50 and rabbit anti -
human αSMA and Tuj-1  antibodies (Abcam) were diluted 1:100 and 1:500 respectively. Wells were 
incubated with primary antibody at room temperature for 2 hours and washed 3 times with DPBS. 
The secondary antibody was Alexa Fluor 488 donkey anti-rabbit (Thermo Fisher Scientific); both 
antibodies were diluted 1:750 in the same solution as the primary antibodies and incubated in 
darkness for 2 hours at room temperature then washed 3 times in DPBS.  
Hoechst staining was performed, using Hoechst stain (Sigma Aldrich) diluted 1:75,000 in DPBS. Wells 
were incubated in darkness for 15 minutes before washing 3 times in DPBS leaving a fourth wash in 
the wells to prevent the samples from becoming dry. Wells were visualised using a Zeiss Observer 
Z.1 fluorescence microscope (Carl Zeiss, Cambridge, UK). 
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2.1.6  Flow Cytometry 
Flow cytometry was used to assess the proportion of cells expressing differentiation markers 
throughout differentiation. Unless otherwise noted, all centrifugation steps are 1,000 g, 10 minutes. 
Culture medium was removed, and the cells were washed with PBS (without Ca2+ or Mg2+). The ce lls 
were detached with Accutase by incubating at 37 °C for approximately 6 minutes until detachment 
was observed. Once the cells had detached, the Accutase was diluted with an equal volume of PBS 
and centrifuged. The supernatant was discarded, and the pellet resuspended in 10 mL PBS before 
centrifuging again. The supernatant was discarded and the pellet resuspend in cold fixation buffer 
(Table 2) at room temperature for 30 minutes. After fixation, the buffer was diluted with PBS and 
centrifuged, the supernatant was discarded and the pellet was resuspended in permeabilisation 
buffer (Table 2) and incubated at room temperature for 20 minutes. After permeabilisation, the 
permeabilisation buffer was diluted with PBS and centrifuged again. The supernatant was discarded,  
and the pellet was resuspended in blocking buffer for 30 minutes at room temperature. After 
blocking, the buffer was again diluted and removed by centrifugation. The pellet was then 
resuspended in fluorescence-activated cell sorting (FACS) buffer with the primary antibody  (HNF4a, 
Santa Cruz, Heidelburg, Germany) diluted 1:50 an incubated overnight at 4 °C. 
After incubation with the primary antibody, the buffer was diluted with PBS and removed by 
centrifugation. This step was repeated twice before resuspending the pellet in FACS buffer ( table  2)  
with the secondary antibody diluted 1:750. Care was taken to work in darkness where possible  with 
the photosensitive secondary antibody. The cells were incubated with the secondary antibody at 
room temperature for 2 hours in darkness. The secondary antibody solution was diluted with PBS as 
before and centrifuged and the supernatant was discarded to remove unbound secondary antibody. 
The pellet was resuspended in 1 mL PBS. 1µM DAPI was added immediately before flow cytometry 
analysis using the FACS Canto II (BD Biosciences). 
2.2 Organoids 
2.2.1 Production of conditioned medium 
Medium conditioned by RSPO1 or Wnt3a producing cells was required in the composition of several 
organoid media (Table 2). As directed by Broutier et al. (2016), Cultrex® HA-R-Spondin1-Fc 293T Cells 
and L Wnt-3A (ATCC® CRL-2647™) cells were obtained from AMS Biotechnology and LGC Standards 
(Middlesex, UK) respectively. 
Cells were expanded in Wnt3a- or RSPO1-conditioned growth medium into 500 cm2 plates, once at 
70% confluency; the medium was changed to Wnt3a- or RSPO1-conditioned harvest medium and 
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incubated for 1 week for conditioning. The conditioned harvest medium was centrifuged (500 g, 5 
minutes, 8 °C) to remove any cells before storage. Wnt3a-conditioned medium was stored at 4 °C for 
up to 6 months; RSPO1-conditioned medium was stored at -20 °C for up to 6 months. 
2.2.2 Isolation and culture of hepatic organoids 
Organoids were derived from human liver tissue as described in Broutier et al. (2016) and in detail 
below. 
2.2.3 Tissue Collection 
Tissue specimens were collected from Aintree Hospital, Liverpool, UK from waste tissue from 
hepatobiliary surgeries. Full patient consent and ethical approval from the relevant institutional 
review boards (National Research Ethics Service REC ref: 11/NW/0327) was received. 
Resected tissue was transported in ice-cold HEPES buffered saline (Table 2) and transferred to 
organoid basal medium (Table 2) and stored at 4 °C until isolation a maximum of 48 hours later. 
2.2.4 Single-cell isolation 
For human organoids, approximately 1g of tissue was used per isolation. The tissue was dissociated 
under aseptic conditions using scissors into pieces no larger than 1 mm3. These pieces were washed 
twice in organoid wash medium (Table 2) by pipetting the pieces up and down to remove excess 
blood, floating tissues and fat. The pieces of tissue were allowed to sediment gravitationally and the 
wash medium was discarded. The washed pieces were then resuspended in 10 mL human organoid 
digestion buffer (Table 2) and agitated gently at 37 °C for 30 minutes. The suspension was then 
vigorously pipetted up and down to break up tissue pieces. Depending on the extent of tissue 
digestion, the digestion buffer was either returned to gentle agitation at 37 °C for a further 10 
minutes (repeating this step until sufficient digestion was observed to a maximum of 90 minutes)  or 
proceeded to filtration. 
Digestion was considered complete once the suspension contained 80-100% single cells. The volume 
of the digested suspension was increased to 15 mL with organoid wash medium and passed through 
a 70 µm filter. The volume was then increased to 50 mL using ice-cold organoid wash medium and 
centrifuged (300 g, 5 minutes, 4 °C). The supernatant was discarded and the pellet was resuspended 
in 15 mL of ice-cold organoid wash medium and centrifuged twice (300 g, 5 minutes, 4 °C), 
discarding the supernatant each time. The cells were resuspended in organoid basal medium and 
were centrifuged (300 g, 5 minutes, 4 °C). The pellet at this point was often very small or not visible 
to the naked eye. 
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The supernatant was discarded, and the pellet was resuspended in ice cold BME-2 (AMSBio). Fifty µL 
per well of a pre-warmed 24-well suspension culture plate was carefully pipetted into a dome shape 
and transferred to a CO2 incubator at 37 °C for 10 minutes to fully solidify before adding organoid 
isolation medium (Table 2) at standard culture volume (Table 3). After 3-4 days, the organoid 
isolation medium was changed to organoid expansion medium (Table 2) and changed every 3-4 days 
thereafter. 
2.2.5 Fluorescence-activated cell sorting (FACS) 
In some cases, the isolation of ductal cells was enriched by sorting for EpCAM-positive cells using 
FACS. All centrifugation steps were carried out a 400g, 5 minutes at 8 °C unless otherwise noted. The 
isolation proceeded as described in the single-cell isolation section before resuspending the pelleted 
material in 5 mL of TrypLE (Thermo Fisher Scientific) supplemented with 10 mg/mL DNAseI (Sigma 
Aldrich). The suspension was triturated using a fine pipette tip e.g. 200 µL, and incubated at 37 °C for 
5 minutes. The suspension was repeatedly checked until >90% of the suspension was single ce lls.  10 
mL of cold wash medium was added to stop the digestion and the cells were pelleted by 
centrifugation; this step was repeated once at 500 g. The pelleted material was resuspended in 5 mL 
of wash medium and passed through a 40 µm filter to leave only single cells. The cells were counted 
using a haemocytometer and divided into an experimental and negative control with 90% of the 
material being used for the experimental group. The cells were pelleted by centrifugation (400 g, 5 
minutes, 8 °C) and resuspended in FACS blocking solution (Table 2) for 20 minutes on ice. The cells 
were pelleted by centrifugation and resuspended in 500 µL wash medium supplemented with 5 µg 
DNAseI and 10 µM ROCK inhibitor (Y-27632) before proceeding to antibody incubation. The antibody 
used was APC-conjugated anti-human EpCAM (Biolegend, London, UK) diluted 1:1000 and incubated 
for 1 hour on ice in darkness. The cells were washed twice with 3 mL wash medium and pelleted by 
centrifugation. The cells were resuspended in 500 µL wash medium with 10 µM ROCK inhibitor (Y-
27632). Both the negative control and the experimental sample were divided into DAPI-positive and 
DAPI-negative samples and were sorted using a BD FACS ARIA III. The sorted sample was then plated 
in BME-2 domes as described in the previous section. 
2.2.6 Passaging 
Organoids were passaged approximately two weeks after initial isolation and passaged based on 
density thereafter, once organoids became too dense for their BME-2 domes. Suspension plates 
were prewarmed to 37 °C. The BME-2 dome was disrupted by triturating with a 1 mL pipette tip in 
500 µL organoid basal medium. Up to three domes were then combined into a single 15 mL tube and 
the volume was increased to 15 mL basal medium. This suspension was pipetted up and dow n to 
Chapter 2 
46 
break up the BME-2 and centrifuged (200 g, 5 minutes, 8 °C). 13 mL of the supernatant was 
aspirated, and the organoids were resuspended in the remaining medium with a 200 µL tip in order 
to break the organoids apart. The tube was filled with cold basal medium and centrifuged (250 g, 5 
minutes, 8 °C) to wash out any remaining BME-2 and the supernatant was discarded. The remaining 
cells were resuspended in BME-2 and 50 µL domes were pipetted into the prewarmed plates and 
allowed to solidify at 37 °C for 10 minutes before adding organoid expansion medium. 
2.2.7 Cryopreservation 
Cryopreservation of organoids was performed identically to passaging but instead of resuspending in 
BME-2 for plating after dissociation of the domes, cryopreservation medium was added. Either CS10 
(STEMCELL Technologies) or Cell recovery medium (Thermo Fisher Scientific) was used and the 
suspension was cooled at a rate of 1 °C per minute to -80 °C using a Mr Frosty before transferring to 
liquid nitrogen for long term storage. 
To recover organoids from cryopreservation, the suspension was rapidly warmed using a water bath 
at 37 °C until a small piece of ice remained floating in the tube. The volume was then increased to 10 
mL using organoid basal medium and centrifuged (300 g, 5 minutes, 4 °C). The supernatant was 
discarded, and the pellet resuspended in BME2 and plated in domes as described previously.  
2.2.8 Differentiation 
Once grown to high density, organoids were considered ready for differentiation towards a 
hepatocyte phenotype. Organoids were passaged as described previously and cultured in organoid 
differentiation medium 1 (Table 2) for 5 days, changing the medium every 2-3 days. On day 6 the 
medium was changed to human organoid differentiation medium 2 (Table 2) and changed every 3 
days until day 15.  
2.2.9 Organoid harvesting 
The procedure for harvesting organoids for analysis was identical to the procedure for passaging 
until the point that the organoids would normally be resuspended in BME-2. At this point the 
organoid fragments were washed with PBS to remove any remaining culture medium before lysing in 
Isobaric Tagging for Relative and Absolute Quantification ( iTRAQ) buffer.  
2.2.10Western Blotting 
Protein samples were lysed in radioimmunoprecipitation assay (RIPA) buffer (Sigma Aldrich) and 
separated via SDS-PAGE on 10% acrylamide tris-HCl gel (ProtoGel 30% acrylamide solution, ProtoGel 
resolving buffer and ProtoGel stacking buffer were obtained from AGTC Bioproducts, Hessle, UK). 
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Separated protein bands were transferred to nitrocellulose membrane (GE Healthcare, Amersham, 
UK), transfer was checked using Ponceau Red stain, blocked with 10% blotting-grade blocker (Bio-
Rad, Hemel Hempstead, UK) at room temperature for 1 hour and probe d with rabbit anti-
cytochrome P450 3A4 (1:3000) or rabbit anti-albumin (1:3000) antibody (Overnight, 2% (w/v) 
blocking-grade blocker in tris buffered saline with tween 20 (TBST)) and mouse anti-ß-actin antibody 
(15 min, 1:10000, 2% (w/v) blotting grade blocker in TBST) (all Abcam). Secondary incubation was 
with anti-rabbit IgG-peroxidase (1 hour, 1:5000, 2% (w/v) blotting grade blocker in TBST) or anti-
mouse IgG-peroxidase (1 hour, 1:10000, 2% (w/v) blotting grade blocker in TBST) as appropriate. 
Samples were visualised via chemiluminescence using Western Lighting Plus-ECL (Perkin Elmer),  and 
visualised in a darkroom with Amersham Hyperfilm ECL (GE Healthcare). Once visualised, 
densitometry analysis was performed using ImageJ software (Schneider et al., 2012). 
2.3 Tumorigenicity Study 
2.3.1 Ethics 
These techniques were performed by personal licence holders according to the regulat ions def ined 
within the project licence granted under the Animals (Scientific Procedures) Act 1986 and approved 
by the University of Liverpool ethics committee. Animals were housed at a constant temperature 
and humidity with free access to food and water and a 12-hour like/dark cycle and were acclimatised 
for at least 7 days before any procedures. Animals were humanely sacrificed using a rising 
concentration of carbon dioxide according to the Humane Killing of Animals Under Schedule 1 to the 
Animals (Scientific Procedures) 1 Act 1986. 
2.3.2 Animals used 
Fox Chase SCID beige mice (SCID beige) were used for these studies. SCID beige mice carry the 
mutations Prkdcscid and Lystbg, which combined, produce severe B and T lymphocytopenia and 
defective natural killer cells. Animals were obtained from Charles River (Massachusetts, US). 
2.3.3 CCl4 dosing 
Carbon tetrachloride was administered via intraperitoneal injection to produce acute liver injury. To 
the best of our knowledge, acute dosing with CCl4 had not previously been attempted with SCID 
beige mice. Doses of 1.0, 0.4 and 0.2 mL/kg in olive oil were used. Response to CCl4 was determined 
by ALT activity and histological examination of liver after sacrifice. 0.2 mL/kg was determined to be 
the optimal dose tested to cause liver injury without excessive mortality in the animals. 
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2.3.4 Intrasplenic injection of hepatocyte-like cells 
Animals were treated with 0.2 mL/kg CCl4 by intraperitoneal injection to induce liver injury. After 72 
hours, animals were anaesthetised with isoflurane and prepared for surgery. The spleen was 
exposed and injected with 1x 106 HLCs. Gentle pressure was maintained on the injection site for at 
least 1 minute to prevent bleeding and backflow of the injected cells. The surgical wound was 
sutured closed and the animals were recovered in warmed boxes before returning to their cages. 
The animals were observed for 2 hours after surgery to check for signs of excessive distress or 
discomfort and checked daily for 7 days thereafter. The same procedure was followed for the 
injection of undifferentiated cells, substituting the cell type where appropriate.  
2.3.5 Imaging protocols 
In vivo bioluminescence was detected using an IVIS spectrum (Perkin Elmer, Buckinghamshire, UK). 
Animals were imaged 1 week after surgery and every 1-2 weeks thereafter. Prior to imaging, animals 
were weighed and anaesthetised with isoflurane. Luciferin (15 mg/mL) was administered by 
intraperitoneal injection at a volume of 10 µL/g for a final dose of 150 µg/g. Animals were imaged 
from the front and from the side using the automatic setting to determine exposure time. After 
imaging, the animals were recovered in a warmed box before returning them to their cages.  
2.3.6 Sacrifice and ex vivo imaging 
Animals were sacrificed once signs of discomfort or ill health began to occur, typically around 6 
months of age. Prior to sacrifice animals were anaesthetised and imaged as previously described. 
Immediately after imaging and without allowing animals to wake from anaesthesia, animals were 
administered luciferin by intraperitoneal injection for a second time and sacrificed using a rising 
concentration of CO2. After death was confirmed, blood was recovered by cardiac puncture and 
organs were retrieved. The spleen, liver, kidneys and lungs were retrieved, and luminescence was 
detected using an IVIS spectrum with exposure determined by automatic settings. Tissues were then 
stored either in 4% paraformaldehyde (PFA) or snap-frozen in liquid nitrogen. 
2.3.7 Immunohistochemistry 
Immunohistochemistry was performed at Leahurst Campus, Liverpool by specialists and were scored 
by a veterinary histopathologist (Thoolen et al., 2010, Table 9). Liver and spleen tissues were fixed in 
PFA for 24–48h, were trimmed and routinely embedded in paraffin wax. Consecutive 4 μm thick 
sections were prepared and routinely stained with haematoxylin and eosin (HE). Individual se lected 
cases were further examined with both histochemistry (PAS and Alcian-PAS) or subjected to 
immunohistochemical labelling. For the latter technique, a Dako Autostainer Link 48 was used. 
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Following removal and re-hydration, EnVisionTM FLEX Peroxidase Blocking Reagent was used to 
quench endogenous peroxides. Before addition of the primary antibodies (against Vimentin (clone 
V9, Dako, 1:500), Pan-Cytokeratin (clones AE1/AE3, Dako, 1:200) and GFAP (Dako, Z 0334, 1:1000)), 
goat serum and Fab Fragment (unconjugated Affinipurified Fab fragments goat anti-mouse IgG, 
Stratech Scientific, Ely, UK) blocking steps were serially applied. Following this, slides were incubated 
with the EnVisionTM anti-mouse FLEX/HRP labelled polymer for 20 minutes, rinsed and then 
incubated with the EnVisionTM FLEX DAB + Substrate Chromogen System. Slides were finally 
counterstained with EnVisionTM FLEX Haematoxylin, then rehydrated and mounted as per routine 
histology. 
2.3.8 qPCR 
2.3.8.1 RNA Extraction 
All samples for RNA analysis were lysed in 700 µL QIAzol and stored at -80 °C until used. The 
miRNeasy kit (Qiagen) was used following the manufacturer’s protocol. Briefly, samples were 
thawed and allowed to equilibrate to room temperature for approximately five minutes. 140 µL 
chloroform (Thermo Fisher Scientific) was added to each sample and mixed thoroughly by vortexing 
for 15 seconds. Samples were then incubated at room temperature for 2-3 minutes before 
centrifugation (12,000 g, 4 °C, 15 minutes). The upper aqueous phase was pipetted into a clean tube 
without disturbing the interphase and the remainder was discarded. At this point the remainder of 
the process was either fully automated using the QIAcube protocol ‘Purification of total RNA, 
including small RNAs, from animal tissues and cells (aqueous phase)’ (Qiagen), or proceede d 
manually, as follows. 
Ethanol (100%, 1.5 volumes) was added to the aqueous phase and mixed thoroughly. The sample 
was then passed through the RNeasy mini column by centrifugation (17,000 g, 15 seconds, room 
temperature). 700 µL of buffer RWT was next passed through the column by centrifuging in the 
same manner, the flow through was discarded. 500 µL of buffer RPE was then passed through the 
column in the same manner discarding the flow through, this step was repeated once. The RNA was 
then eluted into 50 µL RNAse-free water by centrifugation as in previous steps. In order to retrieve 
as much RNA as possible this step was repeated once using the flow through of the previous run. 
The RNA concentration of the eluate was determined using a NanoDrop ND-1000 
spectrophotometer (Thermo Fisher Scientific). 
2.3.8.2 Reverse Transcription 
Reverse transcription was performed using the Improm II Reverse Transcription Kit (Promega, 
Southampton, UK) using the following protocol. RNA samples were diluted with RNAse -free water to 
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1000 ng in 24 µL and 1 µL oligodT was added to each sample. These samples were then heated to 70  
°C before cooling on ice. The reaction mixture was prepared as directed by the manufacturer and 25  
µL was added to each reaction. Each sample was mixed thoroughly by pipetting and heated to 25 °C 
for 5 minutes, 42 °C for 1 hour and 70 °C for 15 minutes before cooling on ice. cDNA was stored at -
20 °C until further use. 
2.3.8.3 qPCR 
SYBR Green and TaqMan chemistry were used in this thesis, the chemistry used is noted on each 
occasion. qPCR experiments were carried out using 384-well plates and loading was automated 
using a Qiagility (Qiagen) robot where possible. 
For TaqMan chemistry the volume of each reaction mixture was 20 µL and contained 10 µL TaqMan 
Gene Expression Master Mix (Thermo Fisher Scientific), 1 µL primers (Thermo Fisher Scientific) ,  9 µL 
RNAse-free water and cDNA. Once combined, the plate was sealed and vortexed briefly to mix 
before centrifugation (4,000 g, 1 minute) to collect liquid at the bottom of the wells. Experiments 
were run using a ViiA7 instrument (Thermo Fisher Scientific) following a protocol of: 95 °C for 10 
minutes followed by 40 cycles of 95 °C for 15 seconds and 60 °C for 60 seconds. 
For SYBR green chemistry the volume of each reaction mixture was 25 µL and contained 12.5 µL 
SYBR Green JumpStart Taq ReadyMix (Sigma Aldrich), 1 µL each of forward and reverse primers 
(Eurofins Genomics, Ebersberg, Germany) each at 10 µM, 0.25 µL Rox passive reference dye, 8.25 µL 
of RNAse-free water and 2 µL cDNA. The amount of cDNA was occasionally increased, reducing the 
volume of RNAse-free water for low-abundance targets. Experiments were run using a ViiA7 
instrument following a protocol of: 95 °C for 10 minutes followed by 40 cycles of 95 °C for 15 
seconds and 60 °C for 1 minute. 
Data was processed using the 2-ΔΔCT method (Livak and Schmittgen, 2001) in Microsoft Excel. 
2.3.9 iTRAQ Analysis 
2.3.9.1 Preparation 
In preparation for iTRAQ analysis samples were lysed in iTRAQ buffer, cell samples were initially 
lysed by vortexing, tissue samples were lysed using a steel ball and an oscillating mill. Lysed samples 
were sonicated three times using a sonicating probe ensure complete disruption of any cells in the 
sample before being centrifuged at 18,000 g at 4 °C to remove any insoluble debris from the sample. 
The supernatant was transferred to a new tube and stored at -80 °C for further processing. 
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2.3.9.2 Bradford assay  
It is imperative that the loading of each sample is even for iTRAQ analysis. A Bradford assay was 
performed to determine the concentration of protein in each sample prepared as described abo ve. 
A standard curve of bovine serum albumin was constructed at the following concentrations: 0.25, 
0.2, 0.15, 0.1, 0.05, and 0.025 mg/mL and a blank sample. Samples were diluted in distilled water 
and 20 µL of each diluted sample and standard were loaded into a 96-well flat-bottomed microtitre 
plate. Bradford assay dye reagent (Bio-Rad) was diluted 1:4 with ultrapure water and 200 µL was 
added to each well. Absorbance was measured at 570 nm and protein concentration was 
determined by linear regression to the standard curve. 
2.3.9.3 Coomassie stain 
A Coomassie stain was performed in order to confirm accurate determination of protein 
concentration via Bradford assay. Samples were diluted to 1 mg/mL in x4 Laemmli buffer (Bio-rad), 
prepared according to the manufacturer’s instructions and denatured at 85 °C for 10 minutes before 
cooling on ice. Samples were loaded into a 10% polyacrylamide gel, run at 90V for 10 minutes then 
at 170V until the dye front approached the bottom of the gel. After electrophoresis, the  proteins 
were fixed for 1 hour in 7% glacial acetic acid and 40% (v/v) methanol. After fixation, the gel was 
stained using freshly prepared Coomassie stain (4 parts colloidal Coomassie stain (0.1% (w/v) 
Coomassie brilliant blue G-250 in 2% (w/v) phosphoric acid, 10% (w/v) ammonium sulphate) to 1 
part methanol) for 2 hours. After staining, the gel was destained for 60 seconds with agitation using 
10% acetic acid in 25% (v/v) methanol. Following destaining, the gel was rinsed once in 25% (v/v) 
methanol before destaining at least overnight in 25% (v/v) methanol with agitation on an orbital 
shaker. 
After destaining, the gel was imaged using a GS-800 calibrated imaging densitometer (Bio-Rad) and 
relative density of each gel lane was assessed using Quantity One software (Bio-Rad). 
2.3.8.4 iTRAQ 
iTRAQ analysis was performed by specialist technicians as follows. 100 μg protein in 20 μL was 
denatured using SDS, reduced using tris(2-carboxyethyl) phosphine (TCEP) and capped with methyl 
methanethiosulfonate (MMTS) according to the manufacturer’s protocol (8-plex, Sciex, Cheshire, 
UK). Samples were digested overnight with trypsin and labelled with iTRAQ isobaric tags 113-121. 
Samples were subjected to cation exchange chromatography, to remove unbound trypsin and 
reagent and then diluted to 4 mL with 10 mM potassium dihydrogen phosphate/25% ACN (w/v). The 
pH was adjusted to <3 using phosphoric acid prior to fractionation on a Polysulfoethyl A strong 
cation-exchange column (200 × 4.6 mm, 5 m, 300 Å; Poly LC, Columbia, MD). Fractions of 2 mL 
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were collected and were dried by centrifugation under vacuum (SpeedVac, Eppendorf). Fractions 
were reconstituted in 1 mL of 0.1% TFA and were subsequently desalted using a mRP Hi Recovery 
protein column 4.6 x 50 mm (Agilent, Stockport, UK) on an Infinity 1260 HPLC system (Agilent) prior 
to mass spectrometric analysis. 
Desalted fractions were reconstituted in 40 L 0.1% formic acid and 3 L aliquots were delivered 
into a Triple TOF 6600 (Sciex) via an Eksigent NanoLC 400 System (Sciex) mounted with a 
NanoAcquity 5 µm, 180 µm x 20 mm C18 trap and 1.7 µm, 75 µm X 250 mm analytical column 
(Waters, Herts, UK). A NanoSpray III source was fitted with a 10 μm inner diameter PicoTip emitter 
(New Objective, MA, USA). A gradient of 2−50% ACN/0.1% formic acid (v/v) over 90 min was applied 
to the columns at a flow rate of 300 nL/min. The mass spectrometer was operated in positive ion 
mode (Analyst TF1.7) with survey scans of 250 ms, MS/MS accumulation time of 100 ms and with 
monitoring of the 25 most intense ions (total cycle time 2.75 s). Data were searched using 
ProteinPilot 5 software (Sciex) against the latest UniProt database with iTRAQ as a variable 
modification and MMTS as the cysteine alkylating reagent. The reversed database was used as a 
decoy to determine the false discovery rate (FDR) for protein identification, and only those proteins 
identified within a 1% FDR were evaluated further. Data from iTRAQ analyses were processed using 
Partek (Partek Incorporated, Missouri, USA). 
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2.4 Medium and buffer compositions 











20% (v/v) KnockOut Serum Replacement, 1 mM L-
glutamine (Sigma-Aldrich, Dorset UK), 100 μM MEM 
Non-Essential Amino Acids, 200 μM 2-






15% Embryonic stem-cell FBS (Thermo Fisher 




20% (v/v) KnockOut Serum Replacement, 1% (v/v) 
GlutaMAX (Thermo Fisher Scientific), 100 μM MEM 
Non-Essential Amino Acids, 200 μM 2-





Essential 8 basal 
medium 
Essential 8 supplement (Thermo Fisher Scientific), 1% 
(v/v) penicillin/streptomycin 
Yes 
Essential 8 supplement was added immediately 










B27 supplement, 100ng/mL Activin A (Peprotech), 







20% (v/v) KnockOut Serum Replacement, 1% (v/v) 
GlutaMAX, 100 μM MEM Non-Essential Amino Acids, 







10nM dexamethasone (Sigma-Aldrich), 20 ng/mL 
oncostatin M (PeproTech, London UK), 20 ng/mL 
hepatocyte growth factor (PeproTech) 
Yes 
Recombinant growth factors were added 
immediately prior to use to prevent degradation 
at 4 °C 
Differentiation 
medium 4 






8.3% tryptose phosphate broth, 8.3% embryonic stem-
cell FBS, 10 μM hydrocortisone 21-hemisuccinate, 
0.5% (v/v) insulin, transferrin, selenium, 1% (v/v) 
GlutaMAX, 50ng/mL sodium-L-ascorbate, 100 nM 
dexamethasone, 100 nM dihexa (Active Peptide, 





8.3% tryptose phosphate broth, 8.3% embryonic stem-
cell FBS, 10 μM hydrocortisone 21-hemisuccinate, 1 
No 
Use of this medium composition was eventually 
halted, due to the high acidity of 0.2% ascorbic 
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μM Insulin (bovine pancreas), 1% GlutaMAX, 0.2% 
ascorbic acid, 100 nM dexamethasone, 20 ng/mL 
oncostatin M, 10 ng/mL hepatocyte growth factor 
acid causing poor viability in resultant cells and 




8.3% tryptose phosphate broth, 8.3% embryonic stem-
cell FBS, 10 μM hydrocortisone 21-hemisuccinate, 1 
μM insulin (bovine pancreas), 1% GlutaMAX, 50ng/mL 
sodium-L-ascorbate, 100 nM dexamethasone, 20 







1% penicillin/streptomycin, 1% GlutaMAX, 10mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 













2% B27 supplement (without vitamin A), 1% N2 
supplement, 1 mM N-acetylcysteine, 10% (v/v) RSPO1-
conditioned medium, 10 mM nicotinamide, 10 nM 
recombinant human [Leu15]-gastrin I, 50 ng/mL 
recombinant human EGF, 100 ng/mL recombinant 
No Store at 4 °C for up to 2 weeks 
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human FGF10, 25 ng/mL recombinant human HGF, 10 







25 ng/mL recombinant human Noggin, 30% (v/v) 
Wnt3a-conditioned medium and 10 μM Rho kinase 
(ROCK) inhibitor (Y-27632) 













2% B27 supplement, 1:100 N2 supplement, 1 mM N-
acetylcysteine, 10 nM recombinant human [Leu15]-
gastrin I, 50 ng/mL recombinant human EGF, 25 ng/mL 
recombinant human HGF, 0.5 μM A83-01, 10 μM 
DAPT, 3 μM dexamethasone, 25 ng/mL BMP7, 100 
ng/mL recombinant human FGF19 
No Store at 4 °C for up to 2 weeks 
RPSO1 growth 
medium 








1% penicillin/streptomycin, 1% GlutaMAX and HEPES 
10 mM 
No 
Store at 4 °C for up to 1 month. Once 








1% penicillin/streptomycin, 300 μg/mL Zeocin 




DMEM 10% FBS, 1% penicillin/streptomycin No 
Store at 4 °C for up to 1 month. Once 







137 mM NaCl, 2.6 mM KCl, 8.1mM Na2HPO4 and 1.4 
mM KH2PO4 Adjust pH to 7.4 with HCl 
N/A  
Fixation buffer PBS 2 % paraformaldehyde N/A  
Permeabilisation 
buffer 
PBS 0.1 % Triton X-100 N/A  
FACS buffer PBS 
0.5 % normal donkey serum and 0.05% Sodium Azide 
(NaN3) 
N/A  





piperazineethanesulfonic acid (HEPES), 5mM KCl, 






Table of media and buffer compositions – detailed composition of each buffer and medium used throughout this thesis. Basal medium and all additive  are  
shown. Abbreviations: BMP7 - Bone morphogenic protein 7, DMEM - Dulbecco's modified Eagle's medium, DMSO - Dimethyl sulfoxide, EGF - Epidermal 
growth factor, FBS - Foetal bovine serum, FGF10 - Fibroblast growth factor 10, FGF19 - Fibroblast growth factor 19, FGF2 - Fibroblast growth factor 2, HGF - 





Culture Vessel Type Area (cm2) Routine culture volume (mL) 
6-well plate 9.5 2 
12-well plate 3.8 1 
24-well plate 1.9 0.5 
48-well plate 0.95 0.25 
96-well plate 0.32 0.1 
25cm2 square dish 625 100 
T25 flask 25 5 
T75 flask 75 9 
T175 flask 175 21 
Table 3 
Table of standard culture volumes – list of culture vessels and the standard volumes used 




3 Effects of hypoxia on the production 
of hepatocyte-like cells from induced 





iPSC-HLCs made using the best current protocols are not sufficiently mature for 
transplantation in humans and their phenotype is a hindrance to their use in toxicity 
testing. They display a phenotype closer to that of an immature foetal hepatocyte and lack 
features such as cytochromes P450, phase II enzymes and transporters at physiological 
levels and also express markers of immaturity such as AFP at high levels As such there have 
been many attempts over recent years to improve upon differentiation protocols for HLCs 
and other cell types. 
Differentiation protocols to produce HLCs have advanced from initially undirected 
differentiation, where cells were allowed to spontaneously differentiate or very simple 
directed protocols with only a single stage to enrich for a hepatic fate, to the more complex 
and familiar protocols that are currently common. These protocols are most often 
comprised of three main stages: definitive endoderm specification, hepatic endoderm 
specification and hepatic maturation which may be subdivided into smaller sections. For 
example, in our previous work we utilised a common type of three -stage growth factor-
based differentiation protocol (Heslop et al., 2017). 
Specifically, this protocol uses activin A and Wnt3A followed by activin A alone for definitive 
endoderm specification (Figure 4). Activin A is a TGF-β family member commonly used to 
manipulate the nodal pathway. The nodal pathway is a key element of left-right asymmetry 
and the patterning process and initial generation of mesoderm and endoderm during 
embryogenesis. Endoderm specification requires high levels of activation of the n odal 
pathway compared with mesoderm which leads to the production of anterior primitive 
streak cells and in turn activates mixer homeoproteins beginning a cascade which 
ultimately upregulates endoderm-related genes such as Sox17 whilst downregulating 
mesoderm inducing genes (Shen, 2007; Sui et al., 2013). Wnt signalling is another 
commonly manipulated pathway in the differentiation of pluripotent cells to definitive 
endoderm. The Wnt pathway is activated repeatedly throughout embryo development and 
is involved in definition of the anterior/posterior axis as well as in patterning (Sokol, 2011). 
Though the Wnt pathway itself induces a mesodermal fate if continuously activated it is 
required for efficient generation of the primitive streak from which definitive endoderm is 
derived (Sui et al., 2013).  
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DMSO was used for hepatic endoderm specification in this protocol. DMSO has been shown 
to drive differentiation by downregulating genes associated with ‘stemness’ including Oct -
4, Sox-2, Nanog and Rex-1 (Czysz et al., 2015; Pal et al., 2012). After specification with 
DMSO, cells are considered hepatoblasts, the bipotent progenitor cell type that can give 
rise to only two types of cell, hepatocytes or cholangiocytes. FGF10 and BMP4 are also 
commonly used for the definition of hepatic endoderm and likely more closely  mimic 
embryogenesis but were not used in the protocols in this work (Hannan et al., 2013). 
Hepatocyte growth factor (HGF) is commonly used in the differentiation of HLCs to activate  
c-Met and drive hepatocyte maturation. After formation of the foregut from the def initive  
endoderm, HGF is secreted from the mesenchyme of the liver and septum transversum and 
is implicated in the migration, proliferation and survival of hepatoblasts. Moreover, once 
the hepatoblasts have formed, it is responsible, in conjunction with glucocorticoid 
hormones, Wnt signalling and oncostatin M (OSM) for the differentiation of the foetal 
hepatocytes. OSM is secreted from the hematopoietic cells of the embryonic liver and 
induces metabolic maturation of the hepatocytes by activating the GP130 receptor and the 
JAK/STAT3 signalling pathways (Zorn, 2008).  
The growth factors used during the differentiation of HLCs are often altered to better mimic 
the conditions found during embryogenesis. However, no current protocol has been able to 
produce cells which fully recapitulate the phenotype of human primary hepatocytes (hPH) 
suggesting that there are other factors at play in the generation of fully functional hPH from 
iPSCs. In addition to the modulation of the growth factors, environmental and physical 
characteristics of the differentiation protocol can be altered. Three -dimensional culture 
(e.g. spheroids, bioreactors) and co-culture with non-parenchymal cell types have shown 
promise to improve the maturity of iPSC-HLCs. However, similarly to modulation of growth 
factors, no combination of these factors has been able to fully recapitulate the phenotype 
of adult hPH. 
Another practical aspect to consider in the differentiation of iPSC-HLCs is cost. In order to 
produce enough iPSC-HLCs for large-scale experimentation or transplantation the cost of 
differentiation materials such as growth factors may become prohibitively high. In a recent 
study, a differentiation protocol using small molecules in place of traditional growth factors 
was demonstrated (Siller et al., 2015). Specifically, this protocol uses small molecules to 
replace key growth factors during differentiation. During the first stages of differentiation 
CHIR99021 is substituted where activin A/Wnt3a would typically be used. CHIR99021 is a 
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potent inhibitor of glycogen synthase kinase 3 and a Wnt pathway activator. The Wnt 
pathway is associated with patterning in embryonic development and is commonly 
activated in protocols producing endoderm cells, the authors demonstrate that addition 
and removal of CHIR99021 over 48 hours is sufficient to induce definitive endoderm 
differentiation (Siller et al., 2015). The second stage of differentiation uses DMSO to drive 
differentiation which is also commonly used in growth factor-based protocols and was 
discussed previously. The third stage of the differentiation protocol replaces HGF with N-
hexanoic-Tyr-Ile-(6) aminohexanoic amide (Dihexa), an HGF mimetic, in combination with 
dexamethasone and hydrocortisone-21-hemisuccinate. The advantages to this approach 
are several; firstly, the cost of such a protocol is greatly reduced when compared with 
traditional growth factor-based approaches. In addition, the variability in reagents can be 
reduced since there is no biological component in their production.  
However, it has not yet been fully determined whether the resultant cells are as well 
differentiated as their growth factor-derived counterparts. Since the effects of many 
growth factors are pleiotropic and often incompletely understood, it cannot be determined 
with certainty that a small molecule will perfectly mimic all the pathways that the growth 
factor would interact with. For example, Dihexa, the HGF mimic used in the protocol 
described has been shown to activate c-Met, the main pathway through which HGF 
operates, but has not been shown to interact with heparan sulphate or dermatan sulphate 
which HGF also interacts with, these discrepancies may impact upon differentiation 
(Benoist et al., 2014). 
The use of hypoxic conditions for the routine culture of iPSCs is well established. Hypoxic 
conditions have been shown to reduce the levels of spontaneous differentiation and 
therefore aid in long term culture of iPSCs (Ezashi et al., 2005; Prasad et al., 2009; Zhang 
and Wang, 2013). The rationale behind this technique are readily apparent when the 
oxygen levels during embryogenesis are considered, particularly compared with typical ce ll 
culture conditions where the oxygen level is not controlled from the atmosphere 
(Dunwoodie, 2009). Hypoxic conditions have been shown to increase the expression of 
NANOG in iPSCs compared with atmospheric oxygen whilst leaving cellular reactive oxygen 
species unaffected and also to maintain notch expression (Guo et al., 2013; Prasad et al., 
2009).  
Similarly, oxygen tension in the liver is variable across the lobule and thought to be tied to 
its function (Kietzmann, 2017). The partial pressure of oxygen ranges from 60-65 mmHg in 
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the periportal region to 30-35 mmHg in the perivenous region (Jungermann and Kietzmann, 
2000). Compared with the partial pressure of atmospheric oxygen (approximately 160 
mmHg) this equates to 8-4% atmospheric oxygen across the lobule. The phenotype of 
hepatocytes changes across the lobule, cells periportal region experience a higher oxygen 
tension and are more specialised for gluconeogenesis and glutathione synthesis. Conversely 
hepatocytes in the perivenous region experience a comparatively low oxygen tension and 
are specialised for glucose uptake and express higher levels of CYPs, essential proteins for 
xenobiotic metabolism (Kietzmann, 2017). Moreover, there is evidence that cultured 
primary hepatocytes are better able to resist dedifferentiation under hypoxic conditions 
(Guo et al., 2017), though the situation is complex as improvements in function and 
longevity under very high oxygen conditions and worsened survival in hypoxia have also 
been demonstrated (Kidambi et al., 2009). 
We hypothesised that the use of hypoxia in the culture and differentiation of HLCs may 
produce a more physiological environment and improve the phenotype of the resultant 
cells. Previous studies have used hypoxic conditions to generate HLCs from Wharton’s Jelly -
derived mesenchymal stem cells and showed expression of hepatocyte-specific genes 
including Albumin, CYP3A4 and A1AT in addition to glycogen storage and LDL uptake 
(Prasajak and Leeanansaksiri, 2013). Si Tayeb et al. also demonstrated the use of transient 
hypoxic conditions during the hepatic endoderm stages of differentiation to HLCs using 
iPSCs (Si-Tayeb et al., 2010). Using this protocol, it was shown that highly efficient 
differentiation could be achieved, however, a comparison to normoxic conditions was not 
made. 
We also sought to compare the small molecule-based protocol described by Siller et al. to 
the growth factor based protocol we have used in previous studies (Heslop et al., 2017; 
Siller et al., 2015) and characterise the phenotype of these cells in greater depth than has 
previously been attempted using iTRAQ and qPCR. The effects of hypoxic culture were 
examined during differentiation towards HLCs using both differentiation protocols using 
iTRAQ in the same manner. We hypothesised that by more closely mimicking the levels of 
oxygen found during embryogenesis the phenotype of the HLCs would be closer to that of  
hPH. It was also considered that by differentiating cells under hypoxic conditions the 
resultant phenotype may be closer to that of a perivenous hepatocyte, with greater 
expression of cytochromes P450 enzymes and other concomitant changes associated with 
hepatocytes from this region of the liver lobule. Specifically, we differentiated several 
human iPSC lines under both standard cell culture conditions using atmospheric oxygen and 
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under a controlled hypoxia atmosphere (5% oxygen) using both differentiation protocols. 
To the best of our knowledge, this is the first attempt to differentiate iPSCs under 




 Table 4 
 Donor details of iPSC lines used in chapter 3 - Liv4FA was used for assessment of the phenotype of undifferentiated cells cultured under hypoxic 
conditions, the remaining cell lines were used for differentiation and iTRAQ and qPCR analysis. Information from each tissue donor for iPSC lines. Sex, BMI at 
time of surgery, age at time of surgery, cell type of origin, patient diagnosis and known comorbidities are shown. 
Name Sex BMI Age at isolation Original cell type Diagnosis Co-morbidities 
Liv4FA Male 27.9 66 Fibroblast 
Colorectal carcinoma with 
liver metastases 
Type II diabetes mellitus 
Liv6HB 
Female 31.2 63 Hepatocyte 
Colorectal carcinoma with 
liver metastases 
Hypertension, Chronic liver 
disease, 
Type II diabetes mellitus Liv6HE 




In this study 4 iPSC lines were used, Liv4FA was used for assessment of undifferentiated 
phenotype (Figure 6) and Liv6HB, Liv6HE and Liv7HE were used for assessment of 
phenotype once differentiated (Figure 7-15). These lines were isolated from skin or surgical 
excess liver tissue obtained with informed consent from patients undergoing hepatobiliary 
surgery at Aintree Hospital, Liverpool, UK during a previous study from our lab (Heslop et 
al., 2017). The details associated with each line including age at isolation, sex etc. are 
shown in Table 4. Each line follows the same naming convention in which the last three 
characters inform the details of the cell type. For example, one line used was Liv6HE, in this 
case the number indicates the donor, ‘H’ indicates the cell type of origin, and ‘E’ indicates 
the number of the clone. 
3.2.1 iPSCs cultured in hypoxic conditions show gene expression changes 
Figure 6 shows qPCR analysis of Liv4FA iPSCs cultured under hypoxic conditions compared 
to the same cells cultured under non-oxygen-controlled conditions analysed using qPCR 
with SYBR green chemistry. Cells were cultured under hypoxic conditions for at least 3 
passages prior to experimentation to enable adaptation to the culture conditions.  Data are  
presented as fold difference (2-ΔΔCT) relative to iPSCs cultured under normoxic conditions 
with either GAPDH or β-actin as a control gene. Figure 6A shows the expression of four 
hypoxia-inducible genes, EPO, HIF1A, HSP70 and VEGFA. Although there were no significant 
changes, there was a trend towards increased expression of all genes under hypoxic 
conditions. Figure 6B shows expression of the pluripotency markers OCT4, SOX2 and 
NANOG, expression is increased in hypoxia in all cases and is significantly higher for SOX2 
and NANOG, as determined by a student’s t-test. Figure 6C shows expression of the NRF -2 
pathway markers, GCLC, HO-1 and NRF-2, both HO-1 and NRF-2 are significantly increased 
in hypoxic conditions.  
3.2.2 iPSC-HLCs show hPH-like morphology 
Micrographs of Liv6HE iPSC-HLCs differentiated under each of the tested conditions i.e. 
both differentiation protocols under normoxic and hypoxic conditions  (Figure 5). 
Undifferentiated cells are also shown for comparison (Figure 5E). Scale bars are 100 µm. 
Figure 5A and Figure 5B show the morphology of iPSC-HLCs differentiated using protocol 1 
under normoxic and hypoxic conditions respectively, characteristic polygonal morphology 
associated with hepatocytes is visible in several locations. Figure 5C and Figure 5D show the 
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morphology of iPSC-HLCs differentiated using protocol 2 under normoxic and hypoxic 
conditions respectively, polygonal morphology can be observed in both images. Though not 
apparent at the presented magnification, multinucleate cells, a characteristic trait of hPH, 
were not observed in differentiated cells under any condition. Figure 5E shows the 
morphology of undifferentiated iPSCs, the tight, smooth colony formation and small cell 
size and small cytoplasm are of note. Figure 5F shows the morphology of hPH 24-hours 
after isolation for the purposes of comparison. 
3.2.4 iTRAQ analysis shows incomplete differentiation of iPSC-HLCs 
iTRAQ analysis was performed on iPSCs differentiated to HLCs under each condition. 
Additionally, undifferentiated iPSCs pooled from each line were included as a comparator 
alongside pooled hPH from several donors. Each condition was tested in triplicate and 





Micrographs of iPSC-HLCs differentiated using protocol 1 & 2 under normoxic and hypoxic 
conditions show differences in morphology – (A) iPSC-HLCs differentiated using protocol 1, 
normoxia. (B) iPSC-HLCs differentiated using protocol 1, hypoxia. (C) iPSC-HLCs 
differentiated using protocol 2, normoxia. (D) iPSC-HLCs differentiated using protocol 2, 
hypoxia. (E) undifferentiated iPSCs in normoxic conditions, though the morphology does 
not change when cultured under hypoxic conditions. (F) hPH 24-hours after isolation in 2D 
culture show characteristic polygonal morphology and multinucleate cells. 
Scale bars are 100 µm. Polygonal morphology is apparent in panels B-D but not in panel A. 




3.2.5 Hierarchical clustering analysis (HCA) 
HCA was performed using Partek, the results of this analysis are shown in Figure 7 in which 
each bar represents a single protein and each column represents a single sample. Figure 7 is 
colour coded, green bars indicate downregulation and red bars indicate upregulation 
relative to a pooled control of all samples in the iTRAQ run. In the labelling of this figure, 
protocol 1 and 2 are abbreviated to ‘Hes’ and ‘Sill’, normoxia and hypoxia are abbreviated 
to ‘Norm’ and ‘Hypo’, respectively. The dendrogram shows how closely each sample is 
related with shorter branches representing more similar samples. 
hPH cluster strongly together and are also highly separated from all other samples. 
‘Sil_norm_1’ and ‘Sil_norm_2’ cluster most closely to iPSCs out of all samples though all 
other iPSC-HLCs cluster shortly thereafter except for ‘Hes_hypo_2’ and ‘Hes_hypo_3’ which 
cluster together and away from all other iPSC-HLC lines. From these data it is apparent that 
iPSC-HLCs have diverged from iPSCs but still cluster more closely to them than to HLCs.  
3.2.6 Principal component analysis 
PCA was performed on the dataset using Partek, the results of which are shown in Figure 8. 
The three principal components shown in Figure 8 account for 60.6% of the variability of 
the data with 33.1% assigned to PC1, 16.8% assigned to PC2 and 10.7% assigned to PC3. 
Similarly to HCA (Figure 7), iPSCs are separated from hPH and iPSC-HLCs along PC1, hPH 
separate from iPSC-HLCs mainly along PC2 and PC3 and iPSC-HLCs tend to cluster more 
closely with one another. As shown in the HCA, 2 data points from ‘Hes hypo’ separate 
from the majority of other iPSC-HLCs. 
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Figure 6 
qPCR analysis of Liv4FA iPSCs cultured 
under normoxic and hypoxic conditions – 
(A) Change in expression of hypoxia 
inducible genes EPO, HIF1A, HSP70, VEGFA. 
(B) Change in pluripotency associated genes  
OCT4 SOX2 NANOG. (C) Change in 
expression of NRF-2 pathway related genes 
GCLC HO-1, NRF-2. 
Cells were cultured under hypoxic or 
normoxic conditions for at least three 
passages prior to experimentation to allow 
acclimatisation. qPCR completed using SYBR 
green chemistry. All panels use Liv4FA iPSCs 
(Table 4). Graphs show mean fold difference 
in gene expression. Fold difference was 
calculated using the 2-ΔΔCT method according 
to Livak and Schmittgen (2001) fold 
differences are relative to iPSCs cultured 
under normoxic conditions and normalised 
to GAPDH. Data points show mean fold 
difference, error bars denote error 
calculated as per the 2-ΔΔCT method. 
Asterisks (*) indicate significant differences, 
tested using an unpaired, two-tailed 
Student’s t-test. Increased number of 
asterisks denotes smaller p-values, * = ≤ 








Hierarchical clustering analysis of iPSC-HLCs differentiated using protocol 1 & 2 under 
normoxic and hypoxic conditions – Hierarchical clustering analysis performed using Partek. 
Data pooled from three separate experimental runs. Green bars indicate downregulation 
compared to a pooled control, red bars represent upregulation. The dendrogram indicates 
how closely each sample clusters with shorter branches indicating greater similarity. 
Samples names refer to the following conditions: Hes_norm – Protocol 1, normoxic 
conditions; Hes_hypo – protocol 1, hypoxic conditions; Sil_norm – protocol 2, normoxic 
conditions; Sil_hypo – protocol 2, hypoxic condition; Undif – Undifferentiated iPSCs; PHH –  
Pooled primary human hepatocytes; Pool – technical iTRAQ pool, duplicate sample of 
pooled control used to normalise data. 
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Figure 8 
Principal component analysis of iPSC-HLCs differentiated using protocol 1 & 2 under 
normoxic and hypoxic conditions – Principle component analysis performed using Partek. 
Data pooled from three separate experimental runs. PC1 accounts for 33.1% of the 
variability, PC2 accounts for 16.8% of the variability, PC3 accounts for 10.7% of the 
variability. Samples are colour-coded ad show in the figure legend. Samples names in the 
figure legend refer to the following conditions: Hes norm – Protocol 1, normoxic conditions; 
Hes hypo – protocol 1, hypoxic condtions; Sil norm – protocol 2, normoxic conditions; Sil 
hypo – protocol 2, hypoxic condition; Undiff – Undifferentiated iPSCs; PHH – Pooled 
primary human hepatocytes; Pool – technical iTRAQ pool, duplicate sample of pooled 
control used to normalise data. 
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 3.2.7 Liver-specific genes 
Three lists of liver-specific genes were compiled based on the detected proteins in the 
iTRAQ analyses, categorised as either ‘CYPs’, ‘Phase II’ or ‘Transporters’. The dataset was 
interrogated for expression of these genes which were plotted on bar charts ( Figure  9-14) . 
In each case, blue bars represent non-significant changes (p>0.05), whilst red bars indicate  
significant changes (p ≤0.05) as determined by ANOVA, using Partek. Positive fold 
differences indicate higher expression in the first comparator. A complete list of the 
proteins in each group, abbreviations used, exact values and associated significance (shown 
in Figure 9-14) are tabulated in Appendix 1 (page 235). 
3.2.7.1 Cytochromes P450 
Figure 9 shows protein expression of CYPs in iPSC-HLCs differentiated according to protocol 
1. Figure 9A and Figure 9B show CYP expression in iPSC-HLCs differentiated in normoxia and 
hypoxia respectively, compared to iPSCs. In both cases, all CYPs except CYP2S1 are 
upregulated. In Figure 9A all changes were significant except for CYP4A11 and CYP2D6. In 
Figure 9B all the changes shown were significant except for CYP2A6. Figure 9C and Figure 
9D show CYP expression in iPSC-HLCs differentiated in normoxia and hypoxia respectively, 
compared to hPH, expression of all CYPs was significantly higher in hPH except for CYP2S1 
which was not significantly different. Figure 9E shows a comparison of iPSC-HLCs 
differentiated under normoxia and hypoxia. CYP2D6 was significantly higher in hypoxia 
whilst CYP2A6 was significantly higher in normoxia. All other proteins were non-significantly 
increased in iPSC-HLCs differentiated in hypoxia, except CYP3A4 which was non-significantly 
increased in normoxia. 
Figure 10 shows the CYP expression profile of iPSC-HLCs differentiated using protocol 2 
normoxia and hypoxia. Figure 10A and Figure 10B show iPSC-HLCs differentiated in 
normoxia and hypoxia respectively, versus iPSCs. In both graphs all proteins are significantly 
upregulated in iPSC-HLCs, except CYP2S1 which is significantly downregulated. Figure 10C 
and Figure 10D shows the same iPSC-HLCs compared to hPH. In this case, all the proteins 
are significantly lower than in hPH except for CYP2S1 which, in Figure 10C is non-
significantly higher in iPSC-HLCs and in Figure 10D, is significantly increased. Figure 10E 
shows a comparison of CYP expression between iPSC-HLCs differentiated using protocol 2 
under normal and hypoxic conditions. All proteins are non-significantly increased in 
normoxic conditions except CYP2S1 which is significantly decreased.
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 Figure 9 
Cytochromes P450 expression in iPSC-HLCs differentiated using protocol 1 - (A) Normoxic iPSC-
HLCs versus UD. (B) Hypoxic iPSC-HLCs versus UD. (C) Normoxic iPSC-HLCs versus hPH. (D)  Hypoxic 
iPSC-HLCs versus hPH. (E) Normoxic iPSC-HLCs versus hypoxic iPSC-HLCs. 
Graphs showing the fold difference in CYP expression in iPSC-HLCs differentiated using protocol 1,  
analysed by iTRAQ. Positive values indicate higher expression in the first comparator, bars in red 
show significant changes p ≤ 0.05 determined by ANOVA blue bars are non-significant. Exact values 
for these changes, and associated significance are shown in Appendix 1.  Abbreviations: UD – 
undifferentiated iPSCs, hPH – human primary hepatocytes, CYP – Cytochrome P450, iPSC-HLCs – 




Cytochromes P450 expression in iPSC-HLCs differentiated using protocol 2 - (A) Normoxic iPSC-
HLCs versus UD. (B) Hypoxic iPSC-HLCs versus UD. (C) Normoxic iPSC-HLCs versus hPH. (D)  Hypoxic 
iPSC-HLCs versus hPH. (E) Normoxic iPSC-HLCs versus hypoxic iPSC-HLCs. 
Graphs showing the fold difference in CYP expression in iPSC-HLCs differentiated using protocol 2,  
analysed by iTRAQ. Positive values indicate higher expression in the first comparator,  bars in red 
show significant changes p ≤ 0.05 determined by ANOVA  blue bars are non-significant. Exact values 
for these changes, and associated significance are shown in Appendix 1.  Abbreviations: UD – 
undifferentiated iPSCs, hPH – human primary hepatocytes, CYP – Cytochrome P450, iPSC-HLCs – 
induced pluripotent stem cell-derived hepatocyte-like cells.  
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3.2.7.2 Phase I I metabolism 
Figure 11 shows the phase II metabolism phenotype of iPSC-HLCs differentiated using 
protocol 1. Figure 11A and Figure 11B show normoxic and hypoxic iPSC-HLCs versus 
undifferentiated iPSCs. In Figure 11A UGT2B7, UGT2B10, UGT1A6, SULT1A1, MGST3, 
GSTO1, GSTK1, GSTA2 and COMT are all significantly higher in iPSC-HLCs, other changes are  
non-significant. In Figure 11B, UGT2B7, UGT2B10, SULT1A1, GSTO1, GSTK1, COMT and CAT 
are all significantly higher in iPSC-HLCs whilst GSTP1 is higher in iPSCs, other changes are 
non-significant. Figure 11C and Figure 11D show normoxic and hypoxic iPSC-HLCs 
respectively, versus hPH. In Figure 11C, all proteins were significantly higher in hPH except 
for GSTP1, which was significantly higher in iPSC-HLCs and NQO1, MGST3, GSTM3 and 
GSTM2 which were not significantly different. In Figure 11D, all genes were significantly 
higher in hPH except for GSTP1 and NQO1, which were significantly higher in iPSC-HLCs. 
MGST3, GSTM2 and GSTM3 were not significantly different. Figure 11E shows the 
comparison of phase II metabolism phenotype between normoxia and hypoxia. UGT1A4 is 
significantly higher in hypoxia whilst GSTK1 is significantly higher in normoxia, other 
changes were non-significant. 
Figure 12 shows the phase II metabolism phenotype of iPSC-HLCs differentiated using 
protocol 2. Figure 12A and Figure 12B show normoxic and hypoxic iPSC-HLCs respectively, 
versus iPSCs. In Figure 12A, UGT2B7, UGT2B10, SULT1A1, GSTO1, GSTM2, GSTM3, GSTK1 
and COMT are all significantly higher in iPSC-HLCs, other changes are non-significant. In 
Figure 12B, UGT2B7, UGT2B10, SULT1A1, MGST3, GSTO1, GSTM3, GSTK1 and COMT are all 
significantly higher in iPSC-HLCs, NQO1 and GSTP1 are significantly higher in iPSCs, other 
changes are non-significant. Figure 12C and Figure 12D show normoxic and hypoxic iPSC-
HLCs respectively, versus hPH. In Figure 12C, all proteins were significantly higher in hPH, 
except for GSTP1, GSTM2 and GSTM3 which were significantly higher in iPSC-HLCs and 
NQO1 and MGST3 which were not significantly different. In Figure 12D, all proteins were 
significantly higher in hPH except for GSTP1 and GSTM3 which were significantly higher in 
iPSC-HLCs and NQO1, MGST3 and GSTM2 which were not significantly changed. Figure 12E 
shows the comparison in phase II metabolism enzymes between normoxia and hypoxia. 








Phase II enzyme expression in iPSC-HLCs differentiated using protocol 1 -- (A) Normoxic 
iPSC-HLCs versus UD. (B) Hypoxic iPSC-HLCs versus UD. (C) Normoxic iPSC-HLCs versus hPH. 
(D) Hypoxic iPSC-HLCs versus hPH. (E) Normoxic iPSC-HLCs versus hypoxic iPSC-HLCs. 
Graphs showing the fold difference in Phase II enzyme expression in iPSC-HLCs 
differentiated using protocol 1, analysed by iTRAQ. Positive values indicate higher 
expression in the first comparator, bars in red show significant changes p ≤ 0.05 determined 
by ANOVA blue bars are non-significant. Exact values for these changes, and associated 
significance are shown in Appendix 1.  Abbreviations: UD – undifferentiated iPSCs, hPH – 
human primary hepatocytes,  iPSC-HLCs – induced pluripotent stem cell-derived 
hepatocyte-like cells, UGT - Uridine 5'-diphospho-glucuronosyltransferase, SULT - 
Sulfotransferase, NQO - NAD(P)H dehydrogenase [quinone] 1, MGST - Microsomal 
glutathione S-transferase, GST - Glutathione S transferase, COMT - Catechol O methyl 








Phase II enzyme expression in iPSC-HLCs differentiated using protocol 2 - (A) Normoxic 
iPSC-HLCs versus UD. (B) Hypoxic iPSC-HLCs versus UD. (C) Normoxic iPSC-HLCs versus hPH. 
(D) Hypoxic iPSC-HLCs versus hPH. (E) Normoxic iPSC-HLCs versus hypoxic iPSC-HLCs. 
Graphs showing the fold difference in Phase II enzyme expression in iPSC-HLCs 
differentiated using protocol 2, analysed by iTRAQ. Positive values indicate higher 
expression in the first comparator, bars in red show significant changes p ≤ 0.05 determined 
by ANOVA blue bars are non-significant. Exact values for these changes, and associated 
significance are shown in Appendix 1.  Abbreviations: UD – undifferentiated iPSCs, hPH – 
human primary hepatocytes, iPSC-HLCs – induced pluripotent stem cell-derived hepatocyte-
like cells, UGT - Uridine 5'-diphospho-glucuronosyltransferase, SULT - Sulfotransferase, 
NQO - NAD(P)H dehydrogenase [quinone] 1, MGST - Microsomal glutathione S-transferase, 






Figure 13 shows transporter expression in iPSC-HLCs differentiated using protocol 1. Figure 
13A and Figure 13B show the comparison of iPSC-HLCs differentiated in normoxia and 
hypoxia respectively versus iPSCs. In Figure 13A, VDAC1, VDAC2, GLUT1, MVP, SLC25A24, 
ABCD3 and ABCD1 are all significantly upregulated, whilst ENT1 is significantly 
downregulated, all remaining changes were non-significant. In Figure 13B, VDAC1, VDAC2, 
VDAC3, GLUT3, MVP and SLC25A24 are significantly upregulated and ENT1 and ABCF1 are 
significantly downregulated, all remaining changes were non-significant. Figure 13C and 
Figure 13D show the comparison iPSC-HLCs differentiated in normoxia and hypoxia 
respectively, versus hPH. In Figure 13C VDAC2, GLUT3, GLUT1, ABCC1, MVP, SLC25A24 and 
ABCF1 are significantly increased and GLUT2, SLC25A13 and ABCA6 are significantly 
decreased, all other changes are non-significant. In Figure 13D, VDAC2, VDAC3, GLUT1, 
GLUT3, MVP, SLC25A24 and ABCF1 are significantly upregulated and GLUT2, SLC25A13 and 
ABCD3 are significantly downregulated, all other changes were non-significant. Figure 13E 
shows the comparison of transporter phenotype between cells differentiated in normoxia 
and hypoxia. VDAC2 and VDAC3 are significantly higher in hypoxia and ABCD3 is 
significantly higher in normoxia, all other proteins were not significantly changed. 
Figure 14 shows transporter expression in iPSC-HLCs differentiated using protocol 2. Figure 
14A and Figure 14B show the comparison of iPSC-HLCs differentiated in normoxia and 
hypoxia respectively, versus iPSCs. In Figure 14A VDAC1, VDAC2, GLUT1, MVP, SLC25A24, 
SLC25A12 and ABCD3 are significantly higher in iPSC-HLCs. ENT1 is significantly higher in 
iPSCs, remaining changes are non-significant. In Figure 14B VDAC1, VDAC2, GLUT1, GLUT3, 
SLC25A24 and ABCD3 were all significantly higher in iPSC-HLCs, no other changes were 
significant. Figure 14C and Figure 14D show the comparison of iPSC-HLCs in normoxia and 
hypoxia respectively versus hPH. In Figure 14C, VDAC2, GLUT1, GLUT3, ABCC1 and ABCF1 
were all significantly higher in iPSC-HLCs. GLUT2, SLC25A24 and ABCA6 were all significantly 
higher in hPH, other changes were non-significant. In Figure 14D, VDAC2, GLUT1, GLUT3, 
ABCC1, SLC25A24 and ABCF1 are significantly higher in iPSC-HLCs. GLUT2, SLC25A13, ABCF3 
and ABCD3 were all significantly higher in hPH, remaining changes were non-significant. 
Figure 14E shows a comparison of the transporter phenotype between normoxic and 
hypoxic iPSC-HLCs. SLC25A12 is significantly higher in normoxic conditions whilst GLUT1, 








Transporter expression in iPSC-HLCs differentiated using protocol 1 - (A) Normoxic iPSC-
HLCs versus UD. (B) Hypoxic iPSC-HLCs versus UD. (C) Normoxic iPSC-HLCs versus hPH. (D) 
Hypoxic iPSC-HLCs versus hPH. (E) Normoxic iPSC-HLCs versus hypoxic iPSC-HLCs. 
Graphs showing the fold difference in transporter expression in iPSC-HLCs differentiated 
using protocol 1, analysed by iTRAQ. Positive values indicate higher expression in the first 
comparator, bars in red show significant changes p ≤ 0.05 determined by ANOVA  blue bars 
are non-significant. Exact values for these changes, and associated significance are shown in 
Appendix 1.  Abbreviations: UD – undifferentiated iPSCs, hPH – human primary 
hepatocytes, iPSC-HLCs – induced pluripotent stem cell-derived hepatocyte-like cells, VDAC 
- Voltage dependent anion channel, GLUT - Glucose transporter, ABC - ABC transporter, 









Transporter expression in iPSC-HLCs differentiated using protocol 2 - (A) Normoxic iPSC-
HLCs versus UD. (B) Hypoxic iPSC-HLCs versus UD. (C) Normoxic iPSC-HLCs versus hPH. (D) 
Hypoxic iPSC-HLCs versus hPH. (E) Normoxic iPSC-HLCs versus hypoxic iPSC-HLCs. 
Graphs showing the fold difference in transporter expression in iPSC-HLCs differentiated 
using protocol 2, analysed by iTRAQ. Positive values indicate higher expression in the first 
comparator, bars in red show significant changes p ≤ 0.05 determined by ANOVA  blue bars 
are non-significant. Exact values for these changes, and associated significance are shown in 
Appendix 1.  Abbreviations: UD – undifferentiated iPSCs, hPH – human primary 
hepatocytes, iPSC-HLCs – induced pluripotent stem cell-derived hepatocyte-like cells, VDAC 
- Voltage dependent anion channel, GLUT - Glucose transporter, ABC - ABC transporter, 
MVP - Major vault protein, ENT - Equilibrative nucleoside transporter, SLC - Solute carrier 
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3.2.8 Expression of liver and hypoxia related genes 
qPCR analysis was undertaken on a panel of genes which were unlikely to be readily 
detected by iTRAQ analysis due to low protein expression of these genes (Figure 15). These 
genes included mainly transcription factors where the protein levels are low. A complete 
list of the genes analysed, their fold differences and associated significance is shown in 
Appendix 2. Values are presented as fold difference (2-ΔΔCt) relative to undifferentiated 
iPSCs and were tested in triplicate, the control gene is GAPDH. Significant changes are 
indicated by an asterisk (*) and a connecting bar between the significantly changed samples 
(* =p ≤ 0.05, ** = p ≤ 0.01), determined using a two-tailed, unpaired Student’s t-test. 
Significance testing was not performed relative to hPH. 
Figure 15 A-I shows gene expression in Liv6HB, there were no significantly changed values 
in in panels B, D, E, F, G, H or I. Figure 15A shows fold difference in FOXA2 expression, 
Protocol 1, hypoxia (P1H) shows significantly higher expression than both protocol 2, 
normoxia (P2N) and protocol 2, hypoxia (P2H). Figure 15C shows fold difference in HNF4a 
expression, P1H shows significantly higher expression than P2H and P2N. 
Figure 15 J-R shows gene expression in Liv6HE, there were no significant changes in panels J 
and L. Panel K shows significantly higher VEGF expression in P2H than in P2N. Panel M 
shows significantly increased expression of NRF2 in protocol 1, normoxia (P1N) cells over 
P1H and P2N. P2N shows significantly increased NRF2 expression compared to P1H and 
P2H, which in turn shows significantly greater NRF2 expression than P1H. In panel N the 
expression of ALDOA is significantly increased in P1N compared to P2N. Panel O shows 
significantly increased HSF1 expression in P1N over P1H, P2H and P2N. P1H shows 
significantly less HSF1 expression than P1N and P2H. Panel P shows significantly increased 
HIF1A expression in P1N versus P1H. Panel Q shows expression of CTN NB1, P1N has 
significantly increased expression versus P1H, P2N and P2H. P1H shows significantly less 
CTNNB1 expression than P2N and P2H. Panel R shows NANOG expression, P2N is 
significantly higher than P2H. 
Figure 15 S-AA shows gene expression in Liv7HE, there were no significant changes in 
panels W and AA. Panel S shows significantly higher expression of FOXA2 in P1N versus P2N 
and P2H. Panel T shows significantly higher expression of VEGFA in P1N, than in P2N and 
P2H. Panel U shows significantly higher expression of HNF4a in P1N, than in P1H, P2N and 
P2H. Panel V shows significantly higher expression of NRF2 in P1N, than in P2N and P2H. 
Panel X shows significantly higher expression of HSF1 in P1N, than in P2N and P2H. Panel Y 
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shows significantly lower expression of HIF1 in P1H, than in P2N and P2H. Panel Z shows 











qPCR analysis of iPSC-HLCs differentiated using protocol 1 and 2 under normoxic and hypoxic conditions shows trend toward increased expression under 
normoxic conditions and protocol 1 – (A-I) Fold difference in FOXA2, VEGFA HNF4α, NRF2, ALDOA, HSF1, HIF1A, CTNNB1 and NANOG in PSC-HLCs derived 
from Liv6HB versus undifferentiated iPSCs. (J-R) Identical analysis as performed in section A-I using iPSC-HLCs derived from Liv6HE (S-AA) Identical analysis 
as performed in section A-I using iPSC-HLCs derived from Liv7HE 
Graphs show mean fold difference in gene expression for the gene in the graph title. Fold difference was calculated using the  2-ΔΔCT method (Livak and 
Schmittgen, 2001) using line-matched normoxic iPSCs as a calibrator and GAPDH as a control gene. Horizontal bars show mean fold difference, data points 
show exact values of each replicate, error bars denote standard deviation of the mean. Horizontal bars with asterisks (*) indicate significant differences, 
tested using an unpaired, two-tailed Student’s t-test. Increased number of asterisks denotes smaller p-values, * = ≤ 0.05, ** = ≤ 0.01, *** = ≤ 0.001. Exact 
fold difference values, standard deviation and p-values are shown in Appendix 2. Details of each iPSC line are shown in Table 4. There is a trend towards 
increased gene expression under normoxic conditions and using protocol 1, though the results are inconsistent between cell lines. Abbreviations: ALDOA -  
Aldolase A, FOXA2 - Forkhead box protein A2, GAPDH - Glyceraldehyde 3-phosphate dehydrogenase, HIF1A - Hypoxia inducible factor 1A, HLC - Hepatocyte-
like cell, HNF4a - Hepatocyte nuclear factor 3a, HSF1 - Heat shock factor 1, iPSC - Induced pluripotent stem cell, NRF2 - Nuclear factor erythroid 2-related 
factor 2, P1H - Protocol 1 hypoxia, P1N - Protocol 1 normoxia, P2H - Protocol 2 hypoxia, P2N - Protocol 2 normoxia, VEGFA - Vascular endothelial growth 




iPSC-HLCs potentially offer an unlimited source of hepatocytes for a range of uses from 
transplant to toxicity testing. They are particularly valuable since they can be derived non-
invasively from patients and can theoretically mimic the phenotype of their donor. 
However, despite numerous attempts to improve differentiation, their phenotype is 
generally considered to be closer to that of an immature foetal hepatocyte (Baxter et al., 
2015). These attempts have included alteration of both the chemical and physical 
properties of differentiation to more closely mimic the process of embryonic development. 
In this study we have assessed the performance of two differentiation protocols and the 
effects of oxygen modulation on the differentiation of iPSCs to iPSC-HLCs. Protocol 1 uses a 
more traditional growth factor-based approach whilst protocol 2 uses small molecules to 
mimic the effects of growth factors. We used a hypoxic environment (5% O2, 5% CO2, 90% 
N2) in comparison to standard tissue culture conditions where only CO2 was mechanically 
controlled, atmospheric gases provided the remaining gas composition. 
3.3.1 Effects of hypoxia on undifferentiated iPSCs 
The positive effects of hypoxia on the pluripotency of iPSCs have been known for some 
time, we sought to confirm these results in our lab. Liv4FA iPSCs were cultured under 
hypoxic conditions for several passages and their expression of pluripotency markers, 
hypoxia-inducible genes, and NRF2-related genes was assessed by qPCR (Figure 6). When 
cells were cultured in 5% O2, small but significant increases in the pluripotency markers, 
SOX2 and NANOG were observed (Figure 6B). The increase in OCT4 was of similar 
magnitude but did not achieve significance. These findings agree with literature reports of 
improved pluripotency in hypoxia. We also examined the gene expression of several 
hypoxia inducible genes, all the tested genes showed increased expression which confirmed 
that 5% O2 was sufficient to induce a hypoxia response in iPSCs (Figure 6A). Finally, we also 
examined the gene expression of three NRF-2 pathway-related genes. The NRF-2 pathway 
is the master regulator of the cellular response to oxidative stress which may be expected 
to be active under hypoxic conditions (Mutter et al., 2015). Indeed, NRF-2 and HO-1, an 
NRF-2-regulated gene, were both significantly upregulated in hypoxic iPSCs versus normoxic 
(Figure 6C). Taken together, these results show that 5% O2 induces far-reaching effects in 




3.3.2 Morphological differences between conditions 
Figure 5 shows the morphology of Liv6HE HLCs differentiated under each condition in 
comparison to hPH and iPSCs. Polygonal morphology, like  that of hPH (Figure 5F) can be 
observed in panels B-D. However, this morphology is not apparent in Figure 5A and in 
Figure 5B-D the size of these cells is generally smaller than hPH. Moreover, there are no 
multinucleate cells observable in iPSC-HLCs, which are apparent in hPH. Conversely, the 
morphology is different to that exhibited by iPSCs in Figure 5E where the cells are smaller 
and compacted. 
Whilst morphology is not necessarily required for the biochemical phenotype of the iPSC-
HLCs, it follows that a perfect recapitulation of hPH would also recapitulate their 
morphology. Whilst difficult to quantify, the morphology of iPSC-HLCs differentiated using 
protocol 1 appears to be slightly improved under hypoxic conditions and the morphology of  
cells differentiated using protocol 2 appears to be largely unchanged in either oxygen 
condition. Moreover, the morphology of the cells in Figure 5A is the least like hPH, 
suggesting some shortcomings of this protocol. 
3.3.3 iTRAQ Analyses 
HCA and PCA were both performed on the iTRAQ dataset to examine if any large -scale 
changes occurred due to the differentiation protocols or oxygen conditions ( Figure 7 & 8). 
Both of these analyses showed that iPSC-HLCs were not strongly separated based on any of  
the tested conditions with the exception of two iterations of P1H, the reasons for this are 
unclear but are also observed in Figure 15 during qPCR analysis where VEGFA and ALDOA 
expression in 2/3 points for P1H are very low compared to the third point. It is unclear 
whether these two data points are spurious since, the third point separates from these two 
but clusters closely with the points from other protocols. 
Furthermore, iPSC-HLCs do not cluster closely with hPH. This has been shown repeatedly by 
other studies (Table 1) and it was not expected that alteration of the oxygen level would 
cause iPSC-HLCs to fully recapitulate the phenotype of hPH, rather that hypoxia may 
provide one of many necessary incremental improvements in the phenotype might be 
observed and used in combination with other approaches e.g. 3D culture, co-culture etc. 
Similarly, it is promising that iPSC-HLCs do not cluster closely with iPSCs, this shows that the 




3.3.3.1 Cytochromes P450 expression 
CYPs are an essential part of the phase I metabolism performed by hepatocytes, therefore 
reproduction of their expression is essential for an accurate hepatic phenotype. We 
selected a panel of CYPs and examined their expression using the iTRAQ dataset ( Figures 9 
& 10, Appendix 1). Figure 9 shows the expression of CYPs in iPSC-HLCs differentiated using 
protocol 1. Panel A shows the changes in CYP expression between normoxia and 
undifferentiated cells. The magnitude of these changes was small and only CYP3A4 and 
CYP2S1 exceed a fold-change magnitude of 5. CYP2S1 is repeatedly downregulated during 
the process of differentiation (Figure 9 & 10) and is the only CYP whose expression is close 
to that of hPH (Figure 9C-D & 10C-D), this is a positive indicator for the phenotype of iPSC-
HLCs as CYP2S1 is implicated mainly in extrahepatic xenobiotic metabolism and the 
decrease in expression moves the phenotype closer to that of hPH (Saarikoski et al. ,  2005) . 
Figure 9B shows the CYP expression of iPSC-HLCs differentiated under hypoxic conditions, 
the pattern of expression is largely similar to normoxia. Moreover, there is a trend towards 
increased expression of most CYPs, this is visualised in Figure 9E when compared with ce lls 
differentiated under normoxic conditions. It should be stressed that the magnitude of all 
these changes are small compared to hPH, as shown in Figure 9C and 6D, regardless of 
oxygen conditions, the expression remains lower. 
Using protocol 2, all CYPs except CYP2S1 were significantly increased over undifferentiated 
cells (Figure 10). However, there was no clear trend between normoxia and hypoxia (Figure 
10E), CYP2S1 was the only significantly altered protein which was significantly higher under 
hypoxic conditions and the magnitude of all other changes was less than 2.5. Similarly to 
protocol 1, when compared to hPH, iPSC-HLCs express lower levels of CYPs (Figure 10C & 
D). 
3.3.3.2 Phase I I metabolism enzymes expression 
We next examined the expression of phase II metabolic enzymes in iPSC-HLCs differentiated 
under each condition. The majority of proteins were unchanged or only changed by a small 
magnitude. In Figure 11A, the upregulation of GSTK1 and COMT are of interest because the 
large change in expression during differentiation reduces the difference between hPH and 
these proteins to less than 5-fold indicating more complete differentiation. GSTK1 is a 
member of the GSTK family or the mitochondrial GSTs. It is primarily expressed in the 
mitochondria of the liver, kidney and adrenal glands in humans. Similar expression of GSTK1 
is a positive phenotypic indicator for iPSC-HLCs, particularly since it may indicate the 
adaptation of the mitochondria to a hepatic phenotype. 
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In the comparison of phase II phenotype between oxygen conditions ( Figure 11C & D) the 
majority of proteins are expressed more highly in hPH. When oxygen conditions are 
compared, the magnitude of the changes is small overall (Figure 11E). UGT1-4 is 
significantly increased in iPSC-HLCs differentiated under hypoxic conditions, whilst GSTK1 is 
significantly higher under normoxic conditions. Overall, there is no consistent improvement 
in phase II phenotype for either oxygen condition using protocol 1. 
Under normoxic conditions, COMT, GSTK1, UGT1-4 and UGT2B10 were significantly 
upregulated versus undifferentiated cells and also had a fold difference greater than 5 
(Figure 11D). Under hypoxic conditions, COMT, GSTK1, GSTO1, UGT2B10 and UGT2B7 were 
significantly upregulated and had fold differences greater than 5 (Figure 11E). Interestingly, 
the significantly downregulated proteins, GSTP1 and NQO1 are both modulated by  the 
NRF2 pathway, suggesting a decrease in NRF2 activity in the cells differentiated in hypoxia 
(Mutter et al., 2015; Satoh et al., 2002).  
Compared to hPH, the majority of proteins has significantly lower expression, though 
GSTP1 and GSTM3 are significantly higher in iPSC-HLCs in both oxygen conditions (Figure 
12B & C). Under normoxic conditions GSTM3 is also significantly increased in iPSC-HLCs. For 
protocol 2, SULT1A1 and GSTM2 are significantly upregulated in normoxia over hypoxia, 
(Figure 12E). However, the magnitude of this change, and all other changes, are small.  
3.3.3.3 Transporter Expression 
We next examined transporter expression Figure 13 & 14, Appendix 1). With protocol 1, 
normoxia, VDAC1, MVP, SLC25A24 and ABCD3 are significantly increased by greater than 5-
fold and ENT1 is significantly downregulated by greater than 5-fold (Figure 13A). Under 
hypoxic conditions VDAC1, VDAC2, SLC25A24 and MVP were significantly increased by 
greater than 5-fold (Figure 13B). Both protocols show good expression of MVP, the major 
structural component of the vault organelle (Berger et al., 2009). Vaults may be involved in 
chemoresistance, as MVP is overexpressed in some multidrug resistant cancer cell lines and 
is therefore a positive indicator for the phenotype of iPSC-HLCs (Scheffer et al., 1995). 
The transporter phenotype appears to be relatively well reproduced in iPSC-HLCs (Figure 
13C & D). The majority of changes were either small or non-significant compared to hPH. Of  
the significantly changed proteins, 3 show small changes (<5-fold) and all except GLUT3 
show only modest changes (<15-fold). Increased GLUT3 expression under hypoxic 
conditions (Figure 13B & 14B) may be an effect of oxygen modulation. GLUT3 is a widely 
expressed hypoxia-responsive high affinity glucose transporter which is upregulated in 
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response to hypoxia via the HIF1a pathway, typically in combination with GLUT1 
(Mobasheri et al., 2005). However, it is also possible that high expression of GLUT3 is 
indicative of poor maturation as it is also highly expressed in embryonic tissues before birth 
and also aids in the maintenance of pluripotency under hypoxic conditions (Christensen et 
al., 2015; Mobasheri et al., 2005). 
Both VDAC2 and VDAC3 are significantly higher in hypoxic conditions and ABCD3 is 
significantly higher in normoxic conditions (Figure 13E). ABCD3 shows the largest significant 
change in expression, this change may be due to oxygen modulation. ABCD3 is expressed 
on the membrane of liver peroxisomes whose activity is dependent on the availability of 
molecular oxygen as an electron acceptor (Schönenberger, 2015). However, the magnitude 
of changes in Figure 13E are low overall, suggesting that oxygen modulation had little 
effect. 
When differentiated in normoxia using protocol 2, iPSC-HLCs the majority of changes are 
small or non-significant (Figure 14A-B). In comparison to hPH, the phenotype is favourable 
with 9 and 8 proteins non-significantly different to hPH in normoxia and hypoxia 
respectively (Figure 14C & D). Moreover, in panel C, 4 of the significantly altered proteins 
show small fold differences (<5-fold) and all except ABCA6 show only modest fold 
differences (<15-fold). 
It is interesting that ENT1 is downregulated during differentiation (Figure 13A & B, 14A). 
ENT1 is repressed by HIF1 in response to hypoxia providing cardioprotective effects in mice 
(Eltzschig et al., 2005; Rose et al., 2010). This explains the downregulation observed in 
Figure 13B (hypoxia) but not the downregulation observed in Figure 13A and 14A 
(normoxia), or the lack of an effect in Figure 14B (hypoxia). Taken together, these results 
suggest that the changes in ENT1 are not related to the oxygen tension and may instead 
represent a more general shift towards a hepatic phenotype (Figure 13C-D, 14C-D). ENT1 is 
implicated in the toxicity of fialuridine (McKenzie et al., 1995; Xu et al., 2014). The 
expression of ENT1 was not significantly different to hPH and therefore, iPSC-HLCs from 
each condition could reasonably be expected to model fialuridine toxicity.  
3.3.4 Effects of hypoxia on gene expression in iPSC-HLCs 
Though global proteomic analysis was performed on iPSCs, there are shortcomings of the 
technique that require supplementation with gene expression analysis. Very low 
abundance proteins, such as some transcription factors can be challenging to detect using 
iTRAQ. A panel of relevant genes were examined using qPCR (Figure 15, Appendix 2, page 
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243). In each iPSC-HLC line there was a trend towards increased FOXA2 expression in P1N, 
though the trend is only significant in 6HE. FOXA2 was also significantly increased in P1H 
relative to protocol 2 in Liv6HB. FOXA2, also known as hepatocyte nuclear factor 3a is 
considered a ‘pioneer factor’, whose expression drives hepatocyte specification and 
activates expression of genes such as AFP and albumin (Friedman and Kaestner, 2006). High 
expression of FOXA2 is a positive indicator of phenotype in iPSC-HLCs for these reasons, 
however it should be noted that the expression in hPH is dramatically higher than in iPSC-
HLCs indicating their relative immaturity. 
VEGFA expression was generally higher using protocol 1 (Figure 15 B, K, T), and was 
significantly higher in Liv7HE P1N versus protocol 2 but was variable. In Liv6HE, VEGFA 
expression was significantly higher in low oxygen, though only in protocol 2. VEGFA is an 
angiogenesis factor and hypoxia responsive gene (Ahmed et al., 2016), so increased 
expression in low oxygen conditions is expected (Figure 15K) but it is not clear why there 
should be increased expression in P1H (Figure 15T). The reasons for the high degree of 
variability, particularly in Liv6HE are unclear, though it is apparent that none of the lines or 
protocols show full maturity, as the expression in iPSC-HLCs is similar to that of 
undifferentiated iPSCs and in hPH, expression is approximate ly 10-40-fold higher. 
HNF4a is the most abundant DNA-binding protein in the liver where it regulates the 
expression of HNF1a and also genes related to gluconeogenesis and lipid metabolism 
(Chandra et al., 2013). Like FOXA2, HNF4a was expressed most highly in P1N and generally 
showed increased expression in protocol 1 overall. In Figure 15U, HNF4a expression is 
significantly higher in P1N than P1H, P2N and P2H and in Figure 15C expression in P1H was 
significantly increased over both P2N and P2H. Increased expression of HNF4a is a good 
indicator of hepatic maturity, though expression is still lower than in hPH.  
NRF2 was also examined, some NRF2-related proteins were also investigated by iTRAQ 
(Figure 11 & 12), though direct assessment of the NRF2 transcript may also be informative. 
As previously discussed, NRF2 is the master regulator of the cellular response to oxidative 
stress. Some caution should be placed in the interpretation of NRF2 by qPCR due to the 
mechanism of NRF2 regulation. NRF2 is continuously expressed, translated and 
subsequently degraded when bound by KEAP1, under conditions of oxidative stress, the 
degradation of the protein is impaired, which then enters the nucleus (Mutter et al., 2015) . 
Nonetheless, NRF2 pathway activation is implied by increased transcription and it is 
interesting NRF2 shows increased expression in P1N iPSC-HLCs where it is significantly 
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higher than P1H and P2H Figure 15M & V. Additionally, P2N also shows increased NRF2 
expression and is significantly increased over P1H and P2H (Figure 15M). This suggests an 
increased degree of oxidative stress in cells in a normoxic environment. 
HSF1 is a transcription factor which governs the response to proteotoxic stressors such as 
heat or hypoxia amongst other functions (Dayalan Naidu and Dinkova-Kostova, 2017; 
Vihervaara and Sistonen, 2014). Interestingly, HSF1 was most highly expressed in P1N, 
where it was significantly higher than P1H, P2N and P2H (Figure 15O & X). In addition, both 
P2N and P2H show significantly increased HSF1 expression over P1H (Figure 15O). This is 
contrary to the expectation that hypoxic conditions would induce HSF1 expression and 
though the changes are small this suggests activation of a hypoxia response under normoxic 
conditions. Similarly, the pattern of HIF1A expression is somewhat unclear, HIF1A is the 
master regulator of the cellular hypoxia response and is induced in response to hypoxic 
conditions (Majmundar et al., 2010). In Figure 15P, HIF1A is significantly increased in P1N 
over P1H and in Figure 15Y HIF1A expression is significantly increased in P2N and P2H over 
P1H. It is expected that HIF1A would show greater expression in cells differentiated under 
hypoxic conditions, but this is not always the case. The lack of upregulation of HIF1A in 
iPSC-HLCs is unexpected because HIF1A induction was shown in undifferentiated cells 
(Figure 6), suggesting either that this upregulation was lost during differentiation or the 
hypoxia response is being induced under normoxic conditions.  
CTNNB1 is both a structural protein in adherens junctions and a major ligand in the Wnt 
signalling pathway which is involved in many developmental processes,  the maintenance of 
pluripotency and definition of the perivenous phenotype in the liver (Sokol, 2011). The 
changes in CTNNB1 expression in Figure 15H, Q & Z were small. Nonetheless, some 
conditions significantly changed CTNNB1 expression. In Figure 15Q, CTNNB1 expression was 
significantly increased in P1N over P1H, P2N and P2H and was also significantly increased in 
P2H and P2N over P1H. Similarly, in Figure 15Z P2N is significantly increased over P1H. 
Increased expression of CTNNB1 implies increased activation of the Wnt signalling pathway, 
and may be indicative of several factors, e.g. immaturity, perivenous phenotype. However 
the fold differences are small and similar to the level of expression found in hPH which 
were not enriched for perivenous cells. These results also allude to the difficulty inherent 
with iPSC lines in that even clones from the same donor and cell type (Figure 15Q & Z) show 
differing results possibly due to an altered tendency to differentiate, these findings are in 
agreement with our previous work which shows that clonal and donor differences 
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contribute more than cell type of origin to the overall phenotype of iPSC-HLCs (Heslop et 
al., 2017). 
Finally, the expression of NANOG was also examined in iPSC-HLCs (Figure 15 I, R & AA). 
NANOG is a transcription factor which aids in maintenance of pluripotency and supresses 
differentiation, therefore it is expected that expression would be lower in differentiated 
cells compared with iPSCs. Indeed, NANOG generally showed lower expression in iPSC-HLCs 
than in iPSCs, though only a single significant change was observed in Figure 15 R where 
P2N showed slightly increased expression over P2H. In Figure 15 I, R & AA for P1H, some 
data points are dramatically higher than the majority of other differentiations. These data 
may represent poorly differentiated cells and indicate the possibility of variation between 
experimental runs present with growth factor-based protocols. The relatively high 
expression of NANOG observed in hPH is also of interest, at approximately 2-fold higher 
than in iPSCs, this is an unexpected result and the reasons for increased expression of a 
pluripotency factor in mature cells is unclear.  
3.3.5 A perivenous phenotype? 
We hypothesised that the use of lower oxygen during differentiation may produce iPSC-
HLCs with a perivenous phenotype. The phenotype of hepatocytes changes across the liver 
lobule with those in the periportal region specialising in gluconeogenesis and glutathione 
synthesis whilst those in the perivenous region specialise in glycolysis and show high 
expression of CYPs (Colnot and Perret, 2011). In addition, the perivenous phenotype in vivo  
is characterised by low oxygen and high expression of hypoxia inducible factors and Wnt 
signalling (Kietzmann, 2017). To determine if a perivenous phenotype was produced in 
hypoxic iPSC-HLCs we examined markers of both the periportal and perivenous zones. As 
previously stated, Wnt signalling is increased in perivenous hepatocytes and CTNNB1, a 
major Wnt pathway ligand was examined in Figure 15H, Q & Z, CTNNB1 was not 
consistently increased in hypoxic iPSC-HLCs, indeed in several cases there was increased 
signalling under normoxic conditions (Figure 15Q & Z). CYP expression is also higher in 
perivenous hepatocytes, notably CYP1A2 and CYP2E1 (Colnot and Perret, 2011), these 
proteins were detected in iTRAQ analysis (Figure 9 & 10) but were not significantly changed 
between oxygen conditions. CDH1, ARG1, PCK1/2 and CPS1 show increased expression in 
periportal hepatocytes (Sekine et al., 2009). These proteins were detected in iPSC-HLCs by 
iTRAQ analysis and shown in Appendix 1. Of these proteins, only CDH1 and PCK2 were 
significantly changed in protocol 2 and 1 respectively. CDH1 was increased 2.2-fold in 
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hypoxic iPSC-HLCs. However, contrary to expectation PCK2 was increased by approximately 
1.4-fold in normoxic iPSC-HLCs. 
These results suggest that culture under hypoxic conditions did not produce a perivenous 
phenotype in iPSC-HLCs. The reasons for this are initially unclear, and made more so by the 
loss of HIF1A activation despite maintenance of the hypoxic environment (Figure 15P & Y) . 
It may be the case that cells under normoxic conditions are experiencing some degree of 
hypoxia due to the diffusion of oxygen throughout the medium. In static cultures like those 
used herein, the penetration of oxygen into the culture medium is low, reaching saturation 
slowly, particularly considering the deoxygenation of liquids that occurs during autoclaving, 
though we did not autoclave the culture medium it is probable that it was autoclaved by 
the manufacturer (Somerville and Proctor, 2013). Furthermore, Somerville and Proctor 
(2013) suggest that cells grown below a depth of 1 mm experience anaerobic conditions. 
Given the use of 6-well plates and 2 mL culture volume, the depth of medium in each 
condition was approximately 2.1 mm, therefore it is probable that the oxygen 
concentration perceived by the cells under both normoxic and hypoxic conditions is lower 
than may initially be expected. 
Because the diffusion of oxygen into the culture is governed by Fick’s law where the 
concentration gradient of oxygen between gas and liquid and the thickness of the liquid is 
considered, the time to reach equilibrium will be slowed by hypoxia, moreover the 
consumption of oxygen by cells at the bottom of the liquid should be considered for the 
time taken to reach equilibrium and can potentially prevent the formation of equilibrium in 
highly metabolically active cells (Place et al., 2017). Considering these factors, Place et al. 
calculated the depth of culture medium where cellular oxygen demand meets rate of 
diffusion for a range of cell types and oxygen concentrations under typical (normoxic) 
incubator conditions. The depth for ESCs was calculated and was assumed to be similar to 
iPSCs at 7.1 mm and 8.7 mm to produce conditions similar to a periportal hepatocytes (60 
mmHg O2), or perivenous hepatocytes (40 mmHg O2) respectively, this is greater depth than 
was used in the experiments herein so the cells likely were not oxygen-starved, however, 
hepatocytes have a higher metabolic rate than iPSCs (Place et al., 2017). The maximum 
depth for rat hepatocytes was also calculated and was assumed to be similar to that of 
iPSC-HLCs, to achieve similar oxygen concentrations in these cells a maximum medium 
depth of 1.1 and 0.9 mm for periportal and perivenous respectively would be required. 
Therefore, the depth of medium used in these experiments likely starved even the 
normoxic iPSC-HLCs of oxygen, effectively producing hypoxic conditions over the course of  
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differentiation as the metabolic demand of the cells increased and explaining the lack of 
separation between oxygen conditions (Place et al., 2017). Effectively, the cells under 
hypoxic conditions became increasingly hypoxic over the course of differentiation and may 
have even reached conditions of near anoxia. This realisation helps to explain the increased 
failure rate of differentiations that was casually observed under hypoxic conditions (data 
not shown), cells were likely already fragile from oxygen starvation and more prone to 
detachment and death. 
3.3.6 Conclusions 
In summary, these results show that there is no strong advantage to the use of hypoxia 
during differentiation of iPSCs to iPSC-HLCs. The differences in expression of genes between 
oxygen conditions was typically small and inconsistent between iPSC lines suggesting a that 
clonal variation and other non-defined factors contribute more strongly to the variations in 
expression observed. There were also similar results for the comparison of differentiation 
protocols, the majority of differences observed between either protocol were small and 
inconsistent. HCA did not reveal strong separation based on either oxygen conditions or 
differentiation protocol and PCA showed that all four conditions clustered relatively closely 
together compared to iPSCs and hPH. 
These results also revealed higher variability in iPSC-HLCs produced using protocol 1. There 
are two data points for P1N in Figure 7 & 8 which separate strongly from the other iPSC-
HLCs and high variability in gene expression was frequently observed in HLCs differentiated 
using protocol 1 in Figure 15. This may represent increased variability from the growth 
factor-based protocol. Given the minimal advantages observed in using the growth factor -
based protocol 1 it seems prudent that future studies should use the cheaper and faster 
small molecule-based protocol 2. Though the possibility that improved differentiation may 
be observed with the protocol 1 with more thoroughly optimised differentiation conditions 
cannot be ruled out. Furthermore, since no major advantage appears to have been 
conferred to the hepatocyte phenotype during differentiation under hypoxia, we suggest 
that either normal oxygen levels or even high oxygen levels based on the increased oxygen 
demand of more metabolically active differentiated hepatocytes should be used for future 
studies. These results also agree with published literature regarding the beneficial effects of 
hypoxia on the pluripotency of iPSCs (Figure 6). Therefore, future studies should maintain 
and grow iPSCs under hypoxic conditions and increase the levels of available oxygen to cells 
over the course of differentiation in order to meet the increasing oxygen demand. 
Considering the level of oxygen available to cells in culture as described by Place et al. 
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(2017), the exact oxygen composition of the differentiation atmosphere could be adjusted 




4 Assessing the proteome of human liver organoids and 




Organoids are a recently developed type of 3D culture which produce miniaturised organ-
like structures in a supportive matrix such as Matrigel or BME-2 (Sato et al., 2009). It is 
anticipated that they will be useful in the production of large quantities of mature cells in a 
physiologically-relevant architecture which may be then useful for toxicity testing or 
transplant. Organoids have been derived from several tissues including brain, pancreas, 
kidney, intestine and liver. Organoids are derived from either pluripotent or adult stem cells 
and even cancer cell lines and self-assemble in 3D culture in a range of conformations 
including hollow cysts and dense ‘bunch-of-grapes’ structures. Although organoids have 
only recently been developed, they have already seen widespread use, for example they 
have been used to model: organ development and microcephaly in the brain (Lancaster et 
al., 2013), infectious diseases including Cryptosporidium parvum (Castellanos-Gonzalez et 
al., 2013) and rotaviruses (Finkbeiner et al., 2012), genetic diseases including familial 
multiple intestinal atresia (Bigorgne et al., 2014), cystic fibrosis (Dekkers et al., 2013), α1-
antitrypsin deficiency and Alagille syndrome (Huch et al., 2015). Moreover, drug efficacy 
screening has been performed on pancreatic organoid cultures showing function of several 
compounds including cetuximab and nutlin-3a whilst simultaneously demonstrating the 
possibility of high-throughput screening for organoid cultures (Van De Wetering et al., 
2015). 
Previous studies using human hepatic organoids have made extensive use of RNA 
quantification techniques such as RNAseq and microarrays. However, it is well understood 
that although RNA expression is a worthwhile method to examine cell phenotype there are  
often discrepancies between the levels of RNA expression and the levels of protein 
expression observed. It has been shown that the correlation between mRNA and protein 
expression may be as low as 40-50% (Schwanhüusser et al., 2011; Vogel and Marcotte, 
2012). Since, in most cases, proteins are the functional product of gene expression, a more 
accurate depiction of the true phenotype of human liver organoids can be obtained by 
examining the proteome rather than mRNA. 
In this chapter, we have focussed on the production of human organoids derived from liver 
resident stem cells and their differentiation towards a hepatocyte fate . We sought to 
reproduce the work demonstrated in Broutier et al. (2016). Initially we established 
organoids from several human donors using surgical waste liver tissue and optimised the 
isolation technique for our laboratory. These optimisations included the use of FACS to 
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select for EpCAM-positive cells and more straightforward crude isolations of the cells. Once 
established, we sought to examine the proteomic phenotype of human Chol-Orgs when 
differentiated towards a hepatocyte fate, a key omission in the published data until this 
point. 
4.2 Results 
4.2.1 Rapid isolation of tissue after excision improves isolation success in 
human liver organoids 
In the protocol published by Broutier et al. (2016) the authors state that liver tissue may be 
stored for up to 48 hours at 4 °C in organoid basal medium (Table 2) prior to isolation. We 
performed several isolations on tissue at various time points after resection of the tissue 
and noted a negative correlation between the time after resection and the success of the 
organoid isolation. Isolations performed less than 24 hours after resection. These were 
successful in up to 80% of cases with a precipitous drop in efficiency after this point. This is 
not in agreement with Broutier et al., wherein they reported this reduction in efficiency 
only after 48 hours. 
4.2.2 FACS does not improve isolation success from hum an liver 
organoids 
During this work, we sought to optimise the isolation of Chol-Orgs from human liver tissue. 
In Broutier et al. (2016), the authors discuss the use of FACS as an optional step to isolate 
EpCAM-positive cells as the progenitor cells which give rise to Chol-Orgs. Figure 16 shows 
the gating used on the FACS Aria III to sort the EpCAM-positive cells from the crude cell 
population. Cells were isolated from human liver tissue on three occasions and stained for 
EpCAM using an APC conjugated antibody and the nuclei were stained using DAPI. Gating 
was established during the first run and identical gating was used in each subsequent 
experiment. Gating aims to remove non-relevant cells or debris from the final cell 
suspension. In this case, the first two gates remove cell debris and clusters of cells 
respectively. The third gate uses DAPI-stained nuclei to detect viable cells. The fourth gate  
removes cells which were negative for APC, and consequently EpCAM-negative. 
The gating for each experiment in Figure 16 shows a maximum of 10,000 events, only a 
small portion of the total cell population was allocated for establishing and confirming 
gating and therefore, only 5,024 events were recorded for experimental run 3 where the 
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cell count was very low. The breakdown of events at each gate can be seen in sections F, L 
and R. Based on these results, it can be observed that the proportion of EpCAM-positive 
cells in these sample are low, contributing between 0.7 and 4.0% of the total number of 
cells. This is unsurprising given that EpCAM-positive cells are typically found around the bile  
ducts and comprise a small proportion of the whole liver cell number.  
After concentration of EpCAM-positive cells by FACS had been achieved, the cells were 
plated in BME-2 as normal and were monitored for signs of organoid growth. However, 
very few organoids were observed to arise from these sorted cells ( Figure 18A-B). The 
number of organoids arising from this method was not quantified but was visually 
determinable as lower than the numbers of organoids arising from the crude isolation.  
4.2.3 Human liver organoids established in culture have cystic 
morphology 
Figure 18C-D shows the typical morphology of the Chol-orgs that were derived. These 
results agree with the published literature, which also show the characteristic cystic 
morphology. The size of the organoids varied greatly in some cases up to several 
millimetres in diameter and visible to the naked eye. However, in most cases organoids 
were smaller. 
It is noteworthy that some organoids displayed a dense morphology, as though the cystic 
structure had collapsed. We were not able to investigate these organoids more closely due 
to the inability to separate them from the whole population, but it is unclear whether these 
organoids represent cells spontaneously differentiating towards a hepatocyte fate, as this 
morphology is more common in differentiated organoids, or whether these are organoids 
that have collapsed and failed to proliferate (Figure 18C-F). 
4.2.4 Human liver organoids can be cryopreserved and thawed 
A protocol for cryopreservation was presented in Broutier et al. (2016), we sought to 
replicate this procedure in our lab. We used two commercial freezing media to 
cryopreserve organoids, Recovery Cell Culture Freezing Medium and CryoStor CS10. 
Cryopreservation was performed as described previously and organoids were stored in 
liquid nitrogen for at least one week and up to 4 months. Both media were found to 
perform similarly and it was possible to recover organoids even at the longest time points 




However, we noted that the proliferation rate of organoids that had been cryopreserved 
for long periods was substantially damaged. Though we were not able to easily depict this 
quantifiably. This greatly extended the time taken to produce reasonable quantities of 
organoids to approximately 3 months, in lines where similar proliferation occurred in 2-3 





Sort reports for fluorescence activated cell sorting enrichment of EpCAM-positive cells in 
three liver specimens – (A) Gating for enrichment of EpCAM-positive cells from crude liver 
cell suspension in a single donor. The crude suspension was stained for EpCAM with an APC 
conjugated probe and DAPI as a viability stain. (i) Gating used to select for live cells. (ii) 
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Gating used to select for single cells. (iii) Gating used to select for viable cells, determined 
by absence of DAPI staining. (iv) Gating used to select for EpCAM-positivity, determined by 
presence of APC staining. (v) tabulation of number of events passing through each gate  (B)  
Identical sort for EpCAM-positive cells as shown in section A in a separate donor. Gates in 
sections i-iv sort for the same criteria as section A (C) Identical sort for EpCAM-positive cells 
as shown in section A in a separate donor. Gates in sections i-iv sort for the same criteria as 
section A 
Each point represents a single event e.g. a single cell. Points outside the gating are n ot 
included in subsequent panels. Points in each section are colour-coded as shown in section 
v, these colours are based on the gate at which the cell was excluded, points in grey 
indicate live cells, points in blue indicate singlets, points in amber indicate viable cells and 
points in red indicate EpCAM-positive cells. Colour coding is incomplete for section C-iv. 
These data were generated using a FACS Aria III (BD Biosciences) and analysed using 





Post-sorting reports for fluorescence activated cell sorting enrichment of EpCAM-positive 
cells in three liver specimens – (A) Identical gating to that used in Figure 16A to confirm 
successful gating for enrichment of EpCAM-positive cells in the previous report. The cells 
sorted in this figure are taken from the sorted cells in Figure 16A. (i) G ating used to select 
for live cells. (ii) Gating used to select for single cells. (iii) Gating used to select for viable 
cells, determined by absence of DAPI staining. (iv) Gating used to select for EpCAM-
Chapter 4 
112 
positivity, determined by presence of APC staining. (v) tabulation of number of events 
passing through each gate (B) Identical sort for EpCAM-positive cells as shown in section A 
in a separate donor. Gates in sections i-iv sort for the same criteria as section A (C) Identical 
sort for EpCAM-positive cells as shown in section A in a separate donor. Gates in sections i -
iv sort for the same criteria as section A. 
Each point represents a single event e.g. a single cell. Points outside the gating are not 
included in subsequent panels. Points in each section are colour-coded as shown in section 
v, these colours are based on the gate at which the cell was excluded, points in grey 
indicate live cells, points in blue indicate singlets, points in amber indicate viable cells and 
points in red indicate EpCAM-positive cells. Colour coding is incomplete for section C-iv. 
These data were generated using a FACS Aria III (BD Biosciences) and analysed using 




Micrographs showing organoids isolated by fluorescence activated cell sorting 
enrichment or crude plating, and after differentiation – (A-B) Representative brightfield 
micrographs of cells plated after FACS sorting of EpCAM-positive cells. No organoids are 
visible, the faint ring-structures are bubbles in the BME-2 matrix. No further outgrowth was 
noted from cells isolated using fluorescence activated cell sorting enrichment. (C-D) 
Representative brightfield micrographs of donor 1 organoids at passage 1-2 after isolation 
using the ‘crude-plating’ method (Table 5). Cystic organoid structures are visible in a range 






which may represent collapsed or dead organoids. (E-F) Representative brightfield 
micrographs of donor 1 organoids at day 15 of differentiation. There is a stark change in the 
appearance of the organoids which have mostly become dark and opaque. The cause of the 
gross change in appearance is unclear but was interpreted to be a result of the 
differentiation process. 





Chol-org liver differentiation protocol and sample collection points – Protocol for the 
differentiation of Chol-orgs to a hepatocyte-like fate taken from Broutier et al. (2016). 
Organoids were grown to acceptable density and passaged immediately prior to 
differentiation and differentiated over a period of 15 days. Medium was changed every 2-3 
days as described in chapter 2. Steps in the differentiation protocol are colour-coded, days 
1-5 in orange, use human liver expansion medium (Table 2, page 49) supplemented with 
25ng/mL BMP7, days 6-15 in purple use human liver differentiation medium (Table 2). 
Samples were collected for iTRAQ analysis throughout the differentiation process, at day 0, 
5, 10 and 15. Abbreviations: BMP7 - Bone morphogenic protein 7, iTRAQ - Isobaric tags for 






Micrographs showing donor 1 organoids before and after cryopreservation - 
Representative brightfield images of donor 1 organoids before and after cryopreservation. 
(A) Donor 1 organoids before cryopreservation. Cystic morphology is apparent and few 
dark structures are present. (B) Donor 1 organoids after cryopreservation. Cystic 
morphology has re-emerged after cryopreservation but an increase in dark structures is 
visible possibly indicating an increase in the number of dead or damaged organoids.  
Pictured organoids were cryopreserved using Recovery™ Cell Culture Freezing Medium, 





Coomassie stain to normalise donor 1 iTRAQ loading – A Coomassie stain was performed 
to supplement a Bradford assay to ensure even loading of each sample during iTRAQ 
analysis. (A) image of Coomassie stain for each sample used in donor 1 iTRAQ analysis. 
Captured using a GS-800 calibrated imaging densitometer (Bio-Rad), (B) densitometry 
analysis of the Coomassie stain shown in section A, values are arbitrary units and show 
even loading in all samples. Exact values are shown for each bar below the graph. 
Densitometry performed using Quantity One software (Bio-Rad). Abbreviations: hPH – 





4.2.5 Differentiation of Chol-Orgs to hepatocyte fate 
Once established in culture, we sought to differentiate the Chol-Orgs to a hepatocyte fate 
as described in Broutier et al. (2016), an overview of this process can be found in Figure 19. 
Some morphological changes were observed during this period, particularly the increase in 
tendency for organoids to become dense clusters that appeared dark under a brightfield 
microscope (Figure 18 E & F). 
Table 5 shows the details of each tissue donor used for analysis in this chapter but is not an 
exhaustive list of all isolations performed. Two of the donors are female and one is male, all 
are ethnically white British and have an age range of 20-55. The body mass index of the 
donors are 25, 27.7 and 18.6 which are defined as overweight, overweight and underweight 
respectively, by the World Health Organisation (Madden, 2006). The diagnoses of these 
patients vary for each as does the additional information provided. 
Donor 
# 
Sex Age BMI Ethnicity Diagnosis 















List of liver tissue donors used for production of human liver organoids – donor numbers 
and pertinent information of the donors of liver tissue used for organoid isolation. 
Additional isolations were performed but did not materially contribute to the data 
displayed in this work and were omitted. 
4.2.6 iTRAQ analysis shows p roteomic changes during the hepatic 
differentiation of human liver organoids 
Samples of Chol-orgs differentiated towards a hepatocyte fate from donor 1 (Table 5) at 
day 0, 5, 10 and 15 of the differentiation were produced (Figure 19). An entire 24-well plate  
was allocated to each sample to ensure sufficient cell material for iTRAQ analysis. Samples 
were prepared and analysed as described in the methods section. To ensure even loading 
to each iTRAQ run, Coomassie staining was performed to supplement the Bradford assay. 
Figure 21A visually demonstrates even loading across these samples, densitometry was 
performed using Quantity One software (Bio-Rad) and confirms even loading (Figure 21B). 
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A total of 3343 unique proteins were identified in the sample. Hierarchical clustering 
analysis was performed, in which each sample was compared against a pooled control. 
Organoids at day 0 and day 5 clustered together as did organoids at day 10 and day 15. 
Organoids did not cluster closely with pooled hPH from several donors or donor-matched 
tissue which clustered more closely to one another than any organoid sample and both 
clusters of organoids were closer to one another than hPH or liver tissue ( Figure 22). Figure 
22 is colour-coded to indicate up- or downregulation of each protein detected relative to 
the pooled control, green indicates downregulation and red indicates upregulation. 
A list of liver specific proteins was compiled under the following sections: CYPs, drug 
metabolism enzymes and transporters (DMETs), NRF2 pathway related genes, transporters, 
and biomarkers (Table 6). The iTRAQ dataset was interrogated for presence of these 
proteins and then tested by ANOVA to find any significant differences in expression 
between the following groups: day 0 and day 5 versus day 10 and day 15, day 0 and day 5 
versus hPH, day 0 and day 5 versus liver tissue, day 10 and day 15 versus hPH, and day 10 
and day 15 versus liver tissue. Because day 0 and day 5 and day 10 and day 15 clustered 
closely in hierarchical clustering analysis it was deemed acceptable to treat them as a single  
group in order to enable statistical analysis. The exact values and associated significance of 
all the data in Figure 23-28 are also shown in Table 6. 
Figures 23-28A show the changes in the protein groups shown in Table 6 for 
undifferentiated organoids (day 0 and day 5) versus differentiated organoids (day 10 and 
day 15). None of the proteins in the ‘biomarkers’ group or the ‘NRF2’ group were 
significantly changed (Figure 25A & Figure 27A). In the ‘CYPs’ group, CYP3A5 expression was 
significantly higher in differentiated than in undifferentiated organoids, no other tested CYP 
was significantly altered (Figure 23A). In the ‘DMETs’ group, NIT1, GGT1, UGT2B15 and 
UGT2B7 were all significantly higher in differentiated organoids than in undifferentiated 
(Figure 24A). In the transporters group, ABCF3, ACBB1, SLC12A2, SLC13A5, SLC15A1 and 
SLC2A2 were all significantly higher in differentiated organoids than in undifferentiated 
(Figure 26A). 
Figures 23-28B show the changes in the protein groups shown in Table 6 for 
undifferentiated organoids versus hPH. In the ‘CYPs’ group, CYP4F12 and CYP4V2 are 
significantly higher in hPH, whilst CYP2S1 is significantly higher in undifferentiated 
organoids (Figure 23B). In the ‘DMETs’ group, GGT1, GSTM4 and GSTP1 are all significantly 
higher in undifferentiated organoids than in hPH. Conversely, GSTA1, GSTT1, CES1, ESD, 
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UGT2B10 and UGT2B28 are all significantly higher in hPH than in undifferentiated organoids 
(Figure 24B). In the ‘NRF2’ section, GSTP1, NQO1 and TRXND1 were all significantly higher 
in undifferentiated organoids whilst TRXND2 was significantly higher in hPH (Figure 25B). In 
the ‘Transporters’ section, SLC2A2, SLC12A2 and ABCF1 were significantly higher in 
undifferentiated organoids whilst ABCC1 was significantly higher in hPH (Figure 26B). In the 
‘biomarkers’ section, ALT2 was significantly higher in undifferentiated organoids whilst both 
cytoplasmic and mitochondrial AST were significantly higher in hPH (Figure 27B). 
Figures 23-28C show the changes in the protein groups shown in Table 6 for differentiated 
organoids versus hPH. In the ‘CYPs’ section CYP2S1 is significantly higher in differentiated 
organoids, however, CYP1A2, CYP2A6 and CYP2C19 are significantly higher in hPH ( Figure 
23C). In the ‘DMETs’ section GSTA1, CES1, UGT2B28 and ESD were all significantly higher in 
hPH than differentiated organoids. Conversely, GGT1, GSTM4, UGT1A3, GSTP1 and GSTM3 
were all higher in differentiated organoids than hPH (Figure 24C). In the ‘NRF2’ section 
cytoplasmic TRXND1, NQO1 and GSTP1 were all significantly higher in differentiated 
organoids than hPH (Figure 25C). In the ‘Transporters’ section, ABCB1 and ABCF1 were both 
significantly higher in differentiated organoids than hPH. Conversely bile salt 
sulfotransferase (SULT2A1) and ABCC1 were both significantly higher in hPH (Figure 26C). In 
the biomarkers section both cytoplasmic and mitochondrial AST were significantly higher in 
hPH although ALT2 was significantly higher in differentiated organoids (Figure 27C). 
Figure 29 shows volcano plots of the iTRAQ data, produced using Partek. Volcano plots 
visually represent the change in proteome between organoids versus hepatocytes and liver 
tissue and between hepatocytes and liver tissue individually. Each point represe nts a single  
protein, the x-axis indicates the direction and magnitude of change whilst the y-axis 
indicates the significance of the change. Therefore, the more the volcano plot ‘erupts’ the 
more different the tested samples are. Figure 29A & B show the changes in protein 
expression between organoids and donor-matched liver tissue and pooled hepatocytes 
respectively. Both plots show large scale changes in the proteome indicating large 
difference in protein expression between organoids and these comparators.  However, the 
magnitude and significance of the changes for organoids versus hepatocytes ( Figure 29B) 
tend to be larger than those found between organoids and liver tissue ( Figure 29A) 
Conversely, Figure 29C shows the changes in protein expression between hepatocytes and 
liver tissue. The differences are not as pronounced as in Figure 29A & B indicating that 
hepatocytes and liver tissue are more similar to one another than organoids.  
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4.2.7 Western blot analysis shows expression of mature h epatocyte 
markers 
We performed western blotting on Chol-orgs differentiated towards a hepatocyte fate. We 
gathered samples at 0-, 5-, 10- and 15-days during differentiation and blotted for hepatic 
markers, CYP3A4 and albumin (Figure 30). An increase in albumin expression was observed 
at day 10 and 15 in donor 2 organoids, a small increase in CYP3A4 expression is also 
observable. These changes are mirrored in the densitometry analysis where the increase in 
CYP3A4 and Albumin expression can be seen over the process of differentiation. It is 
noteworthy that in this blot, the levels of β-actin detected in the hPH samples were lower 
than in the other samples. The protein concentration of each sample was normalised by 
Bradford and Coomassie assays before blotting, so the reasons for this discrepancy are 
unclear. Because of this discrepancy, protein levels for densitometry are normalised to 
donor matched tissue instead of hPH. 
Moreover, although western blotting was attempted for donor 3 organoids, we were 
unable to obtain useful results due to limited cell material. This is likely due to the severely 
diminished proliferation of cryopreserved organoids. Due to time constraints of this project 





Hierarchical clustering analysis of differentiated organoids, donor-matched liver tissue 
and hPH – Hierarchical clustering analysis visually represents the similarities between 
iTRAQ samples. Values shown are relative to Pool 119, pool 121 is identical to pool 119 but 
was labelled separately and is therefore included in clustering analysis . Green bars 
represent downregulation, red bars indicate upregulation. The dendrogram indicates how 
similar each sample is, shorter branches indicate greater similarity. Organoids at day 0 and 
day 5 cluster together as do organoids at day 10 and day 15. All organoids separate from 







Cytochromes P450 expression in organoids - Graphs showing the fold change in CYP 
expression in differentiated and undifferentiated organoids analysed by iTRAQ. (A) 
Undifferentiated organoids (day 0 and day 5) versus hPH. (B) Differentiated (day 10 and day 
15) organoids versus hPH. (C) undifferentiated organoids (day 0 and day 5) versus 
differentiated organoids (day 10 and day 15). 
Organoids at day 0 and day 5 and organoids at day 10 and day 15 of differentiation 
clustered together in Figure 22 and were treated as duplicates for the purposes of analysis.  
Positive values indicate higher expression in the first comparator, bars in red show 
significant changes p≤0.05 determined by ANOVA bars in blue show non-significant 
changes. Exact values for these changes and abbreviations used in the text are shown in 
Table 6. Abbreviations: D0 - Differentiation day 0, D5 - Differentiation day 5, D10 - 
Differentiation day 10, D15 - Differentiation day 15, hPH - Human primary hepatocytes, CYP 





D 0  &  D 5  v s . h P H  (D M E T s )
F o ld  c h a n g e
-1 0 0 -8 0 -6 0 -4 0 -2 0 0 2 0
B ile  s a lt  s u lfo tra n s fe ra s e
C a ta la s e
C a te c h o l O -m e th y ltra n s fe ra s e
C o c a in e  e s te ra s e
D e a m in a te d  g lu ta th io n e  a m id a s e
G lu ta th io n e  h y d ro la s e  1  p ro e n z y m e
G lu ta th io n e  p e ro x id a s e  1
G lu ta th io n e  p e ro x id a s e  2
G lu ta th io n e  re d u c ta s e , m ito c h o n d r ia l
G lu ta th io n e  S - tra n s fe ra s e  A 1
G lu ta th io n e  S - tra n s fe ra s e  k a p p a  1
G lu ta th io n e  S - tra n s fe ra s e  M u  1
G lu ta th io n e  S - tra n s fe ra s e  M u  3
G lu ta th io n e  S - tra n s fe ra s e  M u  4
G lu ta th io n e  S - tra n s fe ra s e  o m e g a -1
G lu ta th io n e  S - tra n s fe ra s e  P
G lu ta th io n e  S - tra n s fe ra s e  th e ta -1
G lu ta th io n e  S - tra n s fe ra s e  th e ta -2 B
G lu ta th io n e  s y n th e ta s e
H y d ro x y a c y lg lu ta th io n e  h y d ro la s e , m ito c h o n d r ia l
L a c to y lg lu ta th io n e  ly a s e
L iv e r  c a rb o x y le s te ra s e  1
M ic ro s o m a l g lu ta th io n e  S - tra n s fe ra s e  1
M ic ro s o m a l g lu ta th io n e  S - tra n s fe ra s e  2
M ic ro s o m a l g lu ta th io n e  S - tra n s fe ra s e  3
P h o s p h o lip id  h y d ro p e ro x id e  g lu ta th io n e  p e ro x id a s e
S -fo rm y lg lu ta th io n e  h y d ro la s e
S u lfo tra n s fe ra s e  1 A 1
S u lfo tra n s fe ra s e  1 A 4
S u lfo tra n s fe ra s e  fa m ily  c y to s o lic  1 B  m e m b e r 1
U D P -g lu c u ro n o s y ltra n s fe ra s e  1 -1
U D P -g lu c u ro n o s y ltra n s fe ra s e  1 -3
U D P -g lu c u ro n o s y ltra n s fe ra s e  1 -4
U D P -g lu c u ro n o s y ltra n s fe ra s e  1 -6
U D P -g lu c u ro n o s y ltra n s fe ra s e  1 -9
U D P -g lu c u ro n o s y ltra n s fe ra s e  2 A 3
U D P -g lu c u ro n o s y ltra n s fe ra s e  2 B 1 0
U D P -g lu c u ro n o s y ltra n s fe ra s e  2 B 1 5
U D P -g lu c u ro n o s y ltra n s fe ra s e  2 B 2 8
U D P -g lu c u ro n o s y ltra n s fe ra s e  2 B 4












DMET expression in organoids - Graphs showing the fold change in DMET expression in 
differentiated and undifferentiated organoids analysed by iTRAQ. (A) Undifferentiated 
organoids (day 0 and day 5) versus hPH. (B) Differentiated (day 10 and day 15) organoids 
versus hPH. (C) Undifferentiated organoids (day 0 and day 5) versus differentiated 
organoids (day 10 and day 15). 
Organoids at day 0 and day 5 and organoids at day 10 and day 15 of differentiation 
clustered together in Figure 22 and were treated as duplicates for the purposes of analysis.  
Positive values indicate higher expression in the first comparator, bars in red show 
significant changes p≤0.05 determined by ANOVA bars in blue show non-significant 
changes. Exact values for these changes and abbreviations used in the text are shown in 
Table 6. Abbreviations: D0 - Differentiation day 0, D5 - Differentiation day 5, D10 - 
Differentiation day 10, D15 - Differentiation day 15, hPH - Human primary hepatocytes, 







NRF2 pathway expression in organoids - Graphs showing the fold change in NRF2 pathway 
expression in differentiated and undifferentiated organoids analysed by iTRAQ. (A) 
Undifferentiated organoids (day 0 and day 5) versus hPH. (B) Differentiated (day 10 and day 
15) organoids versus hPH. (C) Undifferentiated organoids (day 0 and day 5) versus 
differentiated organoids (day 10 and day 15). 
Organoids at day 0 and day 5 and organoids at day 10 and day 15 of differentiation 
clustered together in Figure 22 and were treated as duplicates for the purposes of analysis.  
Positive values indicate higher expression in the first comparator, bars in red show 
significant changes p≤0.05 determined by ANOVA bars in blue show non-significant 
changes. Exact values for these changes and abbreviations used in the text are shown in 
Table 6. Abbreviations: D0 - Differentiation day 0, D5 - Differentiation day 5, D10 - 
Differentiation day 10, D15 - Differentiation day 15, hPH - Human primary hepatocytes, 












Transporter expression in organoids - Graphs showing the fold change in transporter 
expression in differentiated and undifferentiated organoids analysed by iTRAQ. (A) 
Undifferentiated organoids (day 0 and day 5) versus hPH. (B) Differentiated (day 10 and day 
15) organoids versus hPH. (C) Undifferentiated organoids (day 0 and day 5) versus 
differentiated organoids (day 10 and day 15). 
Organoids at day 0 and day 5 and organoids at day 10 and day 15 of differentiation 
clustered together in Figure 22 and were treated as duplicates for the purposes of analysis.  
Positive values indicate higher expression in the first comparator, bars in red show 
significant changes p≤0.05 determined by ANOVA bars in blue show non-significant 
changes. Exact values for these changes and abbreviations used in the text are shown in 
Table 6. Abbreviations: D0 - Differentiation day 0, D5 - Differentiation day 5, D10 - 






Biomarker expression in organoids - Graphs showing the fold change in expression of 
biomarkers in differentiated and undifferentiated organoids analysed by iTRAQ. (A) 
Undifferentiated organoids (day 0 and day 5) versus hPH. (B) Differentiated (day 10 and day 
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15) organoids versus hPH. (C) Undifferentiated organoids (day 0 and day 5) versus 
differentiated organoids (day 10 and day 15). 
Organoids at day 0 and day 5 and organoids at day 10 and day 15 of diffe rentiation 
clustered together in Figure 22 and were treated as duplicates for the purposes of analysis.  
Positive values indicate higher expression in the first comparator, bars in red show 
significant changes p≤0.05 determined by ANOVA bars in blue show non-significant 
changes. Exact values for these changes and abbreviations used in the text are shown in 
Table 6. Abbreviations: D0 - Differentiation day 0, D5 - Differentiation day 5, D10 - 




Cholangiocyte marker expression in organoids - Graphs showing the fold change in 
cholangiocyte marker expression in differentiated and undifferentiated organoids analysed 
by iTRAQ. (A) Undifferentiated organoids (day 0 and day 5) versus hPH. (B) Differentiated 
(day 10 and day 15) organoids versus hPH. (C) Undifferentiated organoids (day 0 and day 5)  
versus differentiated organoids (day 10 and day 15). 
Organoids at day 0 and day 5 and organoids at day 10 and day 15 of differentiation 
clustered together in Figure 22 and were treated as duplicates for the purposes of analysis.  






significant changes p≤0.05 determined by ANOVA bars in blue show non-significant 
changes. Exact values for these changes and abbreviations used in the text are shown in 
Table 6. Abbreviations: D0 - Differentiation day 0, D5 - Differentiation day 5, D10 - 





Volcano plots showing changes in protein expression in organoids, hPH and liver tissue  – 
(A) Volcano plot showing change in protein expression between differentiated donor 1 
organoids (day 10 and day 15) and donor 1 liver tissue. (B) Volcano plot showing change in 
protein expression between differentiated donor 1 organoids (day 10 and day 15) and 
pooled hPH. (C) Volcano plot showing change in protein expression between pooled hPH 






Plots showing changes between samples tested during iTRAQ analysis. Values along the x -
axis show fold change and values on the y-axis show significance associated with this 
change. Each point represents a single protein. Significance is colour coded from blue to 
red, indicating greater or lesser significance respectively. Details of donor 1 are shown in 
Table 5. Panel A and B show large scale changes between differentiated human liver 
organoids and tissue and hepatocytes respectively. The differences between tissue and 






Western blotting of donor 2 organoids for CYP3A4 and Albumin – Western blots were 
performed on donor 2 organoid samples taken at day 0, 5, 10 and 15 during differentiation. 
(A) western blotting for CYP3A4, density is expressed in arbitrary values relative to donor-
matched tissue, which is represented by the dotted line. (B) western blotting for albumin, 
density is expressed in arbitrary values relative to donor-matched tissue, which is 
represented by the dotted line. Black arrows indicate the bands used for densitometry 
analysis. Densitometry was performed using ImageJ. hPH*, is included in the images but 
was not included in further analysis as β-actin density for this sample was spuriously low. 
Abbreviations: D0 - Differentiation day 0, D5 - Differentiation day 5, D10 - Differentiation 






















































































































Cytochrome P450 1A2 CYP1A2 -34.146 0.055 -51.523 0.049 -1.330 0.307 
Cytochrome P450 20A1 CYP20A1 1.410 0.501 1.479 0.473 -1.300 0.473 
Cytochrome P450 2A6 CYP2A6 -23.406 0.049 -35.481 0.041 -1.197 0.275 
Cytochrome P450 2B6 CYP2B6 -9.290 0.250 -11.117 0.243 -2.099 0.249 
Cytochrome P450 2C19 CYP2C19 -4.585 0.049 -8.017 0.026 1.803 0.359 
Cytochrome P450 2C8 CYP2C8 -11.623 0.076 -9.683 0.103 -2.080 0.080 
Cytochrome P450 2C9 CYP2C9 -23.915 0.083 -24.322 0.093 -2.051 0.151 
Cytochrome P450 2D6 CYP2D6 -10.407 0.079 -7.482 0.123 -1.811 0.548 
Cytochrome P450 2E1 CYP2E1 -10.439 0.069 -14.928 0.056 -1.153 0.576 
Cytochrome P450 2S1 CYP2S1 10.633 0.016 13.740 0.014 -1.213 0.737 
Cytochrome P450 3A4 CYP3A4 -9.521 0.251 -2.630 0.606 -8.091 0.157 
Cytochrome P450 3A5 CYP3A4 -1.070 0.802 1.259 0.443 -1.556 0.028 
Cytochrome P450 3A7 CYP3A7 -2.083 0.417 1.406 0.708 -4.446 0.066 
Cytochrome P450 4A11 CYP4A11 -23.842 0.089 -32.659 0.082 -1.563 0.276 
Cytochrome P450 4F12 CYP4F12 -1.335 0.107 1.159 0.352 -1.521 0.085 
Cytochrome P450 4V2 CYP4V2 1.267 0.228 1.122 0.538 1.028 0.513 
NADPH--cytochrome P450 reductase CPR 1.463 0.600 2.767 0.237 -2.388 0.261 
DMETs 


















































































































Catechol O-methyltransferase COMT -2.543 0.252 -4.487 0.121 1.535 0.581 
Cocaine esterase COCE -1.009 0.990 2.938 0.230 -3.373 0.217 
Deaminated glutathione amidase NIT1 -1.797 0.181 -1.107 0.796 -1.977 0.025 
Glutathione hydrolase 1 proenzyme GGT1 9.787 0.001 19.055 0.000 -2.080 0.019 
Glutathione peroxidase 1 GPX1 -1.820 0.265 -1.282 0.630 -1.112 0.639 
Glutathione peroxidase 2 GPX2 4.285 0.182 4.634 0.185 1.466 0.442 
Glutathione reductase, mitochondrial GSR 1.271 0.585 1.652 0.315 -1.096 0.784 
Glutathione S-transferase A1 GSTA1 -1.929 0.004 -1.854 0.006 -1.081 0.294 
Glutathione S-transferase kappa 1 GSTK1 -1.977 0.152 -1.879 0.194 -1.253 0.423 
Glutathione S-transferase Mu 1 GSTM1 1.518 0.196 -1.213 0.521 1.862 0.145 
Glutathione S-transferase Mu 3 GSTM3 2.070 0.089 2.858 0.043 -1.159 0.159 
Glutathione S-transferase Mu 4 GSTM4 4.613 0.008 2.793 0.029 1.714 0.168 
Glutathione S-transferase omega-1 GSTO1 -5.012 0.094 -3.819 0.154 -1.803 0.315 
Glutathione S-transferase P GSTP1 4.801 0.048 6.194 0.038 -1.213 0.738 
Glutathione S-transferase theta-1 GSTT1 -4.713 0.022 -2.754 0.073 -1.879 0.201 
Glutathione S-transferase theta-2B GSTT2B -1.450 0.428 -2.642 0.110 1.778 0.312 
Glutathione synthetase GSS -1.124 0.700 -1.117 0.730 1.159 0.344 
Hydroxyacylglutathione hydrolase, mitochondrial HAGH -6.689 0.068 -4.677 0.122 -2.070 0.160 
Lactoylglutathione lyase GLO1 -2.920 0.087 -3.062 0.090 -1.005 0.993 


















































































































Microsomal glutathione S-transferase 1 MGST1 -7.222 0.073 -5.321 0.120 -2.099 0.052 
Microsomal glutathione S-transferase 2 MGST2 -1.232 0.420 -1.300 0.349 -1.072 0.579 
Microsomal glutathione S-transferase 3 MGST3 -1.282 0.297 1.062 0.794 -1.294 0.308 
Phospholipid hydroperoxide glutathione peroxidase GPX4 1.454 0.206 1.706 0.119 -1.247 0.426 
S-formylglutathione hydrolase ESD -4.936 0.037 -5.445 0.037 1.081 0.883 
UDP-glucuronosyltransferase 1-1 UGT1A1 -1.173 0.851 1.138 0.886 -1.318 0.451 
UDP-glucuronosyltransferase 1-3 UGT1A3 -2.242 0.087 -1.660 0.234 -1.170 0.195 
UDP-glucuronosyltransferase 1-4 UGT1A4 -1.634 0.190 -1.300 0.458 -4.188 0.275 
UDP-glucuronosyltransferase 1-6 UGT1A6 1.162 0.146 1.361 0.032 -1.879 0.496 
UDP-glucuronosyltransferase 1-9 UGT1A9 -7.968 0.308 -4.571 0.460 -1.578 0.353 
UDP-glucuronosyltransferase 2A3 UGT2A3 -1.727 0.510 1.005 0.996 -1.811 0.169 
UDP-glucuronosyltransferase 2B10 UGT2B10 -6.486 0.069 -5.834 0.090 -1.803 0.356 
UDP-glucuronosyltransferase 2B15 UGT2B15 -2.406 0.142 -1.652 0.364 -7.145 0.008 
UDP-glucuronosyltransferase 2B28 UGT2B28 -10.999 0.032 -7.907 0.054 -1.330 0.101 
UDP-glucuronosyltransferase 2B4 UGT2B4 -4.860 0.084 1.019 0.979 -3.565 0.140 
UDP-glucuronosyltransferase 2B7 UGT2B7 -2.696 0.002 -1.968 0.009 -3.483 0.011 
NRF2 Pathway 
Glutathione S-transferase A1 GSTA1 4.801 0.048 6.194 0.038 -1.081 0.294 
Heme oxygenase 1 HO1 -1.127 0.762 -1.368 0.474 1.019 0.945 


















































































































Thioredoxin reductase 1, cytoplasmic TRXND1 2.983 0.004 3.581 0.003 -1.288 0.069 
Thioredoxin reductase 2, mitochondrial TRXND2 -1.825 0.032 -1.521 0.088 -1.294 0.134 
Transporters 
ATP-binding cassette sub-family B member 6, mitochondrial ABCB6 -1.141 0.254 -1.132 0.300 -1.028 0.795 
ATP-binding cassette sub-family B member 7, mitochondrial ABCB7 1.000 1.000 -1.086 0.333 1.052 0.380 
ATP-binding cassette sub-family D member 3 ABCD3 -2.598 0.172 1.023 0.970 -3.342 0.097 
ATP-binding cassette sub-family E member 1 ABCE1 -1.100 0.628 1.107 0.626 -1.117 0.434 
ATP-binding cassette sub-family F member 1 ABCF1 2.823 0.023 3.020 0.023 -1.023 0.934 
ATP-binding cassette sub-family F member 2 ABCF2 1.195 0.240 1.276 0.155 -1.014 0.895 
ATP-binding cassette sub-family F member 3 ABCF3 -1.754 0.526 -2.218 0.409 2.032 0.036 
ATP-dependent Clp protease ATP-binding subunit clpX-like, 
mitochondrial 
CLPX -1.047 0.922 -1.368 0.545 1.117 0.794 
Bile acid-CoA:amino acid N-acyltransferase BAAT -13.635 0.086 -14.588 0.093 -1.746 0.106 
Bile salt export pump BSEP -1.486 0.246 -1.507 0.255 -1.132 0.536 
Bile salt sulfotransferase SULT2A1 -32.310 0.057 -81.283 0.037 1.259 0.464 
Canalicular multispecific organic anion transporter 1 ABCC2, MRP2 1.076 0.784 1.452 0.247 -1.355 0.363 
Canalicular multispecific organic anion transporter 2 ABCC3 1.825 0.263 2.500 0.143 -1.265 0.649 
Multidrug resistance protein 1 ABCB1, MDR1 2.148 0.026 3.119 0.010 -1.622 0.009 
Multidrug resistance-associated protein 1 ABCC1, MRP1 1.141 0.832 -1.854 0.382 1.888 0.382 


















































































































Solute carrier family 12 member 2 SLC12A2 1.696 0.062 8.790 0.257 2.259 0.041 
Solute carrier family 13 member 5 SLC13A5 1.003 0.997 -1.265 0.311 -1.950 0.001 
Solute carrier family 15 member 1 SLC15A1 1.389 0.339 1.202 0.841 -2.138 0.038 
Solute carrier family 15 member 4 SLC15A4 -1.141 0.450 2.547 0.056 1.117 0.299 
Solute carrier family 2, facilitated glucose transporter member 1 
GLUT1, 
SLC2A1 
3.039 0.143 -1.175 0.393 2.570 0.096 
Solute carrier family 2, facilitated glucose transporter member 2 
GLUT2, 
SLC2A2 
-13.635 0.044 1.585 0.497 -2.259 0.019 
Solute carrier family 22 member 18 SLC22A18 -1.675 0.707 -9.683 0.071 -2.582 0.378 
Solute carrier organic anion transporter family member 1B3 SLCO1B3 -4.068 0.083 -1.170 0.913 -1.213 0.705 
Solute carrier organic anion transporter family member 2B1 SLCO2B1 1.368 0.096 -4.169 0.091 1.208 0.252 
Voltage-dependent anion-selective channel protein 1 VDAC1 -1.290 0.705 1.180 0.317 -1.419 0.479 
Voltage-dependent anion-selective channel protein 2 VDAC2 2.249 0.185 1.472 0.593 -1.096 0.528 
Voltage-dependent anion-selective channel protein 3 VDAC3 -1.025 0.955 1.253 0.632 -1.127 0.771 
Biomarkers 
Alanine aminotransferase 1 ALT1 -11.07 0.098 -14.322 0.089 -1.387 0.456 
Alanine aminotransferase 2 ALT2 3.30 0.012 3.148 0.016 1.019 0.942 
Aspartate aminotransferase, cytoplasmic AST, GOT1 -6.16 0.005 -3.532 0.016 -1.837 0.126 
Aspartate aminotransferase, mitochondrial AST, GOT2 -7.22 0.017 -10.568 0.012 1.143 0.147 


















































































































High mobility group protein B1 HMGB1 -1.29 0.862 -1.820 0.703 3.133 0.079 
Keratin, type I cytoskeletal 18 CK18 1.09 0.140 1.067 0.266 1.047 0.255 
Keratin, type I cytoskeletal 19 CK19 1.22 0.012 1.253 0.011 -1.005 0.860 
Serum albumin HSA -1.22 0.291 -1.014 0.940 -1.271 0.237 
Table 6 
List of liver relevant protein groups from iTRAQ analysis - Names and abbreviations used for the proteins in figures 23-28 divided into five categories: CYPs, 
DMETs, NRF2 pathway, transporters and biomarkers. Fold change in expression for each protein is shown for three comparisons: undifferentiated (day 0 
and day 5) organoids versus hPH, differentiated organoids (day 10 and day 15) versus hPH and undifferentiated organoids versus dif ferentiated organoids. 
Positive fold changes indicate higher protein expression in the first comparator, negative fold changes indicate greater expression the second comparator. 
Protein fold changes were produced using iTRAQ and analysis was completed using Partek and Microsoft Excel. Significance associated with the fold change 




Human liver organoids offer a promising source of differentiated hepatocytes for a range of  
laboratory and therapeutic uses. However, despite multiple studies examining their gene 
expression profiles, their proteome has not previously been assessed. Investigation of  the 
hepatic phenotype at the proteomic level gives the best approximation of the true 
metabolic potential of these cells, since previous studies have demonstrated that gene 
expression does not necessarily equate to protein expression. In this chapter, we 
established culture methods for the generation, culture, cryopreservation and 
differentiation of human liver organoids, based on the work presented by Broutier et al. 
(2016). We then subjected these organoids to proteomic analysis by iTRAQ and western 
blotting. 
4.3.1 Isolation and culture of human organoids 
We attempted to isolate organoids from resected liver tissue on several occasions. It was 
noted that the probability of success of organoids isolation appeared to negatively correlate 
with the time since the resection of the tissue. We found that our isolations were successful 
80% of the time (n=5) after isolation was performed immediately after the tissue was 
received. If the tissue was stored at 4 °C, for over 24 hours, as described in Broutier et al. 
(2016), we noted a precipitous drop in isolation efficiency where isolation was successful in 
approximately 10% of cases. 
The reasons for this discrepancy are not clear, however we suggest that storage at 4 °C for 
more than 24-hours may lead to the large-scale death of the cells required to establish 
Chol-orgs in vitro. This effect may be compounded by the health of the donors from which 
the tissue was received. These individuals were undergoing hepatobiliary surgery, typically 
to remove either primary liver tumours or metastatic tumours from other organs and 
frequently had poor overall health, e.g. high BMI, polypharmacy etc. These extant health 
issues may impact upon the health of the cells in the biliary tree and therefore damage the 
chances of isolation when compared with, for example, an otherwise healthy cadaveric 
liver. However, we chose not to study this effect further, instead opting to modify our 
protocol to consistently perform organoid isolations as soon after resection as possible. 
We also noted that sorting of EpCAM-positive cells by FACS did not improve isolation 
efficiency. We attempted FACS sorting of EpCAM-positive cells on three occasions, none of  
which resulted in the successful establishment of organoids in acceptable quantities and 
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timeframe. In each isolation we noticed only a very small outgrowth of only very few cells 
which did not propagate into a successful organoid culture. Conversely, when using an 
isolation method which did not employ FACS, instead plating cells which had only been 
enriched by centrifugation, we observed a larger organoid population emerging during a 
shorter timeframe (Figure 18). 
The reasons for this lack of improvement when sorting the cells initially seems paradoxical.  
EpCAM-positive cells are known to be the progenitor cell type of Chol-orgs and therefore 
their enrichment in culture should improve isolation success. However, it appears that in 
our laboratory the enrichment of EpCAM-positive cells in plating was not sufficient to 
outweigh the loss in viability found caused by the FACS process. This loss in viability can be 
observed in Figure 17C, where the post-sorting report shows an increase in dead cells, even 
though these dead cells were gated during the previous sort. The process for staining cells 
for FACS sorting takes several hours and involves several steps in which the cells must be 
handled in a suspension, in combination with the mechanical stresses exerted on the cells 
during FACS, it appears that the viability of these cells is irrecoverably damaged by the 
process of sorting. Moreover, the process of sorting the cells using FACS was logistically 
difficult in our laboratory, it is possible that if the time to prepare and sort the cells, and the  
stresses exerted on them, were minimised then an improvement in plating efficiency could 
be observed. 
The organoids that were isolated showed the characteristic cystic morphology expected 
from Chol-orgs. This is consistent with previous reports which demonstrated similar 
morphologies (Hu et al., 2018; Huch et al., 2015). Additionally, we noted that there was a 
tendency for some organoids to collapse and become dense and dark when observed under 
a brightfield microscope. The reasons for this behaviour are unclear though there are 
several possibilities, in some cases we observed this behaviour after the organoids had 
become larger than 100-200µm, in this case it seems likely that the reasons for the collapse 
were mechanical due to lack of support from the BME-2 matrix. In other cases, the 
organoids collapsed when smaller, conditions which would typically be well supported by 
the BME-2 matrix, in these cases we interpreted this as the death of the organoid though 
due to the difficulty sorting this type of organoid from other healthy ones, we were not 
able to confirm this possibility. 
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4.3.2 Cryopreservation of human organoids 
We attempted to reproduce the cryopreservation techniques presented previously by 
Broutier et al. (2016) with our Chol-orgs. We compared the efficacy of two commercial 
freezing media, Recovery Cell Culture Freezing Medium and CryoStor CS10. We were able 
to cryopreserve and revive organoids without issue using both media. However, it quickly 
became apparent that the organoids were damaged by the cryopreservation process. 
Despite successful recovery and establishment of the organoids, the rate of proliferation 
and growth was severely slowed, the interval between passages increased to several 
months as opposed to approximately 1-3 weeks before cryopreservation. 
The reasons for this loss in proliferative potential are likely to be damage and toxicity to the 
organoids during the freezing process. The freezing medium contains DMSO which is toxic 
to cells and there is also the possibility of mechanical and temperature damage to the 
organoids during the disruption steps of the cryopreservation protocol and when freezing. 
Unfortunately, this damage to the organoid cultures precluded their use in the iTRAQ 
analyses as was initially planned since it was not possible to generate sufficient cell material 
in a timely manner. 
4.3.3. Differentiation of human organoids 
Despite our difficulty in re-establishing proliferative cultures of Chol-orgs we were able to 
proceed with differentiation towards a hepatic fate in three organoid lines. Of these lines, 
only donor 1, was differentiated before cryopreservation and consequently, this was the 
only line used for iTRAQ analysis. Donors 2 and 3 were both differentiated after 
cryopreservation and therefore the amount of cell material was very low. Ultimately, only 
Donor 2 yielded enough cell material for successful western blotting (Figure 30).  
During the differentiation towards hepatocytes as described in Broutier et al. (2016), we 
noticed an increase in the number of organoids which changed from a cystic morphology to 
a dense clustered morphology which was opaque when examined by brightfield 
microscopy. Some examples of this type of morphology can also be seen in Broutier et al. 
(2016), however, the authors also present a brightfield image of a differentiated organoid s 




4.3.4 Proteomic analysis of differentiated organoids 
We analysed the proteome of donor 1 organoids throughout differentiation towards 
hepatocytes using iTRAQ. The results of these analyses are shown in Figures 22-29. Figure 
22 shows the hierarchical clustering of the samples, it is noteworthy that organoids at day 0 
and day 5 cluster together as do organoids at day 10 and 15, this indicates that the 
proteome of the organoids is successfully altered by the differentiation procedure, in this 
case, likely indicating a shift towards a more hepatic phenotype. However, it is also 
important to note that the organoids do not cluster closely with hepatocytes or tissue, the 
target tissue type. This shows that although the phenotype has be en changed by the 
differentiation procedure, the differentiated organoids do not fully recapitulate the 
phenotype of liver tissue or hepatocytes in isolation. The hierarchical clustering also 
includes a control column, this is due to the experimental setup used, two control samples 
were included and the one displayed in Figure 22 is not the same control used to normalise  
the dataset. 
4.3.4.1 Cytochromes P450 
Next, we examined the dataset for liver specific proteins, to examine the functional 
relevance of organoids compared with hepatocytes. These proteins are shown in Table 6, 
and the changes in expression are shown in figures 23-28, significantly changed proteins are 
also summarised in Table 6. First, we examined expression of CYP proteins, which are key 
liver-enriched enzymes responsible for the metabolism of 70-80% of all clinically-used drugs 
(Zanger and Schwab, 2008). There are 57 putative functional CYP enzymes in humans, 
though not all contribute equally to the number of xenobiotics metabolised. CYP3A4, 
CYP2C9, CYP2C8, CYP2E1, and CYP1A2 are the most highly expressed in vivo, whilst CYP2A6, 
CYP2D6, CYP2B6, CYP2C19 and CYP3A5 are comparatively less expressed but still important 
for xenobiotic metabolism (Zanger and Schwab, 2008). Accurate recapitulation of the 
expression patterns of CYP enzymes are essential for an accurate model of the liver for 
toxicity testing, not only are they responsible for metabolism of some compounds, there 
are also cases where CYP enzymes can produce a reactive metabolite which can cause liver 
injury. A well-known example of this is the metabolism of paracetamol during overdose, the 
glutathione-based detoxification pathways are exhausted and the CYP-mediated production 
of the reactive metabolite NAPQI becomes dominant and toxicity is elicited (Holme and 
Jacobsen, 1986; Ramachandran and Jaeschke, 2018). 
Interestingly, in Figure 23C, between differentiated and undifferentiated organoids, the 
only significantly changed CYP protein was CYP3A5, this is unexpected since 90% of the 
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Caucasian population are CYP3A5 nonexpressers and donor 1 is of white British ethnicity. 
CYP3A5 shares 85% sequence homology with CYP3A4 and has been shown to overlap in its 
target specificity, if a genuine result the increase in CYP3A5 is positive for the hepatic 
phenotype (Langman et al., 2015). Furthermore, although non-significant, CYP3A4 shows 
the largest fold difference of any of the CYP proteins in this panel suggesting the acquisition 
of a more mature hepatic phenotype over the process of differentiation. It is also 
noteworthy that although non-significant, there is a trend towards increased expression of  
every CYP protein over differentiation in this panel except CYP4V2 and CYP2C19. 
When undifferentiated organoids are compared with hPH (Figure 23A), the majority of 
proteins were not significantly changed. Though there was a trend to increased expression 
in hPH. These results are expected, hPH should show a more mature hepatic phenotype 
than undifferentiated organoids. CYP expression in organoids was also compared to hPH 
after differentiation (Figure 23B). The majority of changes in CYP expression during 
differentiation were small, however after differentiation CYP1A2, CYP2A6 and CYP2C8 are 
all significantly lower in differentiated organoids than in hPH but were not before 
differentiation suggesting differentiation is having the opposite to the intended effect and 
causing the phenotype of the organoids to diverge from hPH. 
CYP2S1 is consistently upregulated in organoids, before and after differentiation  versus 
hPH. It shares sequence homology with other CYP2 family members and is activated 
through the aryl hydrocarbon receptor in response to dioxin and hypoxia (Rivera et al., 
2007). However, in vivo CYP2S1 is most commonly expressed in extrahepatic epithelial 
tissues and why is it upregulated in hepatic organoids in unclear (Marek et al., 2007; 
Saarikoski et al., 2005). 
4.3.4.2 DMETs 
We next examined the expression of DMETs in organoids before and after differentiation 
and in comparison with hPH. One of the key groups in this panel of proteins are the UDP-
glucuronosyltransferases (UGT), a superfamily of 22 enzymes which mainly facilitate 
glucuronidation, the covalent linkage of glucuronic acid, of lipophilic substrates to increase 
solubility and facilitate renal excretion (Rowland et al., 2013). Another large group of 
enzymes in this group are the glutathione-S-transferases, these enzymes facilitate the 
conjugation of reduced glutathione to various substrates, typically in order to increase their 
solubility and enable further metabolism (Smith et al., 2013). 
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When undifferentiated organoids were compared to differentiated (Figure 24C), UGT2B7, 
UGT2B15, GPX1 and NIT1 were all significantly upregulated. UGT2B7 and UGT2B15 are 
considered to be among the most important UGTs for xenobiotic detoxification (Rowland et 
al., 2013). Increased expression of UGT2B7 and UGT2B15 is a positive indicator for the 
hepatic phenotype of the organoids. NIT1 is implicated in the regeneration of glutathione 
after deamination and is highly conserved (Peracchi et al., 2017). Glutathione metabolism is 
important for the detoxification function of the liver and NIT1 expression is likely a positive  
indicator for the phenotype of human liver organoids. 
In comparison to hPH, undifferentiated organoids show several significantly changed 
proteins. UGT2B10 and GGT1 are significantly changed and have fold changes greater than 
5 (Figure 24A). UGT2B10 is implicated in the glucuronidation of tobacco-specific 
nitrosamines and some antidepressants (Chen et al., 2008; Labriet et al., 2018). It is 
unsurprising that the expression of this UGT is increased in hPH over undifferentiated 
organoids, however, after organoid differentiation, the difference in expression is no longer 
significant (Figure 24B), indicating a trend towards a more mature hepatocyte phenotype. 
GGT1 is implicated in the cleavage of extracellular glutathione to facilitate cysteine uptake 
and the metabolism of compounds which contain a gamma-glutamyl moiety such as 
metabolites of 3,4-(+/-)-methylenedioxymethamphetamine (MDMA) (Bai et al., 2001; 
Wickham et al., 2011). This enzyme is typically enriched in renal tissues but is also 
expressed at low levels in the liver and cholangiocytes (Uhlen et al., 2017). Its significant 
upregulation in undifferentiated organoids may be indicative of a cholangiocyte phenotype. 
When hPH and differentiated organoids are compared, the differences in expression are 
generally small. Only GGT1, GSTP1, ESD and SULT2A1 are significantly changed by greater 
than 5-fold (Figure 24B). GSTP1 is a highly polymorphic member of the GST superfamily 
which has been implicated in chemosensitivity to cisplatin (Sawers et al., 2014). This is a 
positive indicator for their hepatocyte phenotype, however, that organoid expression 
should be markedly higher than that of hPH is of concern. GSTP1 has been implicated in the 
progression of several cancers, this may explain to some extent the increase expression in 
highly proliferative organoid cultures (Checa-Rojas et al., 2018; Louie et al., 2016; 
Martignano et al., 2016). 
ESD catalyses the regeneration of glutathione from S-formylglutathione, and participates in 
methane and formaldehyde metabolism (Uotila and Koivusalo, 1974). The lack of 
expression of this enzyme demonstrates that organoids to not fully recapitulate the hPH 
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phenotype in all respects. SULT2A1 was significantly higher in hPH by a large magnitude 
which increased over the differentiation process. SULT2A1 is highly liver enriched catalyses 
the sulfation of bile acids and a wide array of steroid hormones (Li et al., 2008). SULT2A1 
transcription is induced by PXR, FXR and CAR also implicated in the metabolism of some 
drugs including hydroxytamoxifen (Chatterjee et al., 2005).The reason why this enzyme 
should diverge from the mature hepatocyte phenotype over the process of differentiation 
is unclear but is a poor indicator of the hepatic phenotype of organoids, potentially also 
suggesting that CAR, PXR or FXR are inactive.  
4.3.4.3 NRF2 pathway 
In addition to its role in oxidative stress, NRF2 has been implicated in the maintenance of 
the hepatic phenotype during liver regeneration and, when continuously expressed, is also 
associated with poor prognosis in hepatocellular carcinoma (Beyer et al., 2008; Raghunath 
et al., 2018; Shin et al., 2013; Zou et al., 2014) The organoids in this study are used with the 
intention to recapitulate the oval cell response, therefore activation of the NRF2 pathway 
might be expected. 
When differentiated organoids are compared to undifferentiated, none of the NRF2 
pathway-associated genes are significantly changed (Figure 25C). Furthermore, the 
magnitude of the changes observed are very small, all lower than 1.5-fold change. 
However, this is not the case when compared to hPH (Figure 25A), 3 out of 5 NRF2-related 
proteins are significantly upregulated in undifferentiated organoids compared to hPH, 
these proteins include TRXND1, NQO1 and GSTP1. Conversely, TRXND2 is significantly 
downregulated and HO1 is non-significantly downregulated. Of these changes only NQO1 
shows a fold change of greater than 5. NQO1 reduces a wide array of quinones to 
hydroquinones in vivo, this typically prevents oxidative stress but is also a step in the 
activation of some chemotherapeutics (Oh and Park, 2015; Siegel et al., 2012). Similarly, 
when differentiated organoids are compared to hPH, the same genes are significantly 
upregulated, albeit more strongly (Figure 25B). TRXND2 is no longer significantly 
downregulated and HO-1 remains almost unchanged. Significant upregulation in the 
majority of NRF2 related genes implies a general activation of the NRF2 pathway which 
becomes slightly more profound during differentiation. This upregulation of the NRF2 
pathway is expected when it is considered that the NRF2 pathway is activated during 
hepatocyte regeneration (Beyer et al., 2008; Raghunath et al., 2018; Shin et al., 2013; Zou 




The next panel of proteins that were investigated were transporters. There are several 
major transporter families included in this panel, including members of the Solute carrier 
(SLC) family and ATP-binding cassette transporters (ABC transporters). The transporter 
protein families are among the largest gene families, with 49 known ABC transporters in 
humans (Vasiliou et al., 2009) and 400 SLC transporters (Perland and Fredriksson, 2017). 
Transporter proteins are essential for the maintenance of homeostasis for the movement 
of all manner of soluble molecules across lipid membranes including drugs (Vasiliou et al., 
2009). Because of the essential role that transporters play in drug transport it is also 
necessary that a liver model recapitulates the expression found in vivo. For example, ABCC1 
actively exports many pharmaceuticals from the cell (e.g. doxycycline, irinotecan, 
mitomycin C) effectively conferring resistance to the exported compound by lowering the 
effective exposure (Glavinas et al., 2004; Hodges et al., 2011). If the expression of 
transporters is not accurately reproduced by a liver model, it is possible that predictions 
made regarding drug sensitivity will be skewed. 
The panel of transporters that were investigated in this study are detailed in Table 6. When 
differentiated organoids are compared to undifferentiated, there are small changes overall 
(Figure 26C). When undifferentiated organoids are compared with hPH, GLUT2, ABCC6 and 
ABCE1 are all significantly higher in hPH, conversely, ABCB1 is higher in undifferentiated 
organoids (Figure 26A). The large, but non-significant change in expression of BAAT which is 
higher in hPH is also noteworthy. 
That GLUT2 should be more highly expressed in hPH is unsurprising, it is the primary 
glucose transporter between the liver and the blood and is involved in glucose homeostasis, 
one of the major functions of the liver though it is also expressed in a range of glucose-
sensitive tissues (Thorens, 2015). ABCC6, also referred to as MRP6 is an ABC transporter 
that is enriched in the liver and kidneys and expressed on the mitochondrial membranes 
(Martin et al., 2012). Like other ABC transporters it has a wide substrate specificity 
including some drugs, and is thought to be involved in nilotinib and dasatinib resistance , 
increased expression in organoids is a positive indicator of hepatocyte phenotype (Eadie  et 
al., 2018). 
In the comparison between differentiated organoids and hPH, ABCC6 is significantly higher 
in hPH and ABCC1 and ABCF1 are significantly higher in organoids (Figure 26B). However, 
none of the significantly altered genes shows a fold change greater than 5. It is noteworthy 
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that most transporters in this panel are not significantly changed and the changes that are 
present are of small magnitude, except for KCNH6, BAAT and GLUT2, which show fold 
changes above 5. This is a positive general indicator that the transporter phenotype closely 
matches that of hPH, an essential aspect of the phenotype that some liver models do not 
fully recapitulate (Gao et al., 2017). 
4.3.4.5 Liver Biomarkers 
The penultimate panel of proteins that were analysed from the iTRAQ dataset were 
biomarkers. Biomarkers are used as proxy indicators for larger processes. The biomarkers 
included in this panel are used as indicators of liver damage with the most commonly used 
likely being ALT and AST. Indeed, in chapter 5 we examined elevations in ALT in mice as a 
proxy measurement of liver damage induced by CCl4. It is important that a liver model 
accurately reproduces the expression of biomarkers found in whole organisms and other 
models as this aids their translatability. For example, although it is not included in this 
panel, miR-122 is a highly translatable biomarker (Kia et al., 2015). It is highly conserved 
throughout commonly used model species and can be detected in cell cultures and in the 
circulation of model organisms and patients. The biomarkers in this panel are compared 
against freshly isolated hPH, it should be considered that there is likely some damage 
occurring to the cells during isolation which may skew the expression of these biomarkers. 
Nonetheless, it is expected that organoids should show similar expression in most cases.  
When organoids are compared over the process of  differentiation, none of the proteins 
were significantly changed (Figure 27C). However, when compared with hPH, expression of  
HMGB1, CK18, GLDH and ALT1 in undifferentiated organoids are also not significantly 
different from hPH although the fold change for GLDH and ALT1 is still large (16.4- and 11.0-
fold higher in hPH, respectively) (Figure 27A). These results suggest that undifferentiated 
organoids have a hepatocyte-like phenotype before the differentiation process, as might be 
expected from liver progenitor cells. Nonetheless, there are significant differences between 
hPH and undifferentiated organoids, both forms of AST are significantly decreased by a 
substantial magnitude and ALT2 is significantly increased by a small margin as is CK19. The 
pattern of expression is the same in all proteins after differentiation, though the expression 
in organoids has decreased in every case except cytoplasmic AST (Figure 27B). 
AST is a key biomarker that is routinely used in conjunction with ALT to assess liver damage, 
the use of serum transaminases in this manner is well-established and was first described in 
the 1950s (Karmen et al., 1955). There are two isozymes of AST, one mitochondrial (AST2) 
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one cytoplasmic (AST1). Though both isozymes catalyse the transfer of an amino group 
from aspartate to α-ketoglutarate, their sequences share only approximately 50% identity 
(McGill, 2016; McPhalen et al., 1992). Both AST and ALT are released by the liver when 
damaged, though the relative levels of each can inform the type of damage that is 
occurring, for example, an increased AST/ALT ratio may be indicative of advanced alcoholic 
liver disease (Nyblom et al., 2004). Similarly, it has been suggested that differential analysis 
of the isozymes of AST may be informative of the types of liver damage occurring, Kamiike  
et al. showed that whilst cytoplasmic AST was released quickly after injury, mitochondrial 
AST was released into circulation after a longer period and more extensive cell damage and 
suggested that mitochondrial AST is specifically indicative of apoptosis (Kamiike et al., 
1989).  
That AST should be markedly lower in organoids, even after differentiation is concerning 
when considering their hepatic phenotype. Ideally, their expression would be similar, to 
enable simple translation. Whilst it might be possible to account for these differences 
based on known proteomic screens, this hampers their utility in discovery of new 
biomarkers if they are not reliably expressed at similar levels. Interestingly, although the 
differences are still significant after differentiation, the fold difference is decreased for 
cytoplasmic AST suggesting the possibility of incomplete differentiation to a hepatocyte 
phenotype, this agrees with the global analyses of the proteome which shows 
differentiated organoids still cluster with undifferentiated organoids rather than with hPH 
(Figure 22). 
4.3.4.6 Cholangiocyte markers 
The final panel of proteins which was analysed were markers of cholangiocytes. Since these 
organoids are nominally derived from EpCAM-positive cholangiocytes, we investigated 
whether they retained a cholangiocyte identity before and after differentiation to a hepatic 
fate. These results should be interpreted with caution since FACS enrichment for EpCAM-
positive cells was not used, and therefore the confidence in the exact identity of the 
starting cell type is lower and the organoids may arise from hepatocytes instead as 
discussed by Hu et al. (2018). 
Four commonly used markers of cholangiocytes were detected by iTRAQ analysis, CK19, 
CK7, MUC1 and EpCAM. CK7 and CK19 are keratins used for the routine identification of 
cholangiocytes, neither protein is expressed in healthy hPH but can often be acquired in 
hepatocellular carcinomas (Matsukuma et al., 2012; Shibuya et al., 2011). Similarly, MUC1 
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(also epithelial membrane antigen) is expressed in cholangiocytes and other epithelial cell 
types (Kumagai et al., 2016; Leong et al., 2003). MUC1 is not expressed in healthy 
hepatocytes but is often acquired in hepatocellular carcinoma (Kim et al., 2014). Increased 
expression of these proteins implies an adoption of a cholangiocyte-like phenotype. As 
such, some of the proteins identified in previous panels were assessed for increased 
expression in cholangiocytes. 
All proteins except MUC1 were significantly higher in undifferentiated organoids than in 
hPH and all were significantly higher after differentiation, and MUC1 was the only 
significantly changed protein during differentiation (Figure 28). These results suggest that 
Chol-orgs exhibit some markers of a cholangiocyte phenotype even after differentiation to 
a hepatocyte fate. The relative expression of several cholangiocyte markers increases 
during differentiation, contrary to expectation. However, it should be noted that expression 
in hPH is very low and the relative increase in expression in organoids may appear to be 
greater for this reason. 
GSTP1 expression was higher in organoids than hPH (Figure 25). The degree of GSTP1 
expression in hPH is low and it has also been implicated in chemoresistance in 
cholangiocarcinoma  and therefore may represent an acquisition of a more cholangiocyte-
like phenotype (Nakajima et al., 2003; Söderdahl et al., 2007). Some transporters which 
were significantly upregulated may also represent a shift towards a cholangiocyte 
phenotype, ABCB1 and SLC12A2 are expressed in cholangiocytes (Concepcion et al., 2014; 
Larbcharoensub et al., 2011). Similarly GGT1, which was significantly upregulated in the 
‘DMETs’ section is also expressed in cholangiocytes (Dianat et al., 2014). These results 
generally indicate that human liver organoids have at least a partially cholangiocyte-like 
phenotype but also a hepatocyte like phenotype as discussed in previous sections. A mixed 
cholangiocyte-hepatocyte phenotype has been reported in previous studies using similar 
organoids (Huch et al., 2015). It is not clear from these results whether all cells are 
expressing a mixed phenotype or is there are two distinct populations of cells. A mixed 
phenotype is unlikely to be appealing as a model of hepatotoxicity since it does not mirror 
the in vivo situation, though a mixed population of cells may be desirable. 
Next we examined how the results of this proteomic analysis matched with the analyses 
performed by Huch et al. (2015). First the authors measured the phenotype of 
undifferentiated organoids at different passages, our analysis did not include different 
passages of the same organoids, but all analyses were completed before passage 10, and 
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therefore are comparable to the ‘early passage’ organoids in Huch et al. Moreover, in Huch 
et al. the comparison is made to tissue, whereas the comparisons in figures 22-27 are made 
versus hPH, however, (Figure 29C) shows that for the purposes of comparison, these 
samples are similar. Huch et al showed that serum albumin was undetectable by RT-qPCR, 
however, we readily detected serum albumin in undifferentiated organoids at only 
approximately 1.2-fold lower than hPH (Figure 27). Similarly, Huch et al. showed that CK19 
was undetectable in hPH and higher in early passage organoids, whilst our data show that 
CK19 expression is only approximately 1.2-fold higher in undifferentiated organoids than 
hPH.  
Furthermore, Huch et al. also examined the expression of liver-specific genes before and 
after the differentiation process, notably, serum albumin and CYP3A4. We readily detected 
both proteins in our analysis and were also able to confirm their expression by western 
blotting. In this regard, our results match with those of Huch et al. who showed increased 
expression of both genes during differentiation. When compared against hPH, by proteomic 
analysis (Figure 23B & 23B), we found reduced, but comparable expression of CYP3A4 and 
albumin in differentiated organoids (2.63- and 1.01-fold higher in hPH respectively), by 
western blotting. When compared to donor-matched tissue, our results showed higher 
expression of CYP3A4 and albumin in differentiated organoids than Huch et al. 
(approximately 1.13- and 1.28-fold higher in tissue respectively, Figure 30). Additionally, the 
authors showed an increase in gene expression of CK19 during differentiation, our data 
shows CK19 remains unchanged throughout differentiation (Figure 28C). These data likely 
highlight the differences in expression patterns of RNA and protein as previously noted. 
4.3.5 Conclusions  
Human Chol-orgs can be derived from donor liver tissue in our lab, we have also succeeded 
in culturing, passaging, cryopreserving and differentiating them to a hepatocyte fate. Global 
proteomic analysis shows that although there are changes to the proteome of organoids 
during the process of differentiation, they do not cluster closely with hPH by hierarchical 
clustering analysis. Closer scrutiny of these data indicates that although the global 
proteome does not cluster closely with hPH, differentiated organoids show similar 
expression of key proteins required for drug metabolism and transport. For example, these 
analyses show that 13 out of 16 detected CYP enzymes were either not significantly 
different or significantly higher in organoids than in hPH. Furthermore, the panel of DMETs 
shows that out of 41 proteins, only 4 were significantly higher in hPH, with the remaining 
genes either non-significantly changed or significantly higher in differentiated organoids. 
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The NRF2 pathway is highly active in differentiated organoids with significantly higher 
expression of 3 out of 5 proteins in this panel and none significantly downregulated. The 
pattern is similar again for transporters where only one protein in this panel is significantly 
higher in hPH. These findings are further corroborated by western blotting, performed on a 
separate donor showing expression of CYP3A4 and albumin increasing over the 
differentiation process to levels comparable to donor-matched liver tissue (Figure 30). 
Future studies should aim to increase the statistical power of these experiments. In this 
study only one donor was differentiated in sufficient quantity to enable proteomic analysis.  
Additionally, there are many nascent liver models currently under development, 3D 
cultures of primary and stem cell-derived hepatocytes, systems incorporating flow etc., 
comparison with these models and other currently used models should be performed. Only 
once these comparisons have been made at the proteomic level will it be possible to fully 
determine if liver organoids are a true improvement over extant and upcoming models.  
In summary, differentiated Chol-orgs, recapitulate physiologically relevant levels of some, 
but not all aspects of the hepatic phenotype and some aspects of the cholangiocyte 
phenotype as may be expected from the cell-type of origin. The incomplete hepatic 
phenotype may be related to the completeness of differentiation, similar to the difficulty in 
the stem cell field in driving stem cell-derived HLCs towards a mature phenotype (Baxter et 
al., 2015). It is also possible that the incomplete recapitulation of the hepatic phenotype is 
related to the starting cell type. As discussed previously, the organoids described in 
Broutier et al. (2016) aim to reproduce the oval cell response, which is not the homeostatic 
mechanism for reproduction of hepatocytes. In a recent paper, the Clevers group 
demonstrated reproduction of the homeostatic mechanism of  hepatocyte repopulation, i.e. 
division of mature hepatocytes (Hu et al., 2018). Based on the analyses in this paper, is 
seems likely that they possess a more relevant hepatic phenotype than Chol-orgs when 
differentiated, though with the caveat that the analyses are RNA based and therefore may 
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Stem cells are capable of several fates, self-renewal, differentiation or death. When cells 
are cultured in an undifferentiated state a selective pressure is applied to the cells 
favouring the self-renewal fate. This, in part, accounts for the recurring patterns of 
mutations observed in stem cells in culture, in particular, recurrent mutations of 
chromosomes 12, 17, 20 and X are common (Amps et al., 2011). The 20q11.21 amplicon is 
one such common mutation, occurring in as many as 20% of ESC and iPSC lines after 
prolonged culture and confers a survival advantage (Amps et al., 2011). The 20q11.21 
minimal amplicon is approximately 0.55Mb in length and encodes HM13, ID1, BCL2L1, 
KIF3B and an immature form of miR-1825. The amplicon size is variable and can also 
encode other nearby genes, including the potential oncogene, TPX2.  Recent studies have 
demonstrated that BCL2L1 is likely to be the key driver of the survival advantage observed 
in carrier cells (Avery et al., 2013; Nguyen et al., 2014). Although not the source of the 
survival advantage conferred in vitro, ID1 is another gene expressed in the 20q11.21 
minimal amplicon that is a potential oncogene. 
Previous studies have demonstrated the application of stem cell derived HLCs in mouse 
models where the cells have engrafted and become functional in murine liver (Asgari et al. ,  
2013). Additionally, undifferentiated stem cells with known aberrations have been used in 
vivo to demonstrate enhanced tumorigenicity (Ben-David et al., 2014). Here we present the 
first attempt, to the best of our knowledge, to combine these approaches and use 
differentiated stem cells with a known genetic aberration in vivo to discern the effects of 
the 20q11.21 amplicon on tumorigenicity after differentiation. 
In this study Fox Chase SCID Beige (SCID beige) mice were used. SCID beige mice are  albino 
and carry both the SCID and beige mutations producing a severely immunocompromised 
mouse demonstrating severe T and B lymphocytopaenia with defective natural killer cells 
and a rudimentary thymus (Croy and Chapeau, 1990). For the purposes of this study, SCID 
beige mice were an appropriate model due to their severely immunocompromised status 
and albino fur which facilitated in vivo bioluminescence imaging without shaving. However, 
when compared with other immunocompromised mouse models such as NOD-SCID etc., 
SCID beige mice are relatively understudied. For example, at the time of writing, PubMed 
returns 3668 results for the search term “NOD SCID” but only 311 for the term “SCID 
beige”. Therefore, it was necessary to determine some aspects of this study for the first 
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time, such as the required dose of carbon tetrachloride (CCl4) required to produce acute 
liver injury. 
Acute CCl4 injury was used in this study to better facilitate cell engraftment into the liver as 
described by Payne et al. (2011). Though once widely used, the toxicity of CCl4 has now 
been recognised for over 70 years (Recknagel, 1967). Despite the restrictions on its use in 
other fields, CCl4 is widely used in research as a model hepatotoxin. CCl4 is activated by a 
range of cytochromes P450 (CYP2E1, CYP2B1, CYP2B2, CYP3A) into the trichloromethane 
radical (CCl3∙) which in turn may react with oxygen to form the trichloromethylperoxy 
radical (CCl3OO∙) both of which are highly reactive and can damage cellular macromolecules 
such as DNA and phospholipids. The attack of CCl3∙ on DNA is thought to be an initiator of 
hepatic cancers and CCl3OO∙ can initiate a chain reaction which degrades phospholipids of 
the various cellular membranes. These processes cause sufficient damage, either acutely or 
chronically to cause cell death (Weber et al., 2003). In this work CCl4 was administered to 
induce acute liver damage followed by a period of liver regeneration. Gupta et al. report 
that if cells are administrated during the period of liver regeneration, the transplanted cells 
can proliferate along with the host cells, thereby enhancing engraftment (Gupta et al., 
1999). However, the authors also report that if cells are administered whilst CCl4 is still 
present in the liver the administered cells can also become damaged. Because of this,  ce lls 
were administered 3 days after acute liver injury, longer than the in vivo half-life of CCl4 of 
approximately 7 hours (World Health Organisation, 2004). 
We hypothesised that the presence of amplicon 20q11.21 confers a survival advantage to 
carrier cells in vitro. Similarly, differentiated cells which carry the amplification will be more 
prone to tumour formation when transplanted into the livers of an immunodeficient mouse 
model. Therefore, human ESCs (hESCs) with known 20q11.21 status were differentiated 
into HLCs for transplantation into SCID mice. Luminescent hESCs were generated from the 
MasterShef 7 and MasterShef 8 hESC lines both with and without 20q11.21. These cells 
were differentiated into HLCs and injected intrasplenically into Fox Chase SCID-beige mice 
whose livers had been acutely damaged with CCl4. The engraftment of these cells into the 
liver was then tracked using in vivo luminescence imaging for approximately 4 months and 




5.2.1 Characterisation of MasterShef 7 & 8 -fluc clones 
Four parental hESC lines were used in this study: MS7N, MS7CNV, MS8N and MS8Ab. 
Luminescent copies of these cells were produced by nucleofection with the construct 
shown in Figure 31A and clonally selected using puromycin. Luminescence was confirmed 
and quantified using the IVIS Spectrum and the two most strongly luminescent cell lines 
were selected for each parental cell line (Figure 31B). The 20q11.21 status of each cell line 
is summarised in Table 7. 
 -20q11.21 +20q11.21 
MasterShef 7 MS7N MS7CNV 
MasterShef 8 MS8N MS8Ab 
Table 7 
Table of MasterShef hESC lines showing 20q11.21 status – Each MasterShef line was 
named according to 20q11.21 status, lines denoted as ‘N’ do not carry the 20q11.21 
amplicon, those marked at ‘Ab’ or ‘CNV’ contain the 20aq11.21 amplicon. Luminescent cell 
lines derived from these cells are appended with a 2-character identifier e.g. C7, G7 etc. 
5.2.2 SCID-beige mice are highly sensitive to acute carbon tetrachloride 
toxicity 
To better facilitate engraftment of hESC-HLCs into the liver, acute hepatocellular damage 
was induced using CCl4. To the best of our knowledge, the dose of CCl4 for induction of 
acute liver injury in SCID beige mice has not previously been reported. The range of CCl4 
doses used in other strains of mice varies greatly as high as 10mL/kg (Chen et al., 2018; 
Wang et al., 2013). We used single doses of 1.0, 0.4 and 0.2 mL/kg of CCl4. With 1.0 and 0.4 
mL/kg, animals became unwell before the end of the study. Using 0.2 mL/kg of CCl4 
demonstrated a substantial degree of liver damage (Figure 31C, D) and ALT elevation 
(Figure 31E) at 24 and 72 hours after injection. Therefore, for subsequent experiments 0.2 
mL/kg was used. 
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5.2.3 Teratoma f ormation u sing undifferentiated hESCs with and  
without amplicon 
Undifferentiated hESCs readily form teratomas in rodents. However, changes in teratoma -
forming behaviour in the presence of amplicon 20q11.21 has not previously been 
investigated. We induced liver injury in 16 male SCID beige mice and after 72 hours, 1 × 106 
undifferentiated luminescent MS7N, MS7CNV, MS8N or MS8Ab were injected 
intrasplenically (n=4). Animals were kept for 4 weeks and imaged weekly. Weights of the 
animals were monitored three times a week. 
In the first week, 14/15 animals showed a bioluminescent signal which increased over time 
(Figure 32A, Supplementary Figure 1). The intensity of the signals was significantly higher in 
MS7CNV compared to MS7N in both liver and spleen when imaged ex vivo (P=0.0152 and 
p=0.0002 respectively) though this trend did not continue in MS8Ab and MS8N ( Figure 
32B). Ex vivo imaging demonstrated signal in 14/15 livers and 4/15 spleens in addition to 
































Transfection of undifferentiated hESCs with a luciferase construct and identification of 
appropriate dosage of CCl4 for consistent induction of acute liver injury in Fox Chase SCID 
beige mice - (A) pCAG Firefly Luciferase-2A-Puro map (B) MasterShef 8 normal and 
abnormal cells transfected with pCAG Firefly Luciferase plasmid. Clones were selected with 
puromycin and the two most luminescent from each line were expanded. (C) H&E staining 
of liver tissue. Fox Chase SCID beige mice received a single dose of CCl4 (0.2 or 0.4 mL/kg) or 
olive oil and were sacrificed at 24 or 72 h. After 24 h both 0.2 and 0.4 mL/kg induced severe 
coagulative necrosis of the centrilobular hepatocytes with or without the presence of acute 
haemorrhages. After 72 h, both groups showed a decreased degree of damage and a 
narrowing of the area of coagulative necrosis around the central vein with a continuous rim 
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hepatocytes within the intervening “healthy” parenchyma. Administration of olive oil as 
medium only in the control group did not elicit appreciable morphological degeneration of 
the hepatic parenchyma. (D) Mean hepatocellular damage. Scoring system for liver damage 
in this cohort scored according to Thoolen et al. (2010). (Table 9) (E) ALT activation in SCID-
beige mice 24 and 72 hours after injection with CCl4. Data are displayed as U/L and show 
the mean; error bars show standard deviation. Asterisks denote significance calculated 
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Undifferentiated hESCs with 20q11.21 amplicon induce extensive immature teratoma and 
teratocarcinoma in the murine liver. SCID beige mice were injected with 1×106 of 
undifferentiated MS7N, MS7CNV, MS8N and MS8Ab into the spleen (A) In vivo and ex vivo  
(liver and spleen) bioluminescence imaging of representative mice from each group after 28 
days. See Supplementary Figure 1 for data from all mice. (B) Comparison of 
bioluminescence in livers and spleens imaged ex vivo in different cell lines. Values are 
plotted as total flux (photons/second) Total flux is determined by the total amount of 
luminescence detected from the animal in the IVIS Spectrum during the exposure period, 
error bars show SEM. MS7CNV and MS7N are significantly different for both liver and 
spleen (two-tailed, unpaired t-test, p= 0.0152 and 0.0002 respectively). (C) Bioluminescence 
over time in vivo grouped by cell line. Values are plotted as total flux (photons/second). (D)  
H&E staining of a representative liver and spleen tissue after injection with undifferentiated 
hESCs. (E) Grades of teratoma formation in the liver and spleen of mice injected with 
undifferentiated hESCs. Scoring was performed by a veterinary histopathologist and scored 
according to Thoolen et al. (2010) (Table 9). (F) Representative IHC staining of liver and 
spleen tissue for vimentin and Pan-cytokeratin to confirm the presence of teratoma. 
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In H&E staining, all four cell lines demonstrated immature teratoma and in MS8Ab 
carcinomatous features were also present (Figure 32D). The grade of cystic formation was 
higher in liver (5) and spleen (5) of mice injected with MS7CNV compared to liver (0 -1)  and 
spleen (0) with MS7N though this trend was not apparent in MS8N and MS8Ab (Figure 
32B).  
Vimentin and pan-cytokeratin proteins were expressed in liver and spleen (Figure 32F). 
Vimentin is the first intermediate filament expressed in the cytoplasm of embryonic cells, 
soon replaced by cytokeratins in epithelial tissues during cell differentiation. Therefore, 
coupled with the biphasic pattern of morphological differentiation of the neoplastic cells 
composing the nodular masses in both liver and spleen, the observation of specific 
cytokeratin labelling in structures resembling large acini is supporting of the hypothesis that 
initial epithelial commitment of a proportion of the neoplastic cells is well established. 
Therefore, both mesenchymal and epithelial differentiations are present within most of the 
neoplastic masses.  
5.2.4 Pluripotency assessment of MasterShef hESCs 
Since a random integration method was used to produce the luminescent reporter cells. It 
is possible that the pluripotency of these cells could have been affected. We used an 
embryoid body-forming assay where undifferentiated hESCs are allowed to differentiate 
spontaneously before staining for markers of the three germ layers. If markers of  all three 
germ layers can be detected, the functional pluripotency of the cell is thereby 
demonstrated. 
We generated embryoid bodies from each parental MasterShef line (Figure 33A) and two 
luminescent clones of each, and then stained for alpha-foetoprotein (AFP) as a marker of 
endoderm, neuron-specific beta ‑III tubulin (Tuj-1) as a marker of ectoderm, and alpha 
smooth muscle actin (α-SMA) as a marker of mesoderm and were able to detect all three 
markers in each line tested as indicated in green (Figure 33B), demonstrating that their 
pluripotency was unaffected. 
The protocol described by Greenhough et al. for the prediction of differentiation propensity 
was adapted for use in this study. The original protocol measured the spontaneous 
expression of AFP, albumin and HNF4α in embryoid bodies in order to predict the ability of  
a stem cell line to form HLCs by directed differentiation (Greenhough et al., 2013). We 
adapted this protocol to examine the expression of AFP, albumin and HNF4α using qPCR to 
Chapter 5 
173 
determine if the propensity to differentiate towards HLCs had been altered by the random 
integration of the reporter plasmid. 
Embryoid bodies were formed from each parental cell line and the two most luminescent 
clones were then assessed by qPCR. The results of this experiment (Figure 34) showed that 
in all cases the expression of these three genes was either similar or higher than the 
parental line indicating a similar or increased propensity to differentiate towards HLCs after 
integration of the reporter construct. 
5.2.5 Differentiation protocol development 
The protocol described by Medine et al. (2011) was initially chosen to produce HLCs in this 
study (Figure 35A). However, it was noted that luminescence was lost in HLCs after day 9 of  
differentiation (Figure 35C). Moreover, the proportion of cells expressing HNF4a was 
decreased at day 12 compared with day 8 (data not shown). Additionally, cells 
differentiated using this protocol failed to engraft, as determined by absence of 
luminescence. We reasoned that since luminescence was lost when moving into the final 
stage of differentiation, the cause of the loss of differentiation and luminescence was due 
to the composition of this medium. It was observed that the pH of the L-15 based medium 
was very low (<6) due to addition of 2% (w/v) ascorbic acid (Medine et al., 2011). The 
composition of this medium was adjusted based on a similarly composed medium 
described by Siller et al. (2015), replacing 2% (w/v) ascorbic acid with 50 ng/mL sodium-L-
ascorbate. Cells differentiated using this adapted protocol (Figure 35E) retained 
luminescence until day 12 (Figure 35D) and were able to successfully engraft in vivo (Figure 
35). Other aspects of this differentiation protocol remained unchanged.  
5.2.6 Differentiation efficiency of MasterShef hESCs 
Due to the potential for teratoma formation from undifferentiated cells is was necessary to 
assess the efficiency of the differentiation protocol prior to injection of the cells. The 
efficiency of the differentiation protocol in producing HLCs was assessed using flow 
cytometry where HNF4α expression at day 8 of the differentiation protocol was used as a 
marker of successful hepatic differentiation. A single luminescent clone of each MasterShef  
line (MS7N D6, MS7CNV D7, MS8N E3, MS8Ab D7) was differentiated until day 8 of the 
differentiation protocol described in chapter 2 and in Figure 35 before analysing their 
expression of HNF4α by flow cytometry. At day 8 of differentiation cells were stained for 
HNF4α as described in chapter 2 and their differentiation proportion was assessed. All lines 
showed a high proportion of HNF4a expression, i.e. 90.7%, 87.6%, 96.4% and 80.4% for 
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MS7N_D6, MS7CNV_D7, MS8N_E3 and MS8Ab_D7 respectively (Figure 33C). These 
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Demonstration of pluripotency in transformed MasterShef Fluc ESCs and characterisation of differentiation efficiency to HLCs. (A) Representative 
micrographs showing embryoid body formation in MS8N, MS8Ab, MS7N and MS7CNV ESCs 48 hours after seeding. Embryoid bodies were  also formed for 
all the transformed lines in panel B but are not shown. (B) Representative fluorescence micrographs of spontaneously differentiating embryoid bodies 
adhered to a cell culture surface. Positive staining (in green) for AFP (endoderm), Tuj-1 (ectoderm) and a-SMA (mesoderm) demonstrates formation of  the 
three major germ layers, and therefore, pluripotency. Hoechst was used as a nuclear stain and is shown in blue. Pluripotency was not affected in any of  the 
tested transformed cell lines. (C) Differentiation efficiency towards HLCs shown by flow cytometry. Cells were stained for HNF4a as a marker of 





























































5.2.7 Tumorigenicity of MasterShef HLCs with a mplicon in SCID b eige 
mice 
To test the hypothesis that the presence of amplicon 20q11.21 in human cells used 
therapeutically predisposes to a greater risk of tumorigenicity in a mouse model, 8 
luminescent hESC lines, 4 without and 4 with amplicon 20q11.21, were differentiated into 
HLCs as described above. One million  cells were injected into the spleens of 56 SCID Beige 
mice 72 h after induction of acute liver injury (n=7). After 7 days, the animals were imaged 
using an IVIS Spectrum either weekly or fortnightly for approximately 4 months ( Figure 
36A), after which some animals began to show signs of deteriorating health and the 
experiment was ended. 
A positive control of a relative cancer cell type was used for the purposes of comparison in 
terms of engraftment and proliferation in vivo. HepG2 cells are an immortalised cell line 
which is routinely used as a liver cell model. Because of their liver phenotype and high rate  
of proliferation, they may reasonably be expected to engraft aggressively into the liver of 
an immunocompromised mouse. HepG2 cells expressing the same luciferase reporter were  
produced in the same manner and iPSCs and 1 x106 cells were injected intrasplenically into 
mice 72-hours after CCl4-induced acute liver injury. These animals rapidly developed a 
strong luminescent signal which became saturated after 6 weeks,  the health of these 
animals simultaneously began to decline at which point the experiment was ended ( Figure 
36A-D) 
Thymus tumours were routinely checked for post-mortem and 6 were observed, animals 
with thymus tumours were excluded from all analyses. Luminescent signal was observed in 
livers from 3 animals and in the spleens of 3 animals (Figure 36B).  
In vivo luminescence was tracked over the course of the experiment in each line ( Figure 
36C). These results demonstrate an increased luminescent signal on average in animals 
injected with cells containing the 20q11.21 amplicon. Figure 36D shows the mean 
luminescent signal from all lines grouped according to their 20q11.21 status and show 
increased signal in animals injected with cells containing the amplicon, though these values 
do not reach significance due to high inter-animal variation. 
On average, there were more severe histology scores in the animals where cells containi ng 
the 20q11.21 amplicon were injected (Figure 36F, Table 8). The criteria for these histology 
scores are shown in Table 9. Moreover, the luminescent signal, where observed, was 
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greater in the cells containing the 20q11.21 amplicon. We also quantified the levels of 
human albumin present in the serum. If the cells had successfully engrafted, they would be 
expected to produce human albumin. However, there were undetectable levels of  human 
albumin in all cases except for a single clone, MS8Ab D7, where the concentration was still 
extremely low compared to the levels of human albumin detected in the serum of  animals 




Gene expression in MasterShef Embryoid bodies to assess skewing of differentiation 
propensity – Embryoid bodies differentiate spontaneously, their tendency to differentiate  
into a particular germ layer has been suggested to indicate their ability to differentiate to 
that fate under directed differentiation (Greenhough et al., 2013). In this study it was 
determined whether that propensity to differentiate into the endoderm lineage had been 
affected by integration of luminescence plasmid. Expression of AFP (A), albumin (B) and 
HNF4a (C) analysed using qPCR with SYBR green chemistry in embryoid bodies produced 
from MS7N, MS7CNV, MS8N and MS8Ab and their luminescent clones. Values are 
presented as mean fold change calculated using the 2-ΔΔCT method, error bars show error 
calculated using the same method (Livak and Schmittgen, 2001). All values are presented 






















































































































































































































































































































































































































































































line is presented separately, bars in black show parental cell lines followed by the 





Overview of the differentiation protocol used in this study - adapted from the protocol 
published by Medine et al. 2011. The top bar represents the day of the differentiation 
procedure and the medium and supplements used are shown underneath. Full details of 
the differentiation protocol are in chapter 2. (A) Overview of differentiation protocol used 
in this chapter, (B) Luminescence in ESC-HLCs at day 8 using version 1 of the protocol, (C) 
Luminescence at day 12 of the differentiation protocol using version 1 of the protocol, (D) 
Luminescence at day 12 using version 2 of the protocol, (E) Comparison of the composition 
































1 0 1 0
1 0 1 1
M S 7 N _ E 5
M S 7 N _ D 6
M S 7 C N V _ C 7
M S 7 C N V _ D 7
M S 8 N _ C 3
M S 8 N _ E 3
M S 8 A b _ D 7
M S 8 A b _ G 7
H e p G 2 _ L u c
C D 


























1 0 1 0
1 0 1 1
-2 0 q 1 1 .2 1
+ 2 0 q 1 1 .2 1











































































































































































MasterShef Fluc HLCs sporadically luminesce in vivo and increase liver tissue histology 
scores (A) Representative luminescence images of SCID beige mice 6 weeks post 
intrasplenic injection with MS Fluc HLCs or HepG2 Fluc cells. Luminescence is displayed in 
the coloured overlay with warmer colours indicating higher luminescence intensity. Not all 
animals displayed luminescence after injection with MS Fluc HLCs. (B) Representative ex 
vivo luminescence images of mouse organs. All images show liver (top) and spleen 
(bottom). Luminescence is indicated by the coloured overlays with warmer colours 
indicating greater luminescence intensity. (C) Luminescence over time for each injected ce ll 
line. Luminescence values were recorded for up to 4 months post-injection for each cell line  
using the IVIS. The values are plotted as total flux (photons/second) and error bars show 
SEM. The experiment with HepG2 Fluc cells was halted after 6 weeks since the luminescent 
signal was saturated in the IVIS scanner and the health of the animals began to deteriorate. 
(D) Luminescence over time grouped for cells with or without the 20q11.21 amplicon. 
Values are plotted as total flux (photons/second) and error bars show SEM. (E) Graph 
showing concentration of human albumin in the blood of SCID beige mice after injection 
with MS Fluc HLCs, HepG2 Fluc cells or controls. Blood was collected by cardiac puncture 
and assessed using human Albumin ELISA (Bethyl Laboratories). Values are presented as 
ng/mL. (F) Mean histology scores for liver and spleen tissues separated by tissue and 
amplicon status. Tissues were assessed by a histopathologist and were scored according to 
Thoolen et al. Horizontal black bars indicate the mean and SEM. Mean liver histology score 
was 0.81 with amplicon, 0.19 without, p=0.0281 using the Mann Whitney-U test with 
Bonferroni correction, mean spleen histology score was 0.05 with amplicon, 0.00 without, 
p=0.8264 using the Mann Whitney-U test with Bonferroni correction, details of the criteria 
for each score are shown in Table 9 (G) Haematoxylin and eosin staining of mouse liver 
after injection with MS Fluc HLCs showing hepatic lymphoma. (H) Haematoxylin and eosin  
staining of mouse spleen after injection with MS Fluc HLCs showing splenic lymphoma. (I) 
Haematoxylin and eosin  staining of mouse liver after injection with MS Fluc HLCs showing 
carcinoma. (J) Haematoxylin and eosin  staining of mouse thymus tumour after injection 





-20q11.21 +20q11.21 HepG2 Control -20q11.21 +20q11.21 HepG2 Control 
0‡ 0§ 0 0 0‡ 0§ 0 0 
0‡ 3§ 0 0 0‡ 1§ 0 0 
0‡ 0§ 2 5 0‡ 0§ 0 4 
0‡ 0§  0 0‡ 0§  0 
0§ 0§   0 0§ 0§   0 
0§ 0§  0 0§ 0§  0 
0§ 1‡     0§ 0‡     
0§ 0‡    0§ 0‡    
0§ 0‡     0§ 0‡     
0* 0‡    0* 0‡    
1* 0‡     0* 0‡     
1* 2†    0* 0†    
1* 2†     0* 0†     
0* 2†    0* 0†    
0† 1†     0† 0†     
0† 1†    0† 0†    
  1*       0*     
  1*     0*    
  1*       0*     
  1*     0*    
  1*       0*     
Table 8 
Histology scores for spleen and liver in animals injected with MS cells with or without 
20q11.21 amplicon. Histology performed by a veterinary pathologist and scored according 
to Thoolen et al. For the columns marked ‘-20q11.21’ an asterisk (*), dagger (†), double 
dagger (‡) or section mark (§) indicated that the animal was injected with MS7N  E5, MS7N 
D6, MS8N C3 or MS8N E3 respectively. For the columns marked ‘+20q11.21’ an asterisk (*) ,  
dagger (†), double dagger (‡) or section mark (§) indicated that the animal was injected 
with MS7CNV C7, MS7CNV D7, MS8Ab D7 or MS8Ab G7 respectively. Liver and spleen 
scores for +20q11.21 and -20q11.21 were compared using the Mann Whitney U test with 
Bonferroni correction using the wilcox.test() function in R. Mean liver histology score was 
0.81 with amplicon, 0.19 without, p=0.0281. Mean spleen histology score was 0.05 with 






0 No morphological abnormalities detected. 
1 Discontinuous layers of centrilobular hepatocytes exhibiting coagulative 
necrosis, with kariolysis and kariorrhexis (only zone 3).  
2 Thick continuous layer of centrilobular hepatocytes exhibiting coagulative 
necrosis, with kariolysis and kariorrhexis (only zone 3).  
3 Thick and bridging areas of centrilobular coagulative necrosis (zone 3 and 
most of 2) 
4 Extensive coagulative necrosis involving zones 3 and 2, sparing only a thin 
layer (~2 hepatocytes thick) of periportal hepatocytes 
5 Extensive coagulative necrosis involving zones 3 and 2, and periportal 
hepatocytes including multiple diffuse foci 
Table 9 
Criteria for histology scoring of lesions in liver tissue  – Histological scoring was performed 
by a veterinary pathologist according to Thoolen et al. (Thoolen et al., 2010). Though the 
scoring system described by Thoolen et al. was intended for use in Liver it was also 
arbitrarily applied to spleen. Scoring ranges from 0 to 5, where 0 indicates no detectable 
change in morphology from healthy tissue and 5 indicates the most severe form of lesion 




H&E staining revealed hepatic lymphoma (Figure 36G), splenic lymphoma (Figure 36H), 
carcinoma (Figure 36I) and nodal lymphomas (Figure 36J). The tissues were also scored by a 
veterinary pathologist according to Thoolen et al. (Figure 36H); these scores were 
significantly higher in animals that received cells containing the 20q11.21 amplicon (Table 
8).  
5.3 Discussion 
A major concern over the use of stem cell therapies is the perceived risk of tumorigenicity. 
This is highlighted by recent cases where tumours were found several years post stem cell 
transplantation. In one case, a tumour, derived from the transplanted material, was 
detected four years after foetal neural stem cell transplantation for ataxia telangiectasia 
(Amariglio et al., 2009). A similar case was also reported following the treatment of spinal 
injury with olfactory mucosal cell transplantation; 8 years after treatment, the patient was 
found to have developed a mucosal-like mass at the transplant location (Dlouhy et al., 
2014). Pluripotent stem cells (PSCs) have been shown to cause benign teratomas in 
immune-deficient mice but may also create potentially malignant teratocarcinomas. In the 
short term, a pragmatic position on genetic changes will need to be adopted for the culture  
of human PSCs intended for clinical applications (Andrews et al., 2015), however, more data 
are required on which genetic variants are prone to tumorigenesis and which are safest. 
It is of vital importance that cells used for therapy do not pose a substantial risk to their 
recipients be it from undifferentiated cell survival or by insidious changes to the genotype 
of cultured cells which makes them more prone to form tumours after transplantation 
(Nicolas et al., 2017). In this study we have examined the effects of a common amplicon- 
20q11.21- which is known to confer a survival advantage in vitro (Nguyen et al., 2014). This 
amplicon contains several high risk genes including BCL2L2, ID1 and TPX2, and although the 
survival advantage has been demonstrated to operate via overexpression of BCL2L2 in vitro  
it is not clear whether the advantage will operate through the same mechanism, or at all in 
vivo (Avery et al., 2013). Therefore, we hypothesised that cells containing the 20q11.21 
amplicon would show greater tumour forming potential in vivo than cells without the 
amplification 
In this work we demonstrate for the first time, the engraftment of differentiated cells with 
known 20q11.21 status and show differences in their behaviour after engraftment 
depending on amplicon status. Cells with 20q11.21 engraft more readily in both a 
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differentiated and undifferentiated state. This is demonstrated by the extensive integration 
of undifferentiated MS7CNV cells (Figure 32A) and increased mean luminescent signal from 
lines containing the amplicon when differentiated (Figure 36A, B, I & J). Moreover, the 
extent of pathological change to tissues from cells with the 20q11.21 amplicon is greater as 
determined by mean histology score (Figure 36H, Table 8) (Thoolen et al., 2010). 
These results are unsurprising given the mechanism of the survival advantage conferred by 
20q11.21. Cells containing the amplicon are somewhat protected against cell death induced 
by single-cell passaging. In these experiments the cells were reduced to a s ingle-cell 
suspension for injection, and it is clear that a survival advantage at this stage could lead to 
improved engraftment downstream (Nguyen et al., 2014). It should also be considered that 
the survival advantage conferred to hESCs in vitro may not provide a similar advantage in 
vivo and also that if an advantage is conferred it may not operate via the same mechanism. 
Specifically, although BCL-XL has been shown to be responsible for the survival advantage 
conferred in vitro and has been found to be upregulated in several cancers (Jin et al., 2017) ,  
ID1 and TPX2 were both considered as candidate drivers of the selective advantage of 
20q11.21 in vitro. TPX2 is involved in the progression of the cell cycle and is often 
overexpressed in hepatocellular carcinoma (Shu et al., 2017), therefore the relevance of 
overexpression in transplanted cells is clear. The effects of ID1 are highly pleiotropic, 
however it is implicated in promoting cell-cycle progression, prevention of differentiation 
and tumour progression (Aloia et al., 2014; Roschger and Cabrele, 2017; Tournay and 
Benezra, 2015; Zhang et al., 2007). Additionally, ID1 is often found to be overexpressed in a 
number of cancer cell types including hepatocellular carcinoma (Roschger and Cabrele, 
2017; Sharma et al., 2016). Therefore, it is also possible that an increase in tumorigenicity 
could be attributed to ID1 overexpression. 
5.3.1 Pluripotency is maintained after transformation with luciferase 
reporter 
Random integration of nucleic acids into the genome of a cell can produce unintended side 
effects should the integrated portion disrupt the expression of genes essential to cell 
function. Though unlikely given the size of the genome, it was important to determine that 
pluripotency and differentiation propensity had been maintained after transformation with 
the luciferase reporter. Using an embryoid body forming assay, the formation of all three 
germ layers was demonstrated at the protein level (Figure 33B). This is a positive result as 
pluripotency was required for this study. However, the genomic location of plasmid 
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integration was not determined and it was possible that even though pluripotency was 
maintained, the propensity to differentiate to each germ layer was changed. Not all stem 
cell lines share an equal propensity to differentiate towards hepatocyte like cells, and it is 
conceivable that disruption of an essential gene for the proper formation of the hepatic ce ll 
fate could be disrupted without damaging a cell’s ability to form endoderm markers in the 
embryoid body forming assay. Moreover it has been suggested that the tendency to 
express hepatic markers spontaneously can dictate a stem cell line’s ability to form HLCs 
(Greenhough et al., 2013). Therefore, we also quantitatively examined the expression of 
several hepatic markers in embryoid bodies produced from the transformed lines using 
qPCR (Figure 34). 
The results in Figure 34 are unexpected, the expression of AFP in both MS7N and MS7CNV 
appears to be increased in the transformed lines relative to the parental line. Similarly,  the 
expression of albumin appears to be improved in MS7N transformed lines versus parental 
and the expression of HNF4a is improved in transformed lines versus parental for MS7CNV. 
In other cases, expression is similar between parental and transformed lines as might be 
expected. These results seem initially paradoxical, the luciferase reporter construct may 
have integrated in such a way to produce deranged expression of these genes but this 
would not explain how multiple genes were affected (e.g. AFP and HNF4a in MS7CNV) nor 
the regularity with which they occurred. However, when the stochastic nature of embryoid 
body formation is considered these results may be understood. Since the differentiation of  
cells during embryoid body formation is non-directed the embryoid bodies in both MS7N 
and MS7CNV parental line have only poorly entered the endoderm germ layer. It is 
probable that were this experiment repeated these cells may form endoderm more readily 
and show similar expression to MS8N and MS8Ab. Ultimately, although there were 
discrepancies in the number of hepatic markers expressed, most of the transformed lines 
showed enough expression of the tested hepatic markers to proceed to directed 
differentiation and were later shown to differentiate without issue (Figure 35 & 36). 
Interestingly, these results did not predict the less complete differentiation of MS8Ab, 
which showed the lowest proportion of HNF4a-expressing cells at day 8 of differentiation 
(80%, Figure 33) compared with MS7CNV which formed HNF4a more efficiently (88%). 
5.3.2 CCl4-induced acute liver injury in SCID beige mice 
To the best of our knowledge, this study is the first example of acute CCl4-induced liver 
injury in SCID beige mice for engraftment of differentiated cells. SCID beige mice were 
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chosen for this study due to their SCID status, displaying severe B and T lymphocytopaenia 
and defective natural killer cells, making them suitable xenograft candidates. Additionally, 
albino fur is more suited to long-term luminescence imaging since it does not obscure the 
luminescent signal as much as dark fur and therefore does not require shaving. However, 
there are some shortcomings of this engraftment model which have limited the application 
of this study. The SCID beige mouse is not as widely used as other SCID strains, such as the 
NOD-SCID or NOG which have long been known to develop lifespan limiting thymus 
tumours at 6-8 months of age (Custer et al., 1985; Yasuda et al., 2017). Many of the SCID 
beige mice also shared this tendency to develop lifespan-limiting thymic lymphomas as 6 
animals in this study were found to have developed tumours. This tendency was limiting to 
the overall goals of the study where the aim was to maintain the mice long-term (i.e. over 6 
months) which was not possible. Though the development of lymphomas in SCID beige 
mice is not surprising, due to the shared mutation in Prkdcscid, we are not aware of 
literature reports of this propensity. 
5.3.3 Inconsistent detection of luminescent signal after injection of HLCs 
In vivo imaging was used during this study to track the fate of luminescent cells in a 
repeatable and non-destructive manner. This allowed for the use of fewer animals than 
would have otherwise been possible, in line with the key tenets of the 3R’s. Moreover, it 
was possible to observe the same animal and cells repeatedly to track how the engraftment 
progressed, we were able to determine from an early time point if the cells were 
successfully engrafted based on the presence of a luminescent signal. However, there were 
also limitations to this approach, imaging in this manner allows only a 2D view of the 
luminescent signal, although as shown in supplementary figures 2-10 imaging the animals in 
different directions can allow for better triangulation of the source of the signal. This 
proved problematic as it was not possible to reliably determine whether the observed 
signals originated from the liver, spleen or both. Moreover, the signal was partially 
attenuated by the animal’s body meaning that only more intense signals could be detected. 
Future studies may consider the use of more sensitive techniques such as those  utilising far-
red luminescence recently employed by Yeh et al. (2017) or Iwano et al. (2018) which are 
reported to enable better tissue penetration and sensitivity. 
Intrasplenic injection was chosen as the delivery route for both undifferentiated and 
differentiated cells, as it has previously been successfully used by Payne et al. (2011). 
Alternative methods including portal vein infusion were considered but ultimately not used 
Chapter 5 
191 
due to the higher technical complexity and potential for complications. In most animals, 
engraftment of undifferentiated cells could be detected by the presence of a luminescent 
signal (Figure 32). Supplementary figure 1 shows the time course of engraftment in detail, 
at least a small signal was observed in every animal except one injected with MS8Ab. The 
outcome of these signals was divided, in 6 animals the signal was lost over time and in 
those where the signal retained the intensity increased over time, with the exception of 2 
animals injected with MS8N where the signal remained similar throughout the experiment. 
These results demonstrate the efficient engraftment and proliferation of undifferentiated 
cells in vivo. 
After injection of differentiated cells, no luminescent signal was observed or became 
undetectable after several weeks in 42/45 animals which survived surgery, as shown in 
supplementary figures 2-10. The cause of the lack of signal is unclear, though we can 
predict several possibilities. The transplanted cells may have failed to integrate once 
differentiated, however, literature reports using similar protocols to this study observed 
long-term survival of engrafted cells in vivo, making this possibility unlikely (Payne et al., 
2011; Takayama et al., 2017). There were minor differences in the differentiation protocol, 
strain of mice and cell lines used, therefore it is possible that these discrepancies may have 
prevented integration of HLCs in this study. 
It is also possible that only the undifferentiated proportion of cells survived transplantation 
and formed the few luminescent signals observed in Figure 36 and supplementary figures 2-
10 and that the differentiated cells have failed to engraft. This possibility is appealing 
because the engraftment potential of undifferentiated cells and their presence after this 
differentiation protocol has been demonstrated (Figure 32 & 33). Based on flow cytometry 
analysis (Figure 33C) it was demonstrated that a substantial proportion (19.4%) of the cells 
do not express HNF4α and likely did not form HLCs. Furthermore, the 3 animals which 
showed luminescent signals long-term were all injected with MS8Ab-derived HLCs, this line  
showed the lowest differentiation proportion of 80.6% (Figure 33C). The undifferentiated 
population of cells may give rise to the sporadic luminescent signals observed. However, 
were this the case it might be expected that the undifferentiated proportion of the cells 
would produce a luminescent signal more frequently. The presence of human albumin in 
Figure 36E suggests that at least some hESC-HLCs have engrafted but does not discount the 
possibility that the luminescent signal was derived from undifferentiated cells. This 
possibility would be relatively simple to evaluate through the use of cell sorting to purify 
only differentiated cells prior to injection or through the use of a more modern and highly 
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efficient differentiation protocol such as the recent study utilising laminins by Takayama et 
al. (2017). 
Finally, the failure to produce a luminescent signal in many animals may be an indicator of 
inter-animal variation, though the animals are of the same strain, they cannot necessarily 
be expected to behave identically and minor discrepancies in the induction and extent of 
acute liver injury and injection of the HLCs may influence the propensity to integrate.  
Taken together, these results show that consistent engraftment of cells in all mice with 
hESC-HLCs was not achieved, as indicated by the lack of luminescent signal in many animals 
(supplementary figures 2-10). Possibly, a different mouse model may have been more 
suitable for the purposes of this experiment. For example, NOD-SCID gamma mice are 
reported to have a lifespan in excess of 16 months whilst still retaining a severely 
immunocompromised status (Shultz et al., 2005). Alternatively, a more complete model of 
humanisation could have been used wherein the survival of the animal depends on the 
engraftment of the injected cells. For example, TK-NOG mice are a mouse humanisation 
model which express viral thymidine kinase specifically in the hepatocytes allowing for 
selective deletion of the host hepatocytes using ganciclovir allowing for efficient 
repopulation (Hasegawa et al., 2011). Other humanisation models exist, including 
fumarylacetoacetate hydrolase (fah) deficient mice which lack the fah gene. This phenotype 
is lethal without treatment with NTBC and is permissive of repopulation with non-fah 
deficient hepatocytes (Grompe, 2017). For the purpose of these experiments these animal 
models were prohibitively expensive, but future studies may consider their use. The use of  
a more complete humanisation model would provide greater confidence in the integration 
of the transplanted cells and the subsequent effects. 
5.3.4 Poor expression of human albumin in HLC-injected mice 
The expression of human albumin was examined in Figure 36E but was largely undetected 
except for a single clone. Interestingly, the animal from which the serum containing human 
albumin was taken did not show a luminescent signal, suggesting either attenuation of  the 
signal or only a small number of cells. The lack of detectable albumin in almost all lines after 
4 months (Figure 36C-E) suggests that the cells have engrafted poorly, failed to survive 
long-term or dedifferentiated after injection as reported by Payne et al. (2011), though we 
did not specifically test for this possibility. Human albumin was readily detectable in the 
serum of animals injected with HepG2 cells, however, these animals were only maintained 
for 6 weeks after injection as opposed to approximately four months for animals injected 
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with HLCs and it is possible that there would have been an increased quantity of human 
albumin in the HLC-injected animals at this time point. However, early experiments 
indicated that SCID beige mice failed to clot in response to collection of serum via tail 
bleeding, this was compounded by the small overall size of the animals and the relatively 
high serum requirement of albumin ELISA and therefore examination of albumin at 
additional time points was not possible. 
The detection of human albumin, even at extremely low levels demonstrates that hESC-
HLCs have engrafted and survived long-term in at least one animal, that there is no 
luminescent signal is concerning as it suggests possible attenuation of the signal either in 
the hESC-HLCs or by the body of the animal. This highlights a potential limitation of the 
imaging approach used as discussed previously. 
5.3.5 SCID beige mice spontaneously form thymic lymphomas 
The observation that SCID beige mice were similarly susceptible to spontaneous formation 
of thymic lymphoma as other SCID strains somewhat hampered these experiments. Initially 
it was planned to assess the long-term effects of engraftment over a period of 6 months 
after injection. However, given that mice were obtained at 8 weeks of age and began to 
develop lifespan-limiting thymic lymphomas around 6 months of age, this was not possible.  
5.3.6 Conclusions 
There are concerns that stem cell-derived cells pose an oncogenic risk when transplanted 
which must be allayed before they can progress to clinical use. However, testing for 
tumorigenicity is inherently challenging, in vitro models are unable to model engraftment 
and tumour growth to a satisfactory degree. Therefore, immunocompromised animal 
models must be used as an approximation of the response in humans. These re sults show 
for the first time the effects of transplant of an extremely common genetic aberration in 
human stem cells in a differentiated cell. It should also be considered that, like other 
therapies, stem cell therapies will always carry some degree of risk to the patient. By 
determining commonly occurring genetic risk factors such as 20q11.21 and other 
aberrations linked to increased tumorigenic potential, cells intended for transplant can be 
quickly triaged to minimise risk whilst allowing the use of potentially valuable therapies 
without an excessive burden of testing. 
In summary, these results show engraftment of differentiated cells into an animal model 
and demonstration of a change in cell phenotype based on a commonly acquired culture 
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adaptation. Specifically, these results likely demonstrate an increased risk and severity of 
malignancies in animals injected with cells containing the 20q11.21 amplicon. The results 
are impactful to the wider field of translational medicine as future studies should take  care  
to screen lines known to harbour common amplicons when they are being considered for 
use in transplant. Future studies in this area should also consider the use of a more 
complete humanisation model e.g. TK-NOG or fah (-/-) mice where survival of the animal 
depends on engraftment, or a longer-lived immunocompromised model such as a NOD-
SCID gamma which would provide more certainty of the survival of the engrafting cells and 








This thesis represents our efforts to develop and characterise nascent stem cell-based in 
vitro hepatocyte models. This work is necessary to produce better models of hepatotoxicity 
than are currently possible and may eventually be used in cell therapies and for transplant 
once safety issues have been more thoroughly addressed. Current models of hepatotoxicity 
are insufficient to tackle drug-induced liver injury because they lack physiological relevance, 
in the case of commonly used cancer cell lines. Or fall short in stability, availability and 
reproducibility in the case of hPH. 
PSC-derived  HLCs are a promising alternative hepatocyte model. They can be produced 
non-invasively and can be readily expanded in vitro. Hepatic organoids are another nascent 
in vitro model of hepatocytes which exploit the regenerative mechanisms of the liver to 
produce HLCs. Organoids are most commonly isolated invasively and currently offer a closer 
approximation of in vivo liver than HLCs. Both models can reproducibly model multiple 
genotypes, but differ in terms of genetic stability. 
Our work has used advanced techniques to better understand models of hepatotoxicity  
including iTRAQ and qPCR. The three main projects of this thesis were to examine the 
effects of a hypoxic environment on the differentiation of human induced pluripotent stem 
cells (iPSCs) to HLCs. Secondly, to establish human liver organoids in our laboratory and 
examine their phenotype on a proteomic level and thirdly, to examine the effects of the 
20q11.21 amplicon on the tumorigenicity of human embryonic stem cell (hESC) -derived  
HLCs when transplanted into SCID beige mice with livers which were acutely damaged with 
CCl4. 
6.2 The effects of a hypoxic environment on the 
differentiation of iPSC-HLCs and comparison of two 
differentiation protocols 
PSC-HLCs are a promising model to produce high-quality hepatocytes, however they are 
hindered by poor physiological relevance compared to hPH or organoids. The development 
of differentiation protocols for iPSC-HLCs has not changed dramatically in recent years in 
terms of additives to differentiation media. Instead there has been a focus on the 
adaptation of the culture conditions to improve physiological relevance, including 3D 
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culture and laminins to mimic the conditions of embryogenesis. Though oxygen levels have 
been modulated for the maintenance of PSCs, the use of lowered oxygen has not been 
widely examined for the differentiation of HLCs. 
In chapter 3, the effects of low-oxygen on the differentiation of iPSC-HLCs were examined 
and two differentiation protocols were compared. The results of these experiments showed 
only minor separation between tested conditions. The use of low oxygen did not appear to 
improve the phenotype of the HLCs as predicted and the two protocols did not separate 
strongly based on principal component analysis or hierarchical clustering.  
The lack of separation based on differentiation protocol suggests that protocol 2, which is 
cheaper, is the most suitable for large scale culture where the decreased costs and 
increased reproducibility offered by protocol 2 are key factors. However, the use of  serum 
in this protocol should be considered, modern protocols are typically serum free, 
particularly those intended for medicinal use. Serum is a biological component whose 
composition is not defined. Future studies should consider the replacement of serum in this 
protocol with serum-free alternatives such as Knockout Serum Replacement as is used in 
earlier stages of the same protocol to produce a xeno- and serum-free differentiation 
protocol. 
This work represents the first attempt that we are aware of to differentiate iPSCs to HLCs 
under hypoxic conditions, though similar methods using mesenchymal stem cells exist 
(Prasajak and Leeanansaksiri, 2013). We observed no evidence of adoption of a perivenous 
phenotype under hypoxic conditions and observed activation of hypox ia inducible factors 
under normoxic conditions. 
This indicates a potential hypoxia response under normoxic conditions likely due to the 
increasing metabolic oxygen demand (MOD) of differentiating cells combined with the rate  
of diffusion of oxygen throughout the culture medium. As PSCs differentiate to HLCs, their 
MOD presumably increases to become like a hepatocyte (Figure 37). Increasing MOD like ly 
produced a progressively increasing hypoxic cell environment even under normoxic 
conditions and cells cultured under hypoxic conditions likely experienced conditions of 
near-anoxia (Figure 37, Place et al. (2017)). These very low oxygen conditions likely explain 
the casually observed, poorer success rate of differentiations under hypoxic conditions and 
may have led to cells beginning to die off as cells became more metabolically active 




Schematic of increasing oxygen demand during differentiation and oxygen levels supplied 
by hypoxic and normoxic culture conditions – progress throughout differentiation from 
iPSCs to HLCs is shown on the x-axis. Arbitrary oxygen level is shown on the y axis. The red 
dotted line indicates increasing oxygen demand throughout the differentiation, the blue 
dotted line indicates the oxygen level of cells cultured under hypoxic conditions, the green 
dotted line shows the oxygen level of cells cultured under normoxic conditions. (1) levels of  
oxygen in normoxic culture are higher than physiological oxygen for iPSCs. (2) Normoxic 
culture provides near physiological oxygen levels during the later stages of differentiation 
but remains slightly hypoxic (3) Hypoxic conditions provide physiological conditions for 
oxygen demand for iPSCs. (4) hypoxic culture is insufficient to satisfy increased metabolic 
oxygen demand of HLCs. (5) Metabolic oxygen demand of HLCs increases beyond what can 





Furthermore, an improvement in the phenotype of hepatic cell lines when cultured under 
hyperoxic conditions was recently shown, improvements in CYP3A4 expression and 
ammonia elimination in HepaRG and C3A cells was observed (van Wenum et al., 2018). 
These results suggest that future studies should investigate the use of hyperoxia or 
increasing oxygen levels during differentiation to match increasing MOD and observe if 
HLCs under these conditions adopt a zonal phenotype. 
6.3 The establishment of human liver organoids and 
characterisation by proteomic analysis  
Liver organoids were recently established for the first time in a series of papers by the 
Clever’s lab and show promise as a model of hepatotoxicity and liver regeneration. Two 
major types of liver organoids have been described to date which exploit the two main 
pathways of liver regeneration. In chapter 5 we established the culture of hepatic organoids 
derived from EpCAM-positive cells in our laboratory and examined their phenotype more 
closely than has previously been attempted using iTRAQ analysis. 
Our results demonstrated that differentiated and undifferentiated organoids clustered 
separately by hierarchical clustering analysis, and though they separated from hPH, showed 
good recapitulation of key liver-specific proteins, with the expression of many CYPs, 
transporters and DMETs, not significantly different from hPH. Interestingly, although 
differentiated and undifferentiated organoids separated based on hierarchical clustering 
analysis, the expression of many liver-related proteins was not significantly changed by 
differentiation. 
Overall these results show that hepatic organoids, derived from EpCAM-positive cells offer 
good recapitulation of the hepatic phenotype, particularly transporters. Future studies 
should aim to compare organoids with other emerging models such as iPSC-HLCs and 
organoids derived from hepatocytes to determine whether they represent a true 
improvement over these models. 
There were some shortcomings of this study, cryopreservation severely retarded organoid 
growth after thawing and therefore, iTRAQ analysis was only completed in a single donor. 
Future work should repeat this analysis in additional donors to determine if the phenotype 
is reproducible and establish a cryopreservation protocol that does not cause growth 
retardation in cryopreserved organoids. 
Chapter 6 
200 
The expansion of EpCAM-positive cells in vivo is the minor pathway in the production of 
hepatocytes. Exploitation of the major method of cell repopulation i.e. from e xtant 
hepatocytes, may produce better quality cells as suggested by Hu et al. (2018). However, 
this study also uses RNA-based methods to determine phenotype so closer scrutiny with 
proteomic analysis may reveal a more accurate approximation of the true phenotype. 
Therefore, future studies should also attempt to produce organoids from hepatocytes and 
compare their proteome to those produced from EpCAM-positive cells. This experiment 
would reveal not only which type of organoid produces a better model for hepatotoxicity 
but may also provide insights into the differences, if any, between cells produced by the 
two major routes of hepatocyte repopulation in the liver. 
Organoids show an improved hepatic phenotype compared with iPSC-HLCs as is apparent 
from the comparisons made to hPH in chapters 3 and 4. Their good recapitulation of 
mature liver characteristics makes them the best option for hepatotoxicity screening of the 
nascent models discussed in this thesis. However, the manner in which they are cultured 
i.e. in semi-solid domes, with imprecise control of cell numbers during passaging may 
hinder their use in high-throughput screening where he matrix may interfere with testing 
compounds and the precise cell number must be controlled. By comparison, iPSC-HLCs do 
not share these issues, using more traditional 2D cultures which are currently in use for 
toxicity testing though currently their phenotype is not necessarily a large enough 
improvement to warrant a switch away from simpler and cheaper immortalised cell lines.  
In conclusion, organoids appear to be capable of good recapitulation of the hepatic 
phenotype, but this should be compared more thoroughly against other emerging models 
such as PSC-HLCs and other types of liver organoids. After which, their use in toxicity testing 
must be addressed. Currently, organoid toxicity testing is not yet fully realised and few 
toxicity screens have been reported to date (Van De Wetering et al., 2015). The manner in 
which organoids are cultured is labour-intensive and does not easily allow for close control 
of the number of cells per culture due to passaging using organoid fragments , future 
studies may investigate the development of single-cell passaging protocols to enable the 
necessary degrees of control over cell number. These issues must be overcome and 
automated, if the organoids are to be used in high-throughput screening. 
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6.4 The Effects of the 20q11.21 amplicon on the 
tumorigenicity of hESC-HLCs in vivo 
With the advent of personalised medicine there is great potential for the use of isogenic 
cells for cell therapies and transplant. However, the safety of such techniques has not yet 
been fully established. Cells accrue mutations over time in culture which may make the 
more prone to tumour formation later. In chapter 5 we examined the effects of a common 
amplicon of the tumour forming potential of hESC- HLCs. 
The results of this chapter showed significantly increased histology scores and increased 
luminescent signal in the livers of mice which were injected with cells containing the 
20q11.21 amplicon. Therefore, we can conclude that cells should likely be screened for the 
presence of the 20q11.21 amplicon prior to use in transplantation. This is the first literature 
example of the transplant of cells with known 20q11.21 status which demonstrated a 
change in behaviour of the cells in vivo and is a key milestone in determining what 
characteristics of a pluripotent cells are potentially harmful if intended for transplant. 
Future studies may consider testing other commonly occurring amplicons in a similar 
manner to build a library of aberrations that are unacceptable for transplanted cells.  
The work in this chapter used Fox Chase SCID beige mice, an uncommon SCID mouse strain 
which led to several drawbacks. We are not aware of previous reports of the tendency to 
form lifespan-limiting thymus tumours in this strain. Were this not the case, the study 
would have been continued for 6 months after transplantation of the cells. Future studies 
should consider the use of a longer-lived strain of SCID mouse such as the NOD SCID 
Gamma. 
Additionally, results were hampered by loss of luminescence after injection of  HLCs in many 
animals and the poor detection of albumin. This was interpreted largely as engraftment 
failure in the differentiated cells though the reasons for this failure are unclear. Future 
studies may consider the use of recent highly efficient differentiation protocols or the use 
of obligate humanisation models such as TK-NOG or fah deficient mice to increase the 




6.5 Final Comments 
To conclude, the hypotheses investigated in this thesis will be commented upon 
individually. 
6.5.1 Hypothesis 1: 
During embryonic development, hepatocytes are exposed to low oxygen conditions and the 
phenotype of mature hepatocytes varies across the lobule and is influenced by oxygen 
tension. By differentiating iPSC-HLCs under hypoxic conditions their phenotype will be 
improved and more closely mimic that of a perivenous hepatocyte. 
Comment: Cells differentiated under hypoxic conditions showed little to no consistent 
improvement over those differentiated under normoxic conditions. Nor did cells 
differentiated in hypoxia show an increase in perivenous markers. Therefore, we find this 
hypothesis to be rejected. Future studies should investigate the use of hyperoxia to 
determine if a pericentral phenotype may be achieved. 
6.5.2 Hypothesis 2: 
Organoids have been demonstrated to show a mature hepatic phenotype by examining 
gene expression. Examining their proteomic phenotype will produce a truer representation 
of their hepatic phenotype. 
Comment: Hepatic organoids were established in culture and differentiated. Assessment 
using iTRAQ analysis showed that although organoids cluster separately from hPH, their 
expression of a large number of liver-specific proteins is not significantly different from hPH 
and therefore the hepatic phenotype is well represented and the difference in clustering 
analysis is likely due to the proliferative nature of the cells or mixed cholangiocyte 
phenotype. Therefore the hypotheses cannot be rejected under the conditions of this 
study. Future studies should aim to increase the number of replicates in this experiment to 
confirm these findings and determine a cryopreservation technique that does not retard 
the growth of cryopreserved organoids and should also aim to confirm these findings using 
activity assays. 
6.5.3 Hypothesis 3: 
The presence of amplicon 20q11.21 confers a survival advantage to carrier cells in vitro. 
Similarly, differentiated cells which carry the amplification will be more prone to tumour 
formation when transplanted into the livers of an immunodeficient mouse model. 
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Comment: HLCs differentiated from ESCs containing the 20q11.21 amplicon produced 
greater luminescent signal in vivo and showed significantly increased histology scores in the 
liver. Therefore, we find this hypothesis to be supported. However, it should be noted that 
the injected HLCs were found to be non-functional in vivo as determined by albumin 
expression Future studies should make use of a humanisation model in which survival of 
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Cytochrome P450 1A2 CYP1A2 -1.537 3.36E-01 -57.718 6.59E-07 3.425 1.41E-02 -37.549 2.15E-06 5.265 2.23E-03 
Cytochrome P450 2A6 CYP2D6 2.201 3.60E-02 -21.283 9.26E-07 3.010 6.36E-03 -46.844 7.67E-08 1.368 3.67E-01 
Cytochrome P450 2C8 CYP3D6 -1.314 4.27E-01 -46.699 7.19E-08 2.763 9.87E-03 -35.535 1.62E-07 3.631 2.17E-03 
Cytochrome P450 2C9 CYP2C9 -1.166 5.96E-01 -88.185 2.04E-09 3.653 6.24E-04 -75.625 3.05E-09 4.259 2.48E-04 
Cytochrome P450 2D6 CYP2D6 -2.831 2.34E-02 -57.893 3.12E-07 1.537 3.04E-01 -20.447 6.95E-06 4.352 3.21E-03 
Cytochrome P450 2E1 CYP2E1 -1.054 8.35E-01 -38.610 4.30E-09 1.803 3.36E-02 -36.645 5.06E-09 1.900 2.28E-02 
Cytochrome P450 2S1 CYP2S1 -1.282 5.20E-01 1.437 3.53E-01 -9.726 5.63E-05 1.842 1.29E-01 -7.584 1.60E-04 
Cytochrome P450 3A4 CYP3A4 1.041 9.46E-01 -69.595 8.87E-06 5.738 1.05E-02 -72.434 8.07E-06 5.513 1.20E-02 
Cytochrome P450 4A11 CYP4A11 -1.131 8.23E-01 -74.243 3.79E-06 2.974 6.60E-02 -65.647 5.09E-06 3.363 4.39E-02 
TRANSPORTERS 
ATP-binding cassette sub-family A 
member 6 
ABCA6 -2.070 3.65E-01 -6.690 3.01E-02 1.206 8.13E-01 -3.232 1.55E-01 2.496 2.60E-01 
ATP-binding cassette sub-family D 
member 1 
ABCD1 1.537 2.74E-01 1.148 7.19E-01 2.866 1.58E-02 -1.339 4.52E-01 1.865 1.23E-01 
ATP-binding cassette sub-family D 
member 3 
ABCD3 3.332 4.85E-02 -3.153 5.81E-02 7.967 2.59E-03 -10.503 1.05E-03 2.391 1.38E-01 
ATP-binding cassette sub-family E 
member 1 
ABCE1 1.217 6.00E-01 1.057 8.82E-01 -1.722 1.62E-01 -1.152 7.05E-01 -2.096 6.53E-02 
ATP-binding cassette sub-family F 
member 1 
ABCF1 1.389 3.49E-01 4.144 1.20E-03 -2.057 5.39E-02 2.983 7.11E-03 -2.858 9.00E-03 
ATP-binding cassette sub-family F 
member 3 
ABCF3 -1.110 7.79E-01 -1.251 5.50E-01 -1.031 9.34E-01 -1.127 7.48E-01 1.076 8.43E-01 
Calcium-binding mitochondrial 
carrier protein Aralar1 
SLC25A12 1.748 9.66E-02 -1.041 9.00E-01 1.876 6.50E-02 -1.819 7.74E-02 1.073 8.24E-01 
Protein Abbreviation Prot. 1 normoxia vs. Protocol 1 normoxia Protocol 1 normoxia Protocol 1 hypoxia Protocol 1 hypoxia 
Chapter 6 
206 
















carrier protein Aralar2 
SLC25A13 -1.022 9.55E-01 -7.114 2.16E-04 1.334 4.58E-01 -6.962 2.38E-04 1.363 4.26E-01 
Calcium-binding mitochondrial 
carrier protein SCaMC-1 
SLC25A24 1.198 5.96E-01 7.703 5.04E-05 7.243 6.69E-05 6.428 1.17E-04 6.044 1.58E-04 
Equilibrative nucleoside transporter 1 ENT1 -2.039 1.13E-01 -1.335 5.02E-01 -7.223 4.76E-04 1.528 3.29E-01 -3.542 1.04E-02 
Major vault protein MVP -1.015 9.79E-01 4.758 1.55E-02 8.317 2.40E-03 4.830 1.47E-02 8.444 2.29E-03 
Multidrug resistance-associated 
protein 1 
ABCC1, MRP1 1.876 9.61E-02 2.646 1.63E-02 -1.019 9.58E-01 1.411 3.43E-01 -1.911 8.77E-02 
Solute carrier family 2, facilitated 
glucose transporter member 1 
GLUT1 1.523 1.88E-01 8.577 1.20E-05 2.208 2.21E-02 5.632 9.45E-05 1.450 2.42E-01 
Solute carrier family 2, facilitated 
glucose transporter member 2 
GLUT2 1.463 5.62E-01 -10.250 3.35E-03 2.519 1.73E-01 -14.994 1.14E-03 1.722 4.11E-01 
Solute carrier family 2, facilitated 
glucose transporter member 3 
GLUT3 -2.384 1.62E-01 13.304 8.02E-04 1.947 2.75E-01 31.715 6.88E-05 4.641 2.18E-02 
Voltage-dependent anion-selective 
channel protein 1 
VDAC1 1.177 6.07E-01 -1.012 9.69E-01 6.176 7.24E-05 -1.191 5.81E-01 5.248 1.67E-04 
Voltage-dependent anion-selective 
channel protein 2 
VDAC2 -2.181 7.62E-03 4.311 6.25E-05 2.558 2.29E-03 9.403 8.78E-07 5.580 1.33E-05 
Voltage-dependent anion-selective 
channel protein 3 
VDAC3 -1.711 1.26E-02 1.163 4.27E-01 1.398 9.27E-02 1.989 2.76E-03 2.392 4.66E-04 
PHASE II 
Catalase CAT -1.372 3.70E-01 -36.761 1.89E-07 1.738 1.30E-01 -26.795 5.10E-07 2.384 2.51E-02 
Catechol O-methyltransferase COMT 2.057 8.09E-02 -4.325 2.23E-03 12.625 2.20E-05 -8.898 8.81E-05 6.137 4.38E-04 
Glutathione S-transferase A2 GSTA2 1.385 7.09E-01 -12.744 1.13E-02 7.425 3.65E-02 -17.646 5.58E-03 5.362 7.22E-02 
Glutathione S-transferase kappa 1 GSTK1 2.606 3.40E-02 -4.392 3.06E-03 9.695 1.03E-04 -11.446 5.43E-05 3.720 6.56E-03 
Glutathione S-transferase Mu 2 GSTM2 1.080 7.42E-01 1.210 4.21E-01 -1.006 9.80E-01 1.120 6.28E-01 -1.086 7.23E-01 




Prot. 1 normoxia vs. 
prot. 1 hypoxia 
Protocol 1 normoxia 
vs hPH 
Protocol 1 normoxia 
vs UD 
Protocol 1 hypoxia 
vs. hPH 
















Glutathione S-transferase omega-1 GSTO1 -1.070 8.64E-01 -13.634 2.04E-05 12.248 3.05E-05 -12.744 2.62E-05 13.103 2.36E-05 
Glutathione S-transferase P GSTP1 1.267 5.01E-01 28.141 4.45E-07 -1.912 8.13E-02 22.217 9.75E-07 -2.422 2.33E-02 
Glutathione S-transferase theta-1 GSTT1 -1.468 4.76E-01 -16.044 1.84E-04 1.060 9.13E-01 -10.929 6.34E-04 1.556 4.14E-01 
Microsomal glutathione S-transferase 
1 
MGST1 1.454 5.49E-01 -20.702 3.11E-04 1.711 3.93E-01 -30.101 1.14E-04 1.177 7.93E-01 
Microsomal glutathione S-transferase 
3 
MGST3 1.224 6.19E-01 -1.419 3.95E-01 2.696 2.79E-02 -1.737 1.89E-01 2.202 6.99E-02 
NAD(P)H dehydrogenase [quinone] 1 NQO1 -1.232 6.04E-01 2.333 5.18E-02 1.495 3.26E-01 2.875 1.96E-02 1.842 1.45E-01 
Sulfotransferase 1A1 SULT1A1 1.759 1.04E-01 -28.577 2.26E-07 8.818 1.98E-05 -50.280 4.05E-08 5.012 3.01E-04 
UDP-glucuronosyltransferase 1-4 UGT1A4 -3.721 4.33E-02 -42.856 3.11E-05 -1.315 6.47E-01 -11.516 1.23E-03 2.831 9.88E-02 
UDP-glucuronosyltransferase 1-6 UGT1A6 1.202 5.84E-01 -6.331 1.07E-04 1.831 8.88E-02 -7.609 4.47E-05 1.523 2.22E-01 
UDP-glucuronosyltransferase 1-9 UGT1A9 1.459 5.27E-01 -9.609 2.09E-03 -1.566 4.54E-01 -14.015 6.59E-04 -2.284 1.80E-01 
UDP-glucuronosyltransferase 2B10 UGT2B10 -1.124 8.21E-01 -112.038 7.18E-07 3.478 2.92E-02 -99.711 9.36E-07 3.908 1.90E-02 
UDP-glucuronosyltransferase 2B15 UGT2B15 -2.797 1.43E-01 -14.765 1.46E-03 1.290 7.04E-01 -5.280 2.61E-02 3.609 7.41E-02 
UDP-glucuronosyltransferase 2B4 UGT2B4 -1.437 5.36E-01 -66.492 8.55E-06 2.399 1.50E-01 -46.275 2.08E-05 3.447 5.04E-02 
UDP-glucuronosyltransferase 2B7 UGT2B7 -1.842 1.46E-01 -41.178 6.53E-07 5.122 1.34E-03 -22.355 4.26E-06 9.434 9.79E-05 
ZONAL MARKERS 
Arginase-1 ARG1 -1.459 2.25E-01 -85.243 3.76E-09 3.908 5.98E-04 -58.425 1.03E-08 5.702 7.36E-05 
Phosphoenolpyruvate carboxykinase 
[GTP], mitochondrial 
PCK2 -1.446 4.91E-02 -10.702 7.98E-09 6.486 1.14E-07 -7.403 5.34E-08 9.375 1.53E-08 
Phosphoenolpyruvate carboxykinase, 
cytosolic [GTP] 
PCK1 1.228 7.14E-01 -38.139 2.35E-05 3.542 3.94E-02 -46.848 1.38E-05 2.884 7.69E-02 
Carbamoyl-phosphate synthase 
[ammonia], mitochondrial 




Prot. 2 normoxia vs. 
prot. 2 hypoxia 
Protocol 2 normoxia 
vs hPH 
Protocol 2 normoxia 
vs UD 
Protocol 2 hypoxia 
vs. hPH 


















Cytochrome P450 1A2 CYP1A2 -1.360 4.88E-01 -45.156 1.28E-06 4.378 4.89E-03 -33.212 3.07E-06 5.953 1.33E-03 
Cytochrome P450 2A6 CYP2D6 1.131 7.20E-01 -24.582 5.67E-07 2.606 1.42E-02 -27.795 3.78E-07 2.305 2.80E-02 
Cytochrome P450 2C8 CYP3D6 1.225 5.53E-01 -21.611 8.18E-07 5.971 1.65E-04 -26.469 4.13E-07 4.875 4.55E-04 
Cytochrome P450 2C9 CYP2C9 -1.221 4.93E-01 -59.157 5.95E-09 5.445 6.20E-05 -48.449 1.05E-08 6.648 2.17E-05 
Cytochrome P450 2D6 CYP2D6 -1.067 8.75E-01 -24.511 3.84E-06 3.631 7.39E-03 -22.977 4.73E-06 3.873 5.48E-03 
Cytochrome P450 2E1 CYP2E1 -1.590 8.36E-02 -24.510 1.94E-08 2.840 1.13E-03 -15.417 1.11E-07 4.515 5.06E-05 
Cytochrome P450 2S1 CYP2S1 -2.929 1.42E-02 1.759 1.58E-01 -7.943 1.31E-04 5.153 9.10E-04 -2.712 2.08E-02 
Cytochrome P450 3A4 CYP3A4 2.102 2.22E-01 -60.808 1.22E-05 6.567 6.83E-03 -127.820 2.27E-06 3.124 7.20E-02 
Cytochrome P450 4A11 CYP4A11 -1.022 9.69E-01 -42.855 1.49E-05 5.152 1.02E-02 -41.937 1.57E-05 5.265 9.49E-03 
TRANSPORTERS 
ATP-binding cassette sub-family A 
member 6 
ABCA7 -3.415 1.38E-01 -16.347 3.56E-03 -2.027 3.79E-01 -4.787 6.57E-02 1.685 5.13E-01 
ATP-binding cassette sub-family D 
member 1 
ABCD1 1.162 6.95E-01 -1.644 2.10E-01 1.518 2.87E-01 -1.911 1.10E-01 1.306 4.90E-01 
ATP-binding cassette sub-family D 
member 3 
ABCD3 1.595 4.11E-01 -3.260 5.21E-02 7.703 2.90E-03 -5.200 1.09E-02 4.829 1.40E-02 
ATP-binding cassette sub-family E 
member 1 
ABCE1 1.380 3.94E-01 1.359 4.16E-01 -1.339 4.40E-01 -1.015 9.67E-01 -1.848 1.18E-01 
ATP-binding cassette sub-family F 
member 1 
ABCF1 -1.006 9.86E-01 4.194 1.13E-03 -2.032 5.74E-02 4.220 1.09E-03 -2.020 5.93E-02 
ATP-binding cassette sub-family F 
member 3 
ABCF3 1.759 1.47E-01 -1.415 3.60E-01 -1.166 6.81E-01 -2.489 2.77E-02 -2.051 7.21E-02 
Calcium-binding mitochondrial 
carrier protein Aralar1 
SLC25A12 2.148 2.97E-02 1.267 4.60E-01 2.473 1.28E-02 -1.696 1.14E-01 1.152 6.57E-01 
Protein Abbreviation Prot. 2 normoxia vs. Protocol 2 normoxia Protocol 2 normoxia Protocol 2 hypoxia Protocol 2 hypoxia 
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carrier protein Aralar2 
SLC25A13 1.776 1.53E-01 -7.919 1.36E-04 1.199 6.39E-01 -14.063 1.38E-05 -1.482 3.17E-01 
Calcium-binding mitochondrial 
carrier protein SCaMC-1 
SLC25A24 -1.437 2.97E-01 5.345 2.90E-04 5.026 3.96E-04 7.680 5.11E-05 7.222 6.78E-05 
Equilibrative nucleoside transporter 1 ENT1 -3.467 1.14E-02 -1.958 1.33E-01 -10.600 1.05E-04 1.770 1.96E-01 -3.057 2.00E-02 
Major vault protein MVP 1.518 4.65E-01 2.083 2.10E-01 3.641 3.77E-02 1.372 5.78E-01 2.399 1.40E-01 
Multidrug resistance-associated 
protein 1 
ABCC1, MRP1 1.103 7.83E-01 3.038 7.78E-03 1.127 7.37E-01 2.754 1.31E-02 1.022 9.52E-01 
Solute carrier family 2, facilitated 
glucose transporter member 1 
GLUT1 -2.583 8.44E-03 12.132 2.66E-06 3.123 2.64E-03 31.334 8.37E-08 8.066 1.60E-05 
Solute carrier family 2, facilitated 
glucose transporter member 2 
GLUT2 -1.195 7.85E-01 -9.787 3.82E-03 2.638 1.54E-01 -8.190 6.40E-03 3.152 9.72E-02 
Solute carrier family 2, facilitated 
glucose transporter member 3 
GLUT3 -9.206 2.48E-03 5.580 1.21E-02 -1.225 7.34E-01 51.367 2.01E-05 7.516 4.69E-03 
Voltage-dependent anion-selective 
channel protein 1 
VDAC1 -1.240 5.00E-01 -1.556 1.77E-01 4.018 7.17E-04 -1.255 4.75E-01 4.981 2.20E-04 
Voltage-dependent anion-selective 
channel protein 2 
VDAC2 -1.131 6.23E-01 4.181 7.59E-05 2.481 2.88E-03 4.728 3.53E-05 2.806 1.16E-03 
Voltage-dependent anion-selective 
channel protein 3 
VDAC3 1.290 1.90E-01 1.206 3.27E-01 1.450 6.54E-02 -1.070 7.19E-01 1.124 5.36E-01 
PHASE II 
Catalase CAT 1.134 7.18E-01 -40.932 1.37E-07 1.561 2.15E-01 -46.417 9.47E-08 1.376 3.66E-01 
Catechol O-methyltransferase COMT -1.195 6.47E-01 -6.386 3.67E-04 8.551 1.04E-04 -5.346 8.22E-04 10.215 5.02E-05 
Glutathione S-transferase A2 GSTA2 -2.235 3.64E-01 -100.628 1.57E-04 -1.064 9.44E-01 -45.015 7.68E-04 2.102 4.00E-01 
Glutathione S-transferase kappa 1 GSTK1 1.060 8.87E-01 -3.698 6.74E-03 11.514 5.31E-05 -3.920 5.16E-03 10.864 6.63E-05 
Glutathione S-transferase Mu 2 GSTM2 2.256 3.87E-03 1.905 1.53E-02 1.566 7.29E-02 -1.184 4.73E-01 -1.441 1.35E-01 
Protein Abbreviation 
Prot. 2 normoxia vs. 
prot. 2 hypoxia 
Protocol 2 normoxia 
vs hPH 
Protocol 2 normoxia 
vs UD 
Protocol 2 hypoxia 
vs. hPH 


















Glutathione S-transferase Mu 3 GSTM3 -1.086 8.64E-01 3.362 2.50E-02 4.259 9.90E-03 3.653 1.81E-02 4.627 7.15E-03 
Glutathione S-transferase omega-1 GSTO1 -1.791 1.58E-01 -43.112 4.82E-07 3.873 4.38E-03 -24.066 2.84E-06 6.939 3.06E-04 
Glutathione S-transferase P GSTP1 1.566 2.13E-01 31.824 3.01E-07 -1.691 1.49E-01 20.326 1.33E-06 -2.647 1.44E-02 
Glutathione S-transferase theta-1 GSTT1 -1.057 9.18E-01 -16.695 1.63E-04 1.019 9.72E-01 -15.799 1.93E-04 1.077 8.90E-01 
Microsomal glutathione S-transferase 
1 
MGST1 -2.215 2.14E-01 -54.109 2.61E-05 -1.527 4.98E-01 -24.431 1.98E-04 1.450 5.51E-01 
Microsomal glutathione S-transferase 
3 
MGST3 -1.206 6.45E-01 -1.675 2.18E-01 2.284 5.94E-02 -1.389 4.24E-01 2.755 2.52E-02 
NAD(P)H dehydrogenase [quinone] 1 NQO1 1.251 5.78E-01 -1.314 4.99E-01 -2.051 9.19E-02 -1.645 2.29E-01 -2.567 3.33E-02 
Sulfotransferase 1A1 SULT1A1 2.038 4.68E-02 -45.995 5.24E-08 5.479 1.91E-04 -93.747 7.68E-09 2.688 9.59E-03 
UDP-glucuronosyltransferase 1-4 UGT1A4 1.318 6.43E-01 -19.350 2.64E-04 1.685 3.87E-01 -25.509 1.22E-04 1.278 6.81E-01 
UDP-glucuronosyltransferase 1-6 UGT1A6 1.259 4.94E-01 -6.349 1.05E-04 1.825 9.01E-02 -7.993 3.57E-05 1.450 2.77E-01 
UDP-glucuronosyltransferase 1-9 UGT1A9 -1.073 9.05E-01 -11.732 1.13E-03 -1.912 2.85E-01 -10.929 1.40E-03 -1.781 3.39E-01 
UDP-glucuronosyltransferase 2B10 UGT2B10 -1.259 6.56E-01 -74.015 1.89E-06 5.265 6.35E-03 -58.797 3.34E-06 6.627 2.74E-03 
UDP-glucuronosyltransferase 2B15 UGT2B15 -1.619 4.77E-01 -22.556 4.73E-04 -1.184 8.01E-01 -13.930 1.72E-03 1.368 6.42E-01 
UDP-glucuronosyltransferase 2B4 UGT2B4 -1.294 6.59E-01 -126.278 2.00E-06 1.263 6.89E-01 -97.595 3.53E-06 1.634 4.05E-01 
UDP-glucuronosyltransferase 2B7 UGT2B7 -2.122 7.99E-02 -74.020 1.34E-07 2.849 2.07E-02 -34.887 1.06E-06 6.045 6.37E-04 
ZONAL MARKERS 
Arginase-1 ARG1 -1.331 3.53E-01 -100.626 2.47E-09 3.311 1.61E-03 -75.630 5.13E-09 4.405 3.00E-04 
Phosphoenolpyruvate carboxykinase 
[GTP], mitochondrial 
PCK2 1.151 4.19E-01 -45.580 3.18E-11 1.523 2.80E-02 -52.483 2.07E-11 1.322 1.23E-01 
Phosphoenolpyruvate carboxykinase, 
cytosolic [GTP] 
PCK1 -1.819 2.96E-01 -47.714 1.32E-05 2.831 8.15E-02 -26.227 6.53E-05 5.151 1.12E-02 
Carbamoyl-phosphate synthase 
[ammonia], mitochondrial 




Fold changes and associated significance in liver-related proteins from iTRAQ analysis of iPSC-HLCs differentiated under hypoxia or normoxia using two protocols - 
Names and abbreviations used for the proteins in Figure 9-14 divided into four categories: CYPs, transporters, phase II metabolism, and zonal markers. Five comparisons are  
made per differentiation protocol, where normoxia and hypoxia are compared against undifferentiated cells (UD), primary human hepatocytes (hPH) and one another. Fold 
changes are presented as a decimal where positive values indicate higher expression in the first comparator listed. Significance was calculated by ANOVA using Partek, p- 














vs. P1N vs. P1H vs. P2N 
Liv6HB 
FOXA2 
1 Normoxia 563.9139 639.8217    
1 Hypoxia 355.0282 76.8648 0.6920   
2 Normoxia 2.0774 2.3652 0.1287 0.0004  
2 Hypoxia 0.2185 0.3090 0.2017 0.0031 0.2424 
VEGFA 
1 Normoxia 2.3019 0.9515    
1 Hypoxia 1.6932 0.9714 0.5477   
2 Normoxia 1.5295 1.2518 0.4211 0.8752  
2 Hypoxia 1.1675 0.6459 0.1305 0.4285 0.6381 
HNF4α 
1 Normoxia 356.9566 334.8480    
1 Hypoxia 151.9462 38.2181 0.4729   
2 Normoxia 9.6668 13.9270 0.0848 0.0019  
2 Hypoxia 0.5043 0.7131 0.1394 0.0049 0.3438 
NRF2 
1 Normoxia 3.8815 2.4596    
1 Hypoxia 2.1201 2.3858 0.4748   
2 Normoxia 2.7233 0.8545 0.3967 0.6323  
2 Hypoxia 3.1936 2.5521 0.5626 0.7524 0.9701 
ALDOA 
1 Normoxia 1.2729 0.3701    
1 Hypoxia 1.1883 0.5841 0.8813   
2 Normoxia 1.1243 0.3042 0.5385 0.7768  
2 Hypoxia 1.3064 0.0737 0.8899 0.7663 0.3189 
HSF1 
1 Normoxia 1.2168 0.1278    
1 Hypoxia 0.6156 0.4284 0.0843   
2 Normoxia 0.9405 0.2208 0.1540 0.2436  
2 Hypoxia 1.0420 0.9203 0.5032 0.6338 0.8967 
HIF1A 
1 Normoxia 2.7960 2.2310    
1 Hypoxia 0.7890 0.4685 0.3250   
2 Normoxia 2.1204 0.7995 0.5940 0.0958  
2 Hypoxia 3.3960 2.6304 0.9863 0.3191 0.6024 
CTNNB1 
1 Normoxia 0.9564 0.2432    
1 Hypoxia 0.7188 0.1429 0.2782   
2 Normoxia 0.6493 0.1942 0.0936 0.6530  
2 Hypoxia 1.0209 0.9664 0.7427 0.8755 0.6751 
NANOG 
1 Normoxia 1.0036 0.7977    
1 Hypoxia 8.8407 8.7569 0.1907   
2 Normoxia 0.0789 0.0180 0.0616 0.0820  
2 Hypoxia 0.0411 0.0542 0.1035 0.1524 0.1010 
Liv6HE 
FOXA2 
1 Normoxia 0.0655 0.0749    
1 Hypoxia 0.0000 0.0000 0.1993   
2 Normoxia 0.0009 0.0015 0.2044 0.3739  
2 Hypoxia 0.0000 0.0001 0.1996 0.2174 0.3965 
VEGFA 
1 Normoxia 0.5651 0.3365    
1 Hypoxia 0.3877 0.6683 0.6597   
2 Normoxia 0.1461 0.0473 0.0908 0.5661  
2 Hypoxia 0.2788 0.0510 0.2129 0.7923 0.0299 
HNF4α 
1 Normoxia 0.5455 0.8330    
1 Hypoxia 0.0000 0.0000 0.3187   
2 Normoxia 0.0086 0.0106 0.3256 0.2328  
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2 Hypoxia 0.0013 0.0014 0.3197 0.1747 0.3031 
NRF2 
1 Normoxia 2.5857 0.9937    
1 Hypoxia 0.0914 0.1582 0.0084   
2 Normoxia 1.6901 0.3225 0.2009 0.0015  
2 Hypoxia 0.8547 0.0248 0.0321 0.0012 0.0110 
ALDOA 
1 Normoxia 0.9082 0.0931    
1 Hypoxia 0.3399 0.5846 0.1052   
2 Normoxia 0.5703 0.2169 0.0356 0.5570  
2 Hypoxia 0.7428 0.2124 0.2149 0.3246 0.3805 
HSF1 
1 Normoxia 1.4670 0.5243    
1 Hypoxia 0.0563 0.0975 0.0064   
2 Normoxia 0.5480 0.1156 0.0332 0.0049  
2 Hypoxia 0.4277 0.0884 0.0210 0.0081 0.2254 
HIF1A 
1 Normoxia 4.1888 2.2250    
1 Hypoxia 0.1590 0.2753 0.0286   
2 Normoxia 2.7443 2.4232 0.4495 0.1402  
2 Hypoxia 1.4611 0.8603 0.1051 0.0670 0.4362 
CTNNB1 
1 Normoxia 1.4882 0.4662    
1 Hypoxia 0.0453 0.0785 0.0035   
2 Normoxia 0.6209 0.2265 0.0329 0.0142  
2 Hypoxia 0.3689 0.1163 0.0106 0.0162 0.1617 
NANOG 
1 Normoxia 0.0487 0.0402    
1 Hypoxia 0.7029 - -   
2 Normoxia 0.0355 0.0044 0.6051 -  
2 Hypoxia 0.0136 0.0106 0.2084 - 0.0292 
Liv7HE 
FOXA2 
1 Normoxia 10.1381 4.7647    
1 Hypoxia 2.6917 4.4598 0.0868   
2 Normoxia 0.6433 0.4184 0.0093 0.3957  
2 Hypoxia 0.2430 0.3557 0.0230 0.3969 0.2415 
VEGFA 
1 Normoxia 1.9626 0.5496    
1 Hypoxia 1.7756 1.1698 0.8109   
2 Normoxia 0.6820 0.2057 0.0071 0.1151  
2 Hypoxia 0.5208 0.1361 0.0116 0.1309 0.2964 
HNF4α 
1 Normoxia 412.5284 140.4492    
1 Hypoxia 69.4695 131.7341 0.0210   
2 Normoxia 8.7222 5.3866 0.0019 0.3923  
2 Hypoxia 5.8517 9.6762 0.0075 0.4522 0.6334 
NRF2 
1 Normoxia 8.9561 1.7914    
1 Hypoxia 5.9987 3.2793 0.2226   
2 Normoxia 4.7386 0.4645 0.0056 0.4755  
2 Hypoxia 4.8882 1.6411 0.0441 0.6189 0.8654 
ALDOA 
1 Normoxia 0.8866 0.0893    
1 Hypoxia 0.8862 0.0720 0.9948   
2 Normoxia 0.8299 0.2898 0.7615 0.7193  
2 Hypoxia 0.8924 0.1715 0.9612 0.9495 0.7562 
HSF1 
1 Normoxia 1.6592 0.1667    
1 Hypoxia 1.2868 0.4873 0.2685   
2 Normoxia 0.9986 0.1949 0.0054 0.3142  
2 Hypoxia 0.6915 0.1918 0.0027 0.1065 0.0925 
HIF1A 1 Normoxia 1.5240 0.4233    
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1 Hypoxia 1.1168 0.3019 0.1940   
2 Normoxia 1.7470 0.2974 0.4461 0.0248  
2 Hypoxia 2.0093 0.4945 0.2662 0.0304 0.4171 
CTNNB1 
1 Normoxia 1.0623 0.2613    
1 Hypoxia 0.8598 0.2369 0.3322   
2 Normoxia 1.2743 0.1652 0.2415 0.0284  
2 Hypoxia 1.1079 0.2724 0.8443 0.2534 0.3567 
NANOG 
1 Normoxia 0.2540 0.1923    
1 Hypoxia 1.4604 2.7443 0.4915   
2 Normoxia 0.1470 0.1579 0.4535 0.3761  
2 Hypoxia 0.0173 0.0140 0.1007 0.4148 0.2247 
Appendix 2 
Fold changes, error and associated significance in expression of liver and hypoxia related genes - Fold changes and 
associated error and significance for the genes in Figure 15 separated based in iPSC line. Fold change was calculated 
using the 2-ΔΔCT method (Livak and Schmittgen, 2001) versus line-matched normoxic iPSCs and using GAPDH as a 
control gene. Fold changes are presented as a decimal where values greater than 1 indicate higher expression in 
iPSC-HLCs. p-values were calculated using an unpaired, two-tailed Student’s t-test and values ≤ 0.05 were considered 















































































































































































Supplementary Figure 1 - Representative bioluminescence images of SCID beige mice intrasplenically injected with 
undifferentiated luminescent hESCs – Animals were injected with 1 x106 undifferentiated luminescent hESCs 72-
hours after induction of acute liver injury with 0.2mL/kg CCl4. Each hESC line (i.e. MS7N, MS7CNV, MS8N and MS8AB) 
is shown individually. Images show luminescence over time from side and front elevations. Red circles show regions 
of interest used to determine luminescence intensity, in this case showing radiance  
(photons/second/cm2/steradian), though total flux (photons/second) was also recorded and was used for later 
experiments. Luminescence intensity is represented by the coloured overlays with warmer colour indicating greater 
intensity. Each scale bar applies only to the image to its immediate left. The order of animals is consistent between 








Supplementary Figure 2 
Representative bioluminescence images of SCID beige mice intrasplenically injected with HepG2_Fluc – Animals 
were injected with 1 x106 luminescent HepG2 cells 72-hours after induction of acute liver injury with 0.2mL/kg CCl4. 
Images show luminescence over time from side and front elevations. Red circles show regions of interest used to 
determine luminescence intensity, in this case showing radiance (photons/second/cm2/steradian), though total f lux  
(photons/second) was also recorded and was used for later experiments. Luminescence intensity is represented by 
the coloured overlays with warmer colour indicating greater intensity. Each scale bar applies only to the image to its 
immediate left. The order of animals is consistent between images. Only values from the front elevation were used 
















Supplementary Figure 3 
Representative bioluminescence images of SCID beige mice intrasplenically injected with MS8Ab_D7 hESC-HLCs  –  
Animals were injected with 1 x106 MS8Ab_D7 luminescent hESCs 72-hours after induction of acute liver injury with 
0.2mL/kg CCl4. Images show luminescence over time from side and front elevations. Red circles show regions of 
































though total flux (photons/second) was also recorded and was used for later experiments. Luminescence intensity is 
represented by the coloured overlays with warmer colour indicating greater intensity. Each scale bar applies only to 
the image to its immediate left. The order of animals is consistent between images some animals were excluded due 
to thymic lymphoma discovered at the end of the experiment and are covered by white boxes.  Only values from the 
















Supplementary Figure 4 
Representative bioluminescence images of SCID beige mice intrasplenically injected with MS8Ab_G7 hESC-HLCs  –  
Animals were injected with 1 x106 MS8Ab_G7 luminescent hESCs 72-hours after induction of acute liver injury with 
0.2mL/kg CCl4. Images show luminescence over time from side and front elevations. Red circles show regions of 
































though total flux (photons/second) was also recorded and was used for later experiments . Luminescence intensity is 
represented by the coloured overlays with warmer colour indicating greater intensity. Each scale bar applies only to 
the image to its immediate left. The order of animals is consistent between images, after week 6, order of the 












Supplementary Figure 5 
Representative bioluminescence images of SCID beige mice intrasplenically injected with MS8N_C3 hESC-HLCs – 
Animals were injected with 1 x106 MS8N_C3 luminescent hESCs 72-hours after induction of acute liver injury with 
0.2mL/kg CCl4. Images show luminescence over time from side and front elevations. Red circles show regions of 
interest used to determine luminescence intensity in this case showing radiance (photons/second/cm2/steradian), 
though total flux (photons/second) was also recorded and was used for later experiments . Luminescence intensity is 
represented by the coloured overlays with warmer colour indicating greater intensity. Each scale bar applies only to 
the image to its immediate left. The order of animals is consistent between images. Only values from the front 


























Supplementary Figure 6 
Representative bioluminescence images of SCID beige mice intrasplenically injected with MS8N_E3 hESC-HLCs – 
Animals were injected with 1 x106 MS8N_E3 luminescent hESCs 72-hours after induction of acute liver injury with 
0.2mL/kg CCl4. Images show luminescence over time from side and front elevations. Red circles show regions of 
interest used to determine luminescence intensity, in this case showing radiance (photons/second/cm2/steradian) , 
though total flux (photons/second) was also recorded and was used for later experiments . Luminescence intensity is 
represented by the coloured overlays with warmer colour indicating greater intensity. Each scale bar applies only to 
the image to its immediate left. The order of animals is consistent between images. Only values from the front 


























Supplementary Figure 7 
Representative bioluminescence images of SCID beige mice intrasplenically injected with MS7CNV_C7 hESC-HLCs – 
Animals were injected with 1 x106 MS7CNV_C7 luminescent hESCs 72-hours after induction of acute liver injury with 
0.2mL/kg CCl4. Images show luminescence over time from side and front elevations. Red circles show regions of 
interest used to determine luminescence intensity, in this case showing radiance (photons/second/cm2/steradian) , 
though total flux (photons/second) was also recorded and was used for later experiments. Luminescence intensity is 
represented by the coloured overlays with warmer colour indicating greater intensity. Each scale bar applies only to 
the image to its immediate left. The order of animals is consistent between images, after week 4, one animal was 
sacrificed due to poor health and the remaining animal is that on the furthest right of the remaining images. Only 




















247   
Chapter 6 
248 
Supplementary Figure 8 
Representative bioluminescence images of SCID beige mice intrasplenically injected with MS7CNV_D7 hESC-HLCs – 
Animals were injected with 1 x106 MS7CNV_D7 luminescent hESCs 72-hours after induction of acute liver injury with 
0.2mL/kg CCl4. Images show luminescence over time from side and front elevations. Red circles show regions of 
interest used to determine luminescence intensity, in this case showing radiance (photons/second/cm2/steradian) , 
though total flux (photons/second) was also recorded and was used for later experiments . Luminescence intensity is 
represented by the coloured overlays with warmer colour indicating greater intensity. Each scale bar applies only to 
the image to its immediate left. The order of animals is consistent between images, some animals were excluded 
due to thymic lymphoma discovered at the end of the experiment and are covered by white boxes. Only values from 


































Supplementary Figure 9 
Representative bioluminescence images of SCID beige mice intrasplenically injected with MS7N_D6 hESC-HLCs – 
Animals were injected with 1 x106 MS7N_D6 luminescent hESCs 72-hours after induction of acute liver injury with 
0.2mL/kg CCl4. Images show luminescence over time from side and front elevations. Red circles  show regions of 
interest used to determine luminescence intensity, in this case showing radiance (photons/second/cm2/steradian) , 
though total flux (photons/second) was also recorded and was used for later experiments . Luminescence intensity is 

























the image to its immediate left. The order of animals is consistent between images some animals were excluded 
after discovery of thymic lymphoma at the end of the experiment and are either not show or covered by white 











































Supplementary Figure 10 
Representative bioluminescence images of SCID beige mice intrasplenically injected with MS7N_E5 hESC-HLCs – 
Animals were injected with 1 x106 MS7N_E5 luminescent hESCs 72-hours after induction of acute liver injury with 
0.2mL/kg CCl4. Images show luminescence over time from side and front elevations. Red circles show regions of 
interest used to determine luminescence intensity, in this case showing radiance (photons/second/cm2/steradian) , 
though total flux (photons/second) was also recorded and was used for later experiments. Luminescence intensity is 
represented by the coloured overlays with warmer colour indicating greater intensity. Each scale bar applies only to 
the image to its immediate left. The order of animals is consistent between images, after week 1, the animals in the 
second row are the two animals to the furthest right in subsequent images. Only values from the front elevation 
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